<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">34830115</PMID><DateCompleted><Year>2021</Year><Month>12</Month><Day>17</Day></DateCompleted><DateRevised><Year>2021</Year><Month>12</Month><Day>17</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>22</Issue><PubDate><Year>2021</Year><Month>Nov</Month><Day>12</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>Nearly 30 Years of Animal Models to Study Amyotrophic Lateral Sclerosis: A Historical Overview and Future Perspectives.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">12236</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms222212236</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is a fatal, multigenic, multifactorial, and non-cell autonomous neurodegenerative disease characterized by upper and lower motor neuron loss. Several genetic mutations lead to ALS development and many emerging gene mutations have been discovered in recent years. Over the decades since 1990, several animal models have been generated to study ALS pathology including both vertebrates and invertebrates such as yeast, worms, flies, zebrafish, mice, rats, guinea pigs, dogs, and non-human primates. Although these models show different peculiarities, they are all useful and complementary to dissect the pathological mechanisms at the basis of motor neuron degeneration and ALS progression, thus contributing to the development of new promising therapeutics. In this review, we describe the up to date and available ALS genetic animal models, classified by the different genetic mutations and divided per species, pointing out their features in modeling, the onset and progression of the pathology, as well as their specific pathological hallmarks. Moreover, we highlight similarities, differences, advantages, and limitations, aimed at helping the researcher to select the most appropriate experimental animal model, when designing a preclinical ALS study.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bonifacino</LastName><ForeName>Tiziana</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-3966-9874</Identifier><AffiliationInfo><Affiliation>Pharmacology and Toxicology Unit, Department of Pharmacy, University of Genoa, 16148 Genoa, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Inter-University Center for the Promotion of the 3Rs Principles in Teaching &amp; Research (Centro 3R), 56122 Genoa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zerbo</LastName><ForeName>Roberta Arianna</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Pharmacology and Toxicology Unit, Department of Pharmacy, University of Genoa, 16148 Genoa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Balbi</LastName><ForeName>Matilde</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-9774-6786</Identifier><AffiliationInfo><Affiliation>Pharmacology and Toxicology Unit, Department of Pharmacy, University of Genoa, 16148 Genoa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Torazza</LastName><ForeName>Carola</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Pharmacology and Toxicology Unit, Department of Pharmacy, University of Genoa, 16148 Genoa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frumento</LastName><ForeName>Giulia</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Pharmacology and Toxicology Unit, Department of Pharmacy, University of Genoa, 16148 Genoa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fedele</LastName><ForeName>Ernesto</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-0386-0925</Identifier><AffiliationInfo><Affiliation>Pharmacology and Toxicology Unit, Department of Pharmacy, University of Genoa, 16148 Genoa, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>IRCCS Ospedale Policlinico San Martino, 16132 Genoa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bonanno</LastName><ForeName>Giambattista</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0003-3744-5786</Identifier><AffiliationInfo><Affiliation>Pharmacology and Toxicology Unit, Department of Pharmacy, University of Genoa, 16148 Genoa, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>IRCCS Ospedale Policlinico San Martino, 16132 Genoa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Milanese</LastName><ForeName>Marco</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-3384-0666</Identifier><AffiliationInfo><Affiliation>Pharmacology and Toxicology Unit, Department of Pharmacy, University of Genoa, 16148 Genoa, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Inter-University Center for the Promotion of the 3Rs Principles in Teaching &amp; Research (Centro 3R), 56122 Genoa, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016456">Historical Article</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>11</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000266" MajorTopicYN="N">history</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="Y">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004285" MajorTopicYN="N">Dogs</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006168" MajorTopicYN="N">Guinea Pigs</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049673" MajorTopicYN="N">History, 20th Century</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049674" MajorTopicYN="N">History, 21st Century</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">dog</Keyword><Keyword MajorTopicYN="N">fly</Keyword><Keyword MajorTopicYN="N">genetic animal models</Keyword><Keyword MajorTopicYN="N">guinea pig</Keyword><Keyword MajorTopicYN="N">mouse</Keyword><Keyword MajorTopicYN="N">non-human primates</Keyword><Keyword MajorTopicYN="N">rat</Keyword><Keyword MajorTopicYN="N">swine</Keyword><Keyword MajorTopicYN="N">worm</Keyword><Keyword MajorTopicYN="N">yeast</Keyword><Keyword MajorTopicYN="N">zebrafish</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>9</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>11</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>11</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>11</Month><Day>27</Day><Hour>1</Hour><Minute>10</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>11</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>12</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34830115</ArticleId><ArticleId IdType="pmc">PMC8619465</ArticleId><ArticleId IdType="doi">10.3390/ijms222212236</ArticleId><ArticleId IdType="pii">ijms222212236</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Brown R.H.J., Al-Chalabi A. Amyotrophic Lateral Sclerosis. N. Engl. J. Med. 2017;377:1602. doi: 10.1056/NEJMra1603471.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1603471</ArticleId><ArticleId IdType="pubmed">29045202</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardiman O., Al-Chalabi A., Chio A., Corr E.M., Logroscino G., Robberecht W., Shaw P.J., Simmons Z., van den Berg L.H. Amyotrophic lateral sclerosis. Nat. Rev. Dis. Prim. 2017;3:17085. doi: 10.1038/nrdp.2017.85.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrdp.2017.85</ArticleId><ArticleId IdType="pubmed">29052611</ArticleId></ArticleIdList></Reference><Reference><Citation>&#x160;t&#x11b;tk&#xe1;&#x159;ov&#xe1; I., Ehler E. Diagnostics of Amyotrophic Lateral Sclerosis: Up to Date. Diagnostics. 2021;11:231. doi: 10.3390/diagnostics11020231.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/diagnostics11020231</ArticleId><ArticleId IdType="pmc">PMC7913557</ArticleId><ArticleId IdType="pubmed">33546386</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Chalabi A., Hardiman O. The epidemiology of ALS: A conspiracy of genes, environment and time. Nat. Rev. Neurol. 2013;9:617&#x2013;628. doi: 10.1038/nrneurol.2013.203.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2013.203</ArticleId><ArticleId IdType="pubmed">24126629</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor J.P., Brown R.H.J., Cleveland D.W. Decoding ALS: From genes to mechanism. Nature. 2016;539:197&#x2013;206. doi: 10.1038/nature20413.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature20413</ArticleId><ArticleId IdType="pmc">PMC5585017</ArticleId><ArticleId IdType="pubmed">27830784</ArticleId></ArticleIdList></Reference><Reference><Citation>Dukkipati S.S., Garrett T.L., Elbasiouny S.M. The vulnerability of spinal motoneurons and soma size plasticity in a mouse model of amyotrophic lateral sclerosis. J. Physiol. 2018;596:1723&#x2013;1745. doi: 10.1113/JP275498.</Citation><ArticleIdList><ArticleId IdType="doi">10.1113/JP275498</ArticleId><ArticleId IdType="pmc">PMC5924829</ArticleId><ArticleId IdType="pubmed">29502344</ArticleId></ArticleIdList></Reference><Reference><Citation>Milanese M., Zappettini S., Onofri F., Musazzi L., Tardito D., Bonifacino T., Messa M., Racagni G., Usai C., Benfenati F., et al. Abnormal exocytotic release of glutamate in a mouse model of amyotrophic lateral sclerosis. J. Neurochem. 2011;116:1028&#x2013;1042. doi: 10.1111/j.1471-4159.2010.07155.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2010.07155.x</ArticleId><ArticleId IdType="pubmed">21175617</ArticleId></ArticleIdList></Reference><Reference><Citation>Pieri M., Caioli S., Canu N., Mercuri N.B., Guatteo E., Zona C. Over-expression of N-type calcium channels in cortical neurons from a mouse model of Amyotrophic Lateral Sclerosis. Exp. Neurol. 2013;247:349&#x2013;358. doi: 10.1016/j.expneurol.2012.11.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2012.11.002</ArticleId><ArticleId IdType="pubmed">23142186</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonifacino T., Musazzi L., Milanese M., Seguini M., Marte A., Gallia E., Cattaneo L., Onofri F., Popoli M., Bonanno G. Altered mechanisms underlying the abnormal glutamate release in amyotrophic lateral sclerosis at a pre-symptomatic stage of the disease. Neurobiol. Dis. 2016;95:122&#x2013;133. doi: 10.1016/j.nbd.2016.07.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2016.07.011</ArticleId><ArticleId IdType="pubmed">27425885</ArticleId></ArticleIdList></Reference><Reference><Citation>Sugiyama K., Tanaka K. Spinal cord-specific deletion of the glutamate transporter GLT1 causes motor neuron death in mice. Biochem. Biophys. Res. Commun. 2018;497:689&#x2013;693. doi: 10.1016/j.bbrc.2018.02.132.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2018.02.132</ArticleId><ArticleId IdType="pubmed">29458024</ArticleId></ArticleIdList></Reference><Reference><Citation>Tedeschi V., Petrozziello T., Secondo A. Calcium Dyshomeostasis and Lysosomal Ca(2+) Dysfunction in Amyotrophic Lateral Sclerosis. Cells. 2019;8:1216. doi: 10.3390/cells8101216.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells8101216</ArticleId><ArticleId IdType="pmc">PMC6829585</ArticleId><ArticleId IdType="pubmed">31597311</ArticleId></ArticleIdList></Reference><Reference><Citation>Armada-Moreira A., Gomes J.I., Pina C.C., Savchak O.K., Gon&#xe7;alves-Ribeiro J., Rei N., Pinto S., Morais T.P., Martins R.S., Ribeiro F.F., et al. Going the Extra (Synaptic) Mile: Excitotoxicity as the Road Toward Neurodegenerative Diseases. Front. Cell. Neurosci. 2020;14:90. doi: 10.3389/fncel.2020.00090.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2020.00090</ArticleId><ArticleId IdType="pmc">PMC7194075</ArticleId><ArticleId IdType="pubmed">32390802</ArticleId></ArticleIdList></Reference><Reference><Citation>Milanese M., Bonifacino T., Fedele E., Rebosio C., Cattaneo L., Benfenati F., Usai C., Bonanno G. Exocytosis regulates trafficking of GABA and glycine heterotransporters in spinal cord glutamatergic synapses: A mechanism for the excessive heterotransporter-induced release of glutamate in experimental amyotrophic lateral sclerosis. Neurobiol. Dis. 2015;74:314&#x2013;324. doi: 10.1016/j.nbd.2014.12.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2014.12.004</ArticleId><ArticleId IdType="pubmed">25497732</ArticleId></ArticleIdList></Reference><Reference><Citation>Stifanese R., Averna M., De Tullio R., Pedrazzi M., Milanese M., Bonifacino T., Bonanno G., Salamino F., Pontremoli S., Melloni E. Role of calpain-1 in the early phase of experimental ALS. Arch. Biochem. Biophys. 2014;562:1&#x2013;8. doi: 10.1016/j.abb.2014.08.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.abb.2014.08.006</ArticleId><ArticleId IdType="pubmed">25151305</ArticleId></ArticleIdList></Reference><Reference><Citation>Hadzhieva M., Kirches E., Wilisch-Neumann A., Pachow D., Wallesch M., Schoenfeld P., Paege I., Vielhaber S., Petri S., Keilhoff G., et al. Dysregulation of iron protein expression in the G93A model of amyotrophic lateral sclerosis. Neuroscience. 2013;230:94&#x2013;101. doi: 10.1016/j.neuroscience.2012.11.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2012.11.021</ArticleId><ArticleId IdType="pubmed">23178912</ArticleId></ArticleIdList></Reference><Reference><Citation>Burlando B., Milanese M., Giordano G., Bonifacino T., Ravera S., Blanchini F., Bonanno G. A multistationary loop model of ALS unveils critical molecular interactions involving mitochondria and glucose metabolism. PLoS ONE. 2020;15:e0244234. doi: 10.1371/journal.pone.0244234.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0244234</ArticleId><ArticleId IdType="pmc">PMC7746301</ArticleId><ArticleId IdType="pubmed">33332476</ArticleId></ArticleIdList></Reference><Reference><Citation>Obrador E., Salvador R., L&#xf3;pez-Blanch R., Jihad-Jebbar A., Vall&#xe9;s S.L., Estrela J.M. Oxidative Stress, Neuroinflammation and Mitochondria in the Pathophysiology of Amyotrophic Lateral Sclerosis. Antioxidants. 2020;9:901. doi: 10.3390/antiox9090901.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antiox9090901</ArticleId><ArticleId IdType="pmc">PMC7555310</ArticleId><ArticleId IdType="pubmed">32971909</ArticleId></ArticleIdList></Reference><Reference><Citation>Morfini G.A., Bosco D.A., Brown H., Gatto R., Kaminska A., Song Y., Molla L., Baker L., Marangoni M.N., Berth S., et al. Inhibition of fast axonal transport by pathogenic SOD1 involves activation of p38 MAP kinase. PLoS ONE. 2013;8:e65235. doi: 10.1371/journal.pone.0065235.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0065235</ArticleId><ArticleId IdType="pmc">PMC3680447</ArticleId><ArticleId IdType="pubmed">23776455</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibbs K.L., Kalmar B., Rhymes E.R., Fellows A.D., Ahmed M., Whiting P., Davies C.H., Greensmith L., Schiavo G. Inhibiting p38 MAPK alpha rescues axonal retrograde transport defects in a mouse model of ALS. Cell Death Dis. 2018;9:596. doi: 10.1038/s41419-018-0624-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41419-018-0624-8</ArticleId><ArticleId IdType="pmc">PMC5964181</ArticleId><ArticleId IdType="pubmed">29789529</ArticleId></ArticleIdList></Reference><Reference><Citation>Burk K., Pasterkamp R.J. Disrupted neuronal trafficking in amyotrophic lateral sclerosis. Acta Neuropathol. 2019;137:859&#x2013;877. doi: 10.1007/s00401-019-01964-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-019-01964-7</ArticleId><ArticleId IdType="pmc">PMC6531423</ArticleId><ArticleId IdType="pubmed">30721407</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki N., Akiyama T., Warita H., Aoki M. Omics Approach to Axonal Dysfunction of Motor Neurons in Amyotrophic Lateral Sclerosis (ALS) Front. Neurosci. 2020;14:194. doi: 10.3389/fnins.2020.00194.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2020.00194</ArticleId><ArticleId IdType="pmc">PMC7109447</ArticleId><ArticleId IdType="pubmed">32269505</ArticleId></ArticleIdList></Reference><Reference><Citation>Brites D., Vaz A.R. Microglia centered pathogenesis in ALS: Insights in cell interconnectivity. Front. Cell. Neurosci. 2014;8:117. doi: 10.3389/fncel.2014.00117.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2014.00117</ArticleId><ArticleId IdType="pmc">PMC4033073</ArticleId><ArticleId IdType="pubmed">24904276</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiarotto G.B., Cartarozzi L.P., Perez M., Biscola N.P., Spejo A.B., Gubert F., Fran&#xe7;a Junior M., Mendez-Otero R., de Oliveira A.L.R. Tempol improves neuroinflammation and delays motor dysfunction in a mouse model (SOD1(G93A)) of ALS. J. Neuroinflamm. 2019;16:218. doi: 10.1186/s12974-019-1598-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-019-1598-x</ArticleId><ArticleId IdType="pmc">PMC6857328</ArticleId><ArticleId IdType="pubmed">31727149</ArticleId></ArticleIdList></Reference><Reference><Citation>Zetterstr&#xf6;m P., Stewart H.G., Bergemalm D., Jonsson P.A., Graffmo K.S., Andersen P.M., Br&#xe4;nnstr&#xf6;m T., Oliveberg M., Marklund S.L. Soluble misfolded subfractions of mutant superoxide dismutase-1s are enriched in spinal cords throughout life in murine ALS models. Proc. Natl. Acad. Sci. USA. 2007;104:14157&#x2013;14162. doi: 10.1073/pnas.0700477104.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0700477104</ArticleId><ArticleId IdType="pmc">PMC1955813</ArticleId><ArticleId IdType="pubmed">17715066</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramesh N., Pandey U.B. Autophagy Dysregulation in ALS: When Protein Aggregates Get Out of Hand. Front. Mol. Neurosci. 2017;10:263. doi: 10.3389/fnmol.2017.00263.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2017.00263</ArticleId><ArticleId IdType="pmc">PMC5572252</ArticleId><ArticleId IdType="pubmed">28878620</ArticleId></ArticleIdList></Reference><Reference><Citation>Bendotti C., Marino M., Cheroni C., Fontana E., Crippa V., Poletti A., De Biasi S. Dysfunction of constitutive and inducible ubiquitin-proteasome system in amyotrophic lateral sclerosis: Implication for protein aggregation and immune response. Prog. Neurobiol. 2012;97:101&#x2013;126. doi: 10.1016/j.pneurobio.2011.10.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pneurobio.2011.10.001</ArticleId><ArticleId IdType="pubmed">22033150</ArticleId></ArticleIdList></Reference><Reference><Citation>Yerbury J.J., Farrawell N.E., McAlary L. Proteome Homeostasis Dysfunction: A Unifying Principle in ALS Pathogenesis. Trends Neurosci. 2020;43:274&#x2013;284. doi: 10.1016/j.tins.2020.03.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tins.2020.03.002</ArticleId><ArticleId IdType="pubmed">32353332</ArticleId></ArticleIdList></Reference><Reference><Citation>Atkin J.D., Farg M.A., Walker A.K., McLean C., Tomas D., Horne M.K. Endoplasmic reticulum stress and induction of the unfolded protein response in human sporadic amyotrophic lateral sclerosis. Neurobiol. Dis. 2008;30:400&#x2013;407. doi: 10.1016/j.nbd.2008.02.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2008.02.009</ArticleId><ArticleId IdType="pubmed">18440237</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaronen M., Goldsteins G., Koistinaho J. ER stress and unfolded protein response in amyotrophic lateral sclerosis-a controversial role of protein disulphide isomerase. Front. Cell. Neurosci. 2014;8:402. doi: 10.3389/fncel.2014.00402.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2014.00402</ArticleId><ArticleId IdType="pmc">PMC4251436</ArticleId><ArticleId IdType="pubmed">25520620</ArticleId></ArticleIdList></Reference><Reference><Citation>Vandoorne T., De Bock K., Van Den Bosch L. Energy metabolism in ALS: An underappreciated opportunity? Acta Neuropathol. 2018;135:489&#x2013;509. doi: 10.1007/s00401-018-1835-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-018-1835-x</ArticleId><ArticleId IdType="pmc">PMC5978930</ArticleId><ArticleId IdType="pubmed">29549424</ArticleId></ArticleIdList></Reference><Reference><Citation>Obrador E., Salvador-Palmer R., L&#xf3;pez-Blanch R., Jihad-Jebbar A., Vall&#xe9;s S.L., Estrela J.M. The Link between Oxidative Stress, Redox Status, Bioenergetics and Mitochondria in the Pathophysiology of ALS. Int. J. Mol. Sci. 2021;22:6352. doi: 10.3390/ijms22126352.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22126352</ArticleId><ArticleId IdType="pmc">PMC8231819</ArticleId><ArticleId IdType="pubmed">34198557</ArticleId></ArticleIdList></Reference><Reference><Citation>Ravera S., Torazza C., Bonifacino T., Provenzano F., Rebosio C., Milanese M., Usai C., Panfoli I., Bonanno G. Altered glucose catabolism in the presynaptic and perisynaptic compartments of SOD1(G93A) mouse spinal cord and motor cortex indicates that mitochondria are the site of bioenergetic imbalance in ALS. J. Neurochem. 2019;151:336&#x2013;350. doi: 10.1111/jnc.14819.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.14819</ArticleId><ArticleId IdType="pubmed">31282572</ArticleId></ArticleIdList></Reference><Reference><Citation>Volkening K., Leystra-Lantz C., Yang W., Jaffee H., Strong M.J. Tar DNA binding protein of 43 kDa (TDP-43), 14-3-3 proteins and copper/zinc superoxide dismutase (SOD1) interact to modulate NFL mRNA stability. Implications for altered RNA processing in amyotrophic lateral sclerosis (ALS) Brain Res. 2009;1305:168&#x2013;182. doi: 10.1016/j.brainres.2009.09.105.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2009.09.105</ArticleId><ArticleId IdType="pubmed">19815002</ArticleId></ArticleIdList></Reference><Reference><Citation>Droppelmann C.A., Campos-Melo D., Ishtiaq M., Volkening K., Strong M.J. RNA metabolism in ALS: When normal processes become pathological. Amyotroph. Lateral Scler. Front. Degener. 2014;15:321&#x2013;336. doi: 10.3109/21678421.2014.881377.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2014.881377</ArticleId><ArticleId IdType="pubmed">24555412</ArticleId></ArticleIdList></Reference><Reference><Citation>Gentile F., Scarlino S., Falzone Y.M., Lunetta C., Tremolizzo L., Quattrini A., Riva N. The Peripheral Nervous System in Amyotrophic Lateral Sclerosis: Opportunities for Translational Research. Front. Neurosci. 2019;13:601. doi: 10.3389/fnins.2019.00601.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2019.00601</ArticleId><ArticleId IdType="pmc">PMC6603245</ArticleId><ArticleId IdType="pubmed">31293369</ArticleId></ArticleIdList></Reference><Reference><Citation>Filipi T., Hermanova Z., Tureckova J., Vanatko O., Anderova A.M. Glial Cells-The Strategic Targets in Amyotrophic Lateral Sclerosis Treatment. J. Clin. Med. 2020;9:261. doi: 10.3390/jcm9010261.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm9010261</ArticleId><ArticleId IdType="pmc">PMC7020059</ArticleId><ArticleId IdType="pubmed">31963681</ArticleId></ArticleIdList></Reference><Reference><Citation>Crab&#xe9; R., Aimond F., Gosset P., Scamps F., Raoul C. How Degeneration of Cells Surrounding Motoneurons Contributes to Amyotrophic Lateral Sclerosis. Cells. 2020;9:2550. doi: 10.3390/cells9122550.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells9122550</ArticleId><ArticleId IdType="pmc">PMC7760029</ArticleId><ArticleId IdType="pubmed">33260927</ArticleId></ArticleIdList></Reference><Reference><Citation>Abramzon Y.A., Fratta P., Traynor B.J., Chia R. The Overlapping Genetics of Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Front. Neurosci. 2020;14:42. doi: 10.3389/fnins.2020.00042.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2020.00042</ArticleId><ArticleId IdType="pmc">PMC7012787</ArticleId><ArticleId IdType="pubmed">32116499</ArticleId></ArticleIdList></Reference><Reference><Citation>Boylan K. Familial Amyotrophic Lateral Sclerosis. Neurol. Clin. 2015;33:807&#x2013;830. doi: 10.1016/j.ncl.2015.07.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ncl.2015.07.001</ArticleId><ArticleId IdType="pmc">PMC4670044</ArticleId><ArticleId IdType="pubmed">26515623</ArticleId></ArticleIdList></Reference><Reference><Citation>Mejzini R., Flynn L.L., Pitout I.L., Fletcher S., Wilton S.D., Akkari P.A. ALS Genetics, Mechanisms, and Therapeutics: Where Are We Now? Front. Neurosci. 2019;13:1310. doi: 10.3389/fnins.2019.01310.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2019.01310</ArticleId><ArticleId IdType="pmc">PMC6909825</ArticleId><ArticleId IdType="pubmed">31866818</ArticleId></ArticleIdList></Reference><Reference><Citation>Shatunov A., Al-Chalabi A. The genetic architecture of ALS. Neurobiol. Dis. 2021;147:105156. doi: 10.1016/j.nbd.2020.105156.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2020.105156</ArticleId><ArticleId IdType="pubmed">33130222</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou Z.-Y., Zhou Z.-R., Che C.-H., Liu C.-Y., He R.-L., Huang H.-P. Genetic epidemiology of amyotrophic lateral sclerosis: A systematic review and meta-analysis. J. Neurol. Neurosurg. Psychiatry. 2017;88:540&#x2013;549. doi: 10.1136/jnnp-2016-315018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2016-315018</ArticleId><ArticleId IdType="pubmed">28057713</ArticleId></ArticleIdList></Reference><Reference><Citation>Shepheard S.R., Parker M.D., Cooper-Knock J., Verber N.S., Tuddenham L., Heath P., Beauchamp N., Place E., Sollars E.S.A., Turner M.R., et al. Value of systematic genetic screening of patients with amyotrophic lateral sclerosis. J. Neurol. Neurosurg. Psychiatry. 2021;92:510&#x2013;518. doi: 10.1136/jnnp-2020-325014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2020-325014</ArticleId><ArticleId IdType="pmc">PMC8053339</ArticleId><ArticleId IdType="pubmed">33589474</ArticleId></ArticleIdList></Reference><Reference><Citation>Schram S., Loeb J.A., Song F. Disease propagation in amyotrophic lateral sclerosis (ALS): An interplay between genetics and environment. J. Neuroinflamm. 2020;17:175. doi: 10.1186/s12974-020-01849-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-020-01849-7</ArticleId><ArticleId IdType="pmc">PMC7276078</ArticleId><ArticleId IdType="pubmed">32505190</ArticleId></ArticleIdList></Reference><Reference><Citation>Grad L.I., Cashman N.R. Prion-like activity of Cu/Zn superoxide dismutase: Implications for amyotrophic lateral sclerosis. Prion. 2014;8:33&#x2013;41. doi: 10.4161/pri.27602.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/pri.27602</ArticleId><ArticleId IdType="pmc">PMC7030911</ArticleId><ArticleId IdType="pubmed">24394345</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Q., Zhou J., Huang C., Huang B., Bi F., Zhou H., Xiao B. Temporal Expression of Mutant TDP-43 Correlates with Early Amyotrophic Lateral Sclerosis Phenotype and Motor Weakness. Curr. Neurovasc. Res. 2018;15:3&#x2013;9. doi: 10.2174/1567202615666180109161541.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1567202615666180109161541</ArticleId><ArticleId IdType="pmc">PMC5997843</ArticleId><ArticleId IdType="pubmed">29313467</ArticleId></ArticleIdList></Reference><Reference><Citation>Kabashi E., Valdmanis P.N., Dion P., Spiegelman D., McConkey B.J., Vande Velde C., Bouchard J.-P., Lacomblez L., Pochigaeva K., Salachas F., et al. TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. Nat. Genet. 2008;40:572&#x2013;574. doi: 10.1038/ng.132.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.132</ArticleId><ArticleId IdType="pubmed">18372902</ArticleId></ArticleIdList></Reference><Reference><Citation>Ederle H., Dormann D. TDP-43 and FUS en route from the nucleus to the cytoplasm. FEBS Lett. 2017;591:1489&#x2013;1507. doi: 10.1002/1873-3468.12646.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/1873-3468.12646</ArticleId><ArticleId IdType="pubmed">28380257</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciryam P., Lambert-Smith I.A., Bean D.M., Freer R., Cid F., Tartaglia G.G., Saunders D.N., Wilson M.R., Oliver S.G., Morimoto R.I., et al. Spinal motor neuron protein supersaturation patterns are associated with inclusion body formation in ALS. Proc. Natl. Acad. Sci. USA. 2017;114:E3935&#x2013;E3943. doi: 10.1073/pnas.1613854114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1613854114</ArticleId><ArticleId IdType="pmc">PMC5441770</ArticleId><ArticleId IdType="pubmed">28396410</ArticleId></ArticleIdList></Reference><Reference><Citation>Wood A., Gurfinkel Y., Polain N., Lamont W., Lyn Rea S. Molecular Mechanisms Underlying TDP-43 Pathology in Cellular and Animal Models of ALS and FTLD. Int. J. Mol. Sci. 2021;22:4705. doi: 10.3390/ijms22094705.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22094705</ArticleId><ArticleId IdType="pmc">PMC8125728</ArticleId><ArticleId IdType="pubmed">33946763</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwiatkowski T.J.J., Bosco D.A., Leclerc A.L., Tamrazian E., Vanderburg C.R., Russ C., Davis A., Gilchrist J., Kasarskis E.J., Munsat T., et al. Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science. 2009;323:1205&#x2013;1208. doi: 10.1126/science.1166066.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1166066</ArticleId><ArticleId IdType="pubmed">19251627</ArticleId></ArticleIdList></Reference><Reference><Citation>Hewitt C., Kirby J., Highley J.R., Hartley J.A., Hibberd R., Hollinger H.C., Williams T.L., Ince P.G., McDermott C.J., Shaw P.J. Novel FUS/TLS mutations and pathology in familial and sporadic amyotrophic lateral sclerosis. Arch. Neurol. 2010;67:455&#x2013;461. doi: 10.1001/archneurol.2010.52.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneurol.2010.52</ArticleId><ArticleId IdType="pubmed">20385912</ArticleId></ArticleIdList></Reference><Reference><Citation>Vance C., Rogelj B., Hortob&#xe1;gyi T., De Vos K.J., Nishimura A.L., Sreedharan J., Hu X., Smith B., Ruddy D., Wright P., et al. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science. 2009;323:1208&#x2013;1211. doi: 10.1126/science.1165942.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1165942</ArticleId><ArticleId IdType="pmc">PMC4516382</ArticleId><ArticleId IdType="pubmed">19251628</ArticleId></ArticleIdList></Reference><Reference><Citation>DeJesus-Hernandez M., Mackenzie I.R., Boeve B.F., Boxer A.L., Baker M., Rutherford N.J., Nicholson A.M., Finch N.A., Flynn H., Adamson J., et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron. 2011;72:245&#x2013;256. doi: 10.1016/j.neuron.2011.09.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2011.09.011</ArticleId><ArticleId IdType="pmc">PMC3202986</ArticleId><ArticleId IdType="pubmed">21944778</ArticleId></ArticleIdList></Reference><Reference><Citation>McGoldrick P., Zhang M., van Blitterswijk M., Sato C., Moreno D., Xiao S., Zhang A.B., McKeever P.M., Weichert A., Schneider R., et al. Unaffected mosaic C9orf72 case: RNA foci, dipeptide proteins, but upregulated C9orf72 expression. Neurology. 2018;90:e323&#x2013;e331. doi: 10.1212/WNL.0000000000004865.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000004865</ArticleId><ArticleId IdType="pmc">PMC5798652</ArticleId><ArticleId IdType="pubmed">29282338</ArticleId></ArticleIdList></Reference><Reference><Citation>Pang W., Hu F. Cellular and physiological functions of C9ORF72 and implications for ALS/FTD. J. Neurochem. 2021;157:334&#x2013;350. doi: 10.1111/jnc.15255.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.15255</ArticleId><ArticleId IdType="pubmed">33259633</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang L., Zhang T., Lu K., Qi S. The progress in C9orf72 research: ALS/FTD pathogenesis, functions and structure. Small GTPases. 2021:1&#x2013;21. doi: 10.1080/21541248.2021.1892443.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21541248.2021.1892443</ArticleId><ArticleId IdType="pubmed">33663328</ArticleId></ArticleIdList></Reference><Reference><Citation>van Blitterswijk M., van Es M.A., Koppers M., van Rheenen W., Medic J., Schelhaas H.J., van der Kooi A.J., de Visser M., Veldink J.H., van den Berg L.H. VAPB and C9orf72 mutations in 1 familial amyotrophic lateral sclerosis patient. Neurobiol. Aging. 2012;33:e1&#x2013;e4. doi: 10.1016/j.neurobiolaging.2012.07.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2012.07.004</ArticleId><ArticleId IdType="pubmed">22878164</ArticleId></ArticleIdList></Reference><Reference><Citation>Gitler A.D., Tsuiji H. There has been an awakening: Emerging mechanisms of C9orf72 mutations in FTD/ALS. Brain Res. 2016;1647:19&#x2013;29. doi: 10.1016/j.brainres.2016.04.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2016.04.004</ArticleId><ArticleId IdType="pmc">PMC5003651</ArticleId><ArticleId IdType="pubmed">27059391</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Gall L., Anakor E., Connolly O., Vijayakumar U.G., Duddy W.J., Duguez S. Molecular and Cellular Mechanisms Affected in ALS. J. Pers. Med. 2020;10:101. doi: 10.3390/jpm10030101.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jpm10030101</ArticleId><ArticleId IdType="pmc">PMC7564998</ArticleId><ArticleId IdType="pubmed">32854276</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruijn L.I., Beal M.F., Becher M.W., Schulz J.B., Wong P.C., Price D.L., Cleveland D.W. Elevated free nitrotyrosine levels, but not protein-bound nitrotyrosine or hydroxyl radicals, throughout amyotrophic lateral sclerosis (ALS)-like disease implicate tyrosine nitration as an aberrant in vivo property of one familial ALS-linked superoxide d. Proc. Natl. Acad. Sci. USA. 1997;94:7606&#x2013;7611. doi: 10.1073/pnas.94.14.7606.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.94.14.7606</ArticleId><ArticleId IdType="pmc">PMC23869</ArticleId><ArticleId IdType="pubmed">9207139</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruijn L.I., Becher M.W., Lee M.K., Anderson K.L., Jenkins N.A., Copeland N.G., Sisodia S.S., Rothstein J.D., Borchelt D.R., Price D.L., et al. ALS-linked SOD1 mutant G85R mediates damage to astrocytes and promotes rapidly progressive disease with SOD1-containing inclusions. Neuron. 1997;18:327&#x2013;338. doi: 10.1016/S0896-6273(00)80272-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0896-6273(00)80272-X</ArticleId><ArticleId IdType="pubmed">9052802</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen D.R., Siddique T., Patterson D., Figlewicz D.A., Sapp P., Hentati A., Donaldson D., Goto J., O&#x2019;Regan J.P., Deng H.X. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 1993;362:59&#x2013;62. doi: 10.1038/362059a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/362059a0</ArticleId><ArticleId IdType="pubmed">8446170</ArticleId></ArticleIdList></Reference><Reference><Citation>Ezzi S.A., Urushitani M., Julien J.-P. Wild-type superoxide dismutase acquires binding and toxic properties of ALS-linked mutant forms through oxidation. J. Neurochem. 2007;102:170&#x2013;178. doi: 10.1111/j.1471-4159.2007.04531.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2007.04531.x</ArticleId><ArticleId IdType="pubmed">17394546</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen K., Bennett S.A., Rana N., Yousuf H., Said M., Taaseen S., Mendo N., Meltser S.M., Torrente M.P. Neurodegenerative Disease Proteinopathies Are Connected to Distinct Histone Post-translational Modification Landscapes. ACS Chem. Neurosci. 2018;9:938&#x2013;948. doi: 10.1021/acschemneuro.7b00297.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acschemneuro.7b00297</ArticleId><ArticleId IdType="pmc">PMC5906139</ArticleId><ArticleId IdType="pubmed">29243911</ArticleId></ArticleIdList></Reference><Reference><Citation>Jhanji R., Behl T., Sehgal A., Bungau S. Mitochondrial dysfunction and traffic jams in amyotrophic lateral sclerosis. Mitochondrion. 2021;58:102&#x2013;110. doi: 10.1016/j.mito.2021.02.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mito.2021.02.008</ArticleId><ArticleId IdType="pubmed">33639271</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y.-J., Tsai P.-Y., Chern Y. Energy Homeostasis and Abnormal RNA Metabolism in Amyotrophic Lateral Sclerosis. Front. Cell. Neurosci. 2017;11:126. doi: 10.3389/fncel.2017.00126.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2017.00126</ArticleId><ArticleId IdType="pmc">PMC5415567</ArticleId><ArticleId IdType="pubmed">28522961</ArticleId></ArticleIdList></Reference><Reference><Citation>Piancone F., La Rosa F., Marventano I., Saresella M., Clerici M. The Role of the Inflammasome in Neurodegenerative Diseases. Molecules. 2021;26:953. doi: 10.3390/molecules26040953.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules26040953</ArticleId><ArticleId IdType="pmc">PMC7916884</ArticleId><ArticleId IdType="pubmed">33670164</ArticleId></ArticleIdList></Reference><Reference><Citation>Leblond C.S., Kaneb H.M., Dion P.A., Rouleau G.A. Dissection of genetic factors associated with amyotrophic lateral sclerosis. Exp. Neurol. 2014;262:91&#x2013;101. doi: 10.1016/j.expneurol.2014.04.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2014.04.013</ArticleId><ArticleId IdType="pubmed">24780888</ArticleId></ArticleIdList></Reference><Reference><Citation>Chia R., Chi&#xf2; A., Traynor B.J. Novel genes associated with amyotrophic lateral sclerosis: Diagnostic and clinical implications. Lancet. Neurol. 2018;17:94&#x2013;102. doi: 10.1016/S1474-4422(17)30401-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(17)30401-5</ArticleId><ArticleId IdType="pmc">PMC5901717</ArticleId><ArticleId IdType="pubmed">29154141</ArticleId></ArticleIdList></Reference><Reference><Citation>Spencer P.S., Lagrange E., Camu W. ALS and environment: Clues from spatial clustering? Rev. Neurol. 2019;175:652&#x2013;663. doi: 10.1016/j.neurol.2019.04.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurol.2019.04.007</ArticleId><ArticleId IdType="pubmed">31230725</ArticleId></ArticleIdList></Reference><Reference><Citation>Babin P.J., Goizet C., Rald&#xfa;a D. Zebrafish models of human motor neuron diseases: Advantages and limitations. Prog. Neurobiol. 2014;118:36&#x2013;58. doi: 10.1016/j.pneurobio.2014.03.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pneurobio.2014.03.001</ArticleId><ArticleId IdType="pubmed">24705136</ArticleId></ArticleIdList></Reference><Reference><Citation>Philips T., Rothstein J.D. Rodent Models of Amyotrophic Lateral Sclerosis. Curr. Protoc. Pharmacol. 2015;69:5.67.1&#x2013;5.67.21. doi: 10.1002/0471141755.ph0567s69.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/0471141755.ph0567s69</ArticleId><ArticleId IdType="pmc">PMC4562058</ArticleId><ArticleId IdType="pubmed">26344214</ArticleId></ArticleIdList></Reference><Reference><Citation>Lutz C. Mouse models of ALS: Past, present and future. Brain Res. 2018;1693:1&#x2013;10. doi: 10.1016/j.brainres.2018.03.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2018.03.024</ArticleId><ArticleId IdType="pubmed">29577886</ArticleId></ArticleIdList></Reference><Reference><Citation>Liguori F., Amadio S., Volont&#xe9; C. Where and Why Modeling Amyotrophic Lateral Sclerosis. Int. J. Mol. Sci. 2021;22:3977. doi: 10.3390/ijms22083977.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22083977</ArticleId><ArticleId IdType="pmc">PMC8070525</ArticleId><ArticleId IdType="pubmed">33921446</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Chalabi A., van den Berg L.H., Veldink J. Gene discovery in amyotrophic lateral sclerosis: Implications for clinical management. Nat. Rev. Neurol. 2017;13:96&#x2013;104. doi: 10.1038/nrneurol.2016.182.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2016.182</ArticleId><ArticleId IdType="pubmed">27982040</ArticleId></ArticleIdList></Reference><Reference><Citation>Venkova-Hristova K., Christov A., Kamaluddin Z., Kobalka P., Hensley K. Progress in therapy development for amyotrophic lateral sclerosis. Neurol. Res. Int. 2012;2012:187234.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3399448</ArticleId><ArticleId IdType="pubmed">22830014</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou Y.-H., Guan P.-P., Zhang S.-Q., Guo Y.-S., Wang P. Rofecoxib Attenuates the Pathogenesis of Amyotrophic Lateral Sclerosis by Alleviating Cyclooxygenase-2-Mediated Mechanisms. Front. Neurosci. 2020;14:817. doi: 10.3389/fnins.2020.00817.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2020.00817</ArticleId><ArticleId IdType="pmc">PMC7438558</ArticleId><ArticleId IdType="pubmed">32903591</ArticleId></ArticleIdList></Reference><Reference><Citation>Medina D.X., Chung E.P., Teague C.D., Bowser R., Sirianni R.W. Intravenously Administered, Retinoid Activating Nanoparticles Increase Lifespan and Reduce Neurodegeneration in the SOD1(G93A) Mouse Model of ALS. Front. Bioeng. Biotechnol. 2020;8:224. doi: 10.3389/fbioe.2020.00224.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fbioe.2020.00224</ArticleId><ArticleId IdType="pmc">PMC7118553</ArticleId><ArticleId IdType="pubmed">32292776</ArticleId></ArticleIdList></Reference><Reference><Citation>Traynor B.J., Bruijn L., Conwit R., Beal F., O&#x2019;Neill G., Fagan S.C., Cudkowicz M.E. Neuroprotective agents for clinical trials in ALS: A systematic assessment. Neurology. 2006;67:20&#x2013;27. doi: 10.1212/01.wnl.0000223353.34006.54.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000223353.34006.54</ArticleId><ArticleId IdType="pubmed">16832072</ArticleId></ArticleIdList></Reference><Reference><Citation>Ito H., Wate R., Zhang J., Ohnishi S., Kaneko S., Ito H., Nakano S., Kusaka H. Treatment with edaravone, initiated at symptom onset, slows motor decline and decreases SOD1 deposition in ALS mice. Exp. Neurol. 2008;213:448&#x2013;455. doi: 10.1016/j.expneurol.2008.07.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2008.07.017</ArticleId><ArticleId IdType="pubmed">18718468</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurney M.E., Pu H., Chiu A.Y., Dal Canto M.C., Polchow C.Y., Alexander D.D., Caliendo J., Hentati A., Kwon Y.W., Deng H.X. Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science. 1994;264:1772&#x2013;1775. doi: 10.1126/science.8209258.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.8209258</ArticleId><ArticleId IdType="pubmed">8209258</ArticleId></ArticleIdList></Reference><Reference><Citation>McCombe P.A., Henderson R.D. Effects of gender in amyotrophic lateral sclerosis. Gend. Med. 2010;7:557&#x2013;570. doi: 10.1016/j.genm.2010.11.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.genm.2010.11.010</ArticleId><ArticleId IdType="pubmed">21195356</ArticleId></ArticleIdList></Reference><Reference><Citation>Bame M., Pentiak P.A., Needleman R., Brusilow W.S.A. Effect of sex on lifespan, disease progression, and the response to methionine sulfoximine in the SOD1 G93A mouse model for ALS. Gend. Med. 2012;9:524&#x2013;535. doi: 10.1016/j.genm.2012.10.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.genm.2012.10.014</ArticleId><ArticleId IdType="pubmed">23217569</ArticleId></ArticleIdList></Reference><Reference><Citation>Heiman-Patterson T.D., Sher R.B., Blankenhorn E.A., Alexander G., Deitch J.S., Kunst C.B., Maragakis N., Cox G. Effect of genetic background on phenotype variability in transgenic mouse models of amyotrophic lateral sclerosis: A window of opportunity in the search for genetic modifiers. Amyotroph. Lateral Scler. Off. Publ. World Fed. Neurol. Res. Gr. Mot. Neuron Dis. 2011;12:79&#x2013;86. doi: 10.3109/17482968.2010.550626.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482968.2010.550626</ArticleId><ArticleId IdType="pubmed">21241159</ArticleId></ArticleIdList></Reference><Reference><Citation>Marino M., Papa S., Crippa V., Nardo G., Peviani M., Cheroni C., Trolese M.C., Lauranzano E., Bonetto V., Poletti A., et al. Differences in protein quality control correlate with phenotype variability in 2 mouse models of familial amyotrophic lateral sclerosis. Neurobiol. Aging. 2015;36:492&#x2013;504. doi: 10.1016/j.neurobiolaging.2014.06.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2014.06.026</ArticleId><ArticleId IdType="pubmed">25085783</ArticleId></ArticleIdList></Reference><Reference><Citation>Joyce P.I., Fratta P., Fisher E.M.C., Acevedo-Arozena A. SOD1 and TDP-43 animal models of amyotrophic lateral sclerosis: Recent advances in understanding disease toward the development of clinical treatments. Mamm. Genome. 2011;22:420&#x2013;448. doi: 10.1007/s00335-011-9339-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00335-011-9339-1</ArticleId><ArticleId IdType="pubmed">21706386</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong P.C., Pardo C.A., Borchelt D.R., Lee M.K., Copeland N.G., Jenkins N.A., Sisodia S.S., Cleveland D.W., Price D.L. An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria. Neuron. 1995;14:1105&#x2013;1116. doi: 10.1016/0896-6273(95)90259-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0896-6273(95)90259-7</ArticleId><ArticleId IdType="pubmed">7605627</ArticleId></ArticleIdList></Reference><Reference><Citation>Ripps M.E., Huntley G.W., Hof P.R., Morrison J.H., Gordon J.W. Transgenic mice expressing an altered murine superoxide dismutase gene provide an animal model of amyotrophic lateral sclerosis. Proc. Natl. Acad. Sci. USA. 1995;92:689&#x2013;693. doi: 10.1073/pnas.92.3.689.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.92.3.689</ArticleId><ArticleId IdType="pmc">PMC42685</ArticleId><ArticleId IdType="pubmed">7846037</ArticleId></ArticleIdList></Reference><Reference><Citation>Howland D.S., Liu J., She Y., Goad B., Maragakis N.J., Kim B., Erickson J., Kulik J., DeVito L., Psaltis G., et al. Focal loss of the glutamate transporter EAAT2 in a transgenic rat model of SOD1 mutant-mediated amyotrophic lateral sclerosis (ALS) Proc. Natl. Acad. Sci. USA. 2002;99:1604&#x2013;1609. doi: 10.1073/pnas.032539299.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.032539299</ArticleId><ArticleId IdType="pmc">PMC122237</ArticleId><ArticleId IdType="pubmed">11818550</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanagi T., Yuasa S., Nakamura Y., Suzuki E., Aoki M., Warita H., Itoyama Y., Uchino S., Kohsaka S., Ohsawa K. Appearance of phagocytic microglia adjacent to motoneurons in spinal cord tissue from a presymptomatic transgenic rat model of amyotrophic lateral sclerosis. J. Neurosci. Res. 2010;88:2736&#x2013;2746. doi: 10.1002/jnr.22424.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jnr.22424</ArticleId><ArticleId IdType="pubmed">20648658</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagai M., Aoki M., Miyoshi I., Kato M., Pasinelli P., Kasai N., Brown R.H.J., Itoyama Y. Rats expressing human cytosolic copper-zinc superoxide dismutase transgenes with amyotrophic lateral sclerosis: Associated mutations develop motor neuron disease. J. Neurosci. 2001;21:9246&#x2013;9254. doi: 10.1523/JNEUROSCI.21-23-09246.2001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.21-23-09246.2001</ArticleId><ArticleId IdType="pmc">PMC6763929</ArticleId><ArticleId IdType="pubmed">11717358</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M., Sampathu D.M., Kwong L.K., Truax A.C., Micsenyi M.C., Chou T.T., Bruce J., Schuck T., Grossman M., Clark C.M., et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314:130&#x2013;133. doi: 10.1126/science.1134108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1134108</ArticleId><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>De Giorgio F., Maduro C., Fisher E.M.C., Acevedo-Arozena A. Transgenic and physiological mouse models give insights into different aspects of amyotrophic lateral sclerosis. Dis. Model. Mech. 2019;12:dmm037424. doi: 10.1242/dmm.037424.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/dmm.037424</ArticleId><ArticleId IdType="pmc">PMC6361152</ArticleId><ArticleId IdType="pubmed">30626575</ArticleId></ArticleIdList></Reference><Reference><Citation>Wegorzewska I., Bell S., Cairns N.J., Miller T.M., Baloh R.H. TDP-43 mutant transgenic mice develop features of ALS and frontotemporal lobar degeneration. Proc. Natl. Acad. Sci. USA. 2009;106:18809&#x2013;18814. doi: 10.1073/pnas.0908767106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0908767106</ArticleId><ArticleId IdType="pmc">PMC2762420</ArticleId><ArticleId IdType="pubmed">19833869</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Y.-F., Gendron T.F., Zhang Y.-J., Lin W.-L., D&#x2019;Alton S., Sheng H., Casey M.C., Tong J., Knight J., Yu X., et al. Wild-type human TDP-43 expression causes TDP-43 phosphorylation, mitochondrial aggregation, motor deficits, and early mortality in transgenic mice. J. Neurosci. 2010;30:10851&#x2013;10859. doi: 10.1523/JNEUROSCI.1630-10.2010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1630-10.2010</ArticleId><ArticleId IdType="pmc">PMC3056148</ArticleId><ArticleId IdType="pubmed">20702714</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Y.-F., Zhang Y.-J., Lin W.-L., Cao X., Stetler C., Dickson D.W., Lewis J., Petrucelli L. Expression of mutant TDP-43 induces neuronal dysfunction in transgenic mice. Mol. Neurodegener. 2011;6:73. doi: 10.1186/1750-1326-6-73.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1750-1326-6-73</ArticleId><ArticleId IdType="pmc">PMC3216869</ArticleId><ArticleId IdType="pubmed">22029574</ArticleId></ArticleIdList></Reference><Reference><Citation>Stallings N.R., Puttaparthi K., Luther C.M., Burns D.K., Elliott J.L. Progressive motor weakness in transgenic mice expressing human TDP-43. Neurobiol. Dis. 2010;40:404&#x2013;414. doi: 10.1016/j.nbd.2010.06.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2010.06.017</ArticleId><ArticleId IdType="pubmed">20621187</ArticleId></ArticleIdList></Reference><Reference><Citation>Wils H., Kleinberger G., Janssens J., Pereson S., Joris G., Cuijt I., Smits V., Ceuterick-de Groote C., Van Broeckhoven C., Kumar-Singh S. TDP-43 transgenic mice develop spastic paralysis and neuronal inclusions characteristic of ALS and frontotemporal lobar degeneration. Proc. Natl. Acad. Sci. USA. 2010;107:3858&#x2013;3863. doi: 10.1073/pnas.0912417107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0912417107</ArticleId><ArticleId IdType="pmc">PMC2840518</ArticleId><ArticleId IdType="pubmed">20133711</ArticleId></ArticleIdList></Reference><Reference><Citation>Shan X., Chiang P.-M., Price D.L., Wong P.C. Altered distributions of Gemini of coiled bodies and mitochondria in motor neurons of TDP-43 transgenic mice. Proc. Natl. Acad. Sci. USA. 2010;107:16325&#x2013;16330. doi: 10.1073/pnas.1003459107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1003459107</ArticleId><ArticleId IdType="pmc">PMC2941282</ArticleId><ArticleId IdType="pubmed">20736350</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold E.S., Ling S.-C., Huelga S.C., Lagier-Tourenne C., Polymenidou M., Ditsworth D., Kordasiewicz H.B., McAlonis-Downes M., Platoshyn O., Parone P.A., et al. ALS-linked TDP-43 mutations produce aberrant RNA splicing and adult-onset motor neuron disease without aggregation or loss of nuclear TDP-43. Proc. Natl. Acad. Sci. USA. 2013;110:E736&#x2013;E745. doi: 10.1073/pnas.1222809110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1222809110</ArticleId><ArticleId IdType="pmc">PMC3581922</ArticleId><ArticleId IdType="pubmed">23382207</ArticleId></ArticleIdList></Reference><Reference><Citation>Stribl C., Samara A., Tr&#xfc;mbach D., Peis R., Neumann M., Fuchs H., Gailus-Durner V., Hrab&#x11b; de Angelis M., Rathkolb B., Wolf E., et al. Mitochondrial dysfunction and decrease in body weight of a transgenic knock-in mouse model for TDP-43. J. Biol. Chem. 2014;289:10769&#x2013;10784. doi: 10.1074/jbc.M113.515940.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M113.515940</ArticleId><ArticleId IdType="pmc">PMC4036193</ArticleId><ArticleId IdType="pubmed">24515116</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitchell J.C., Constable R., So E., Vance C., Scotter E., Glover L., Hortobagyi T., Arnold E.S., Ling S.-C., McAlonis M., et al. Wild type human TDP-43 potentiates ALS-linked mutant TDP-43 driven progressive motor and cortical neuron degeneration with pathological features of ALS. Acta Neuropathol. Commun. 2015;3:36. doi: 10.1186/s40478-015-0212-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-015-0212-4</ArticleId><ArticleId IdType="pmc">PMC4479086</ArticleId><ArticleId IdType="pubmed">26108367</ArticleId></ArticleIdList></Reference><Reference><Citation>Morrice J.R., Gregory-Evans C.Y., Shaw C.A. Animal models of amyotrophic lateral sclerosis: A comparison of model validity. Neural Regen. Res. 2018;13:2050&#x2013;2054.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6199948</ArticleId><ArticleId IdType="pubmed">30323119</ArticleId></ArticleIdList></Reference><Reference><Citation>Swarup V., Phaneuf D., Bareil C., Robertson J., Rouleau G.A., Kriz J., Julien J.-P. Pathological hallmarks of amyotrophic lateral sclerosis/frontotemporal lobar degeneration in transgenic mice produced with TDP-43 genomic fragments. Brain. 2011;134:2610&#x2013;2626. doi: 10.1093/brain/awr159.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awr159</ArticleId><ArticleId IdType="pubmed">21752789</ArticleId></ArticleIdList></Reference><Reference><Citation>Igaz L.M., Kwong L.K., Lee E.B., Chen-Plotkin A., Swanson E., Unger T., Malunda J., Xu Y., Winton M.J., Trojanowski J.Q., et al. Dysregulation of the ALS-associated gene TDP-43 leads to neuronal death and degeneration in mice. J. Clin. Investig. 2011;121:726&#x2013;738. doi: 10.1172/JCI44867.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI44867</ArticleId><ArticleId IdType="pmc">PMC3026736</ArticleId><ArticleId IdType="pubmed">21206091</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker A.K., Spiller K.J., Ge G., Zheng A., Xu Y., Zhou M., Tripathy K., Kwong L.K., Trojanowski J.Q., Lee V.M.-Y. Functional recovery in new mouse models of ALS/FTLD after clearance of pathological cytoplasmic TDP-43. Acta Neuropathol. 2015;130:643&#x2013;660. doi: 10.1007/s00401-015-1460-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-015-1460-x</ArticleId><ArticleId IdType="pmc">PMC5127391</ArticleId><ArticleId IdType="pubmed">26197969</ArticleId></ArticleIdList></Reference><Reference><Citation>Fratta P., Sivakumar P., Humphrey J., Lo K., Ricketts T., Oliveira H., Brito-Armas J.M., Kalmar B., Ule A., Yu Y., et al. Mice with endogenous TDP-43 mutations exhibit gain of splicing function and characteristics of amyotrophic lateral sclerosis. EMBO J. 2018;37:37. doi: 10.15252/embj.201798684.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embj.201798684</ArticleId><ArticleId IdType="pmc">PMC5983119</ArticleId><ArticleId IdType="pubmed">29764981</ArticleId></ArticleIdList></Reference><Reference><Citation>Bendotti C., Bonetto V., Pupillo E., Logroscino G., Al-Chalabi A., Lunetta C., Riva N., Mora G., Lauria G., Weishaupt J.H., et al. Focus on the heterogeneity of amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Front. Degener. 2020;21:485&#x2013;495. doi: 10.1080/21678421.2020.1779298.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2020.1779298</ArticleId><ArticleId IdType="pubmed">32583689</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou H., Huang C., Chen H., Wang D., Landel C.P., Xia P.Y., Bowser R., Liu Y.-J., Xia X.G. Transgenic rat model of neurodegeneration caused by mutation in the TDP gene. PLoS Genet. 2010;6:e1000887. doi: 10.1371/journal.pgen.1000887.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pgen.1000887</ArticleId><ArticleId IdType="pmc">PMC2845661</ArticleId><ArticleId IdType="pubmed">20361056</ArticleId></ArticleIdList></Reference><Reference><Citation>Lagier-Tourenne C., Cleveland D.W. Rethinking ALS: The FUS about TDP-43. Cell. 2009;136:1001&#x2013;1004. doi: 10.1016/j.cell.2009.03.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2009.03.006</ArticleId><ArticleId IdType="pmc">PMC3110083</ArticleId><ArticleId IdType="pubmed">19303844</ArticleId></ArticleIdList></Reference><Reference><Citation>Nolan M., Talbot K., Ansorge O. Pathogenesis of FUS-associated ALS and FTD: Insights from rodent models. Acta Neuropathol. Commun. 2016;4:99. doi: 10.1186/s40478-016-0358-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-016-0358-8</ArticleId><ArticleId IdType="pmc">PMC5011941</ArticleId><ArticleId IdType="pubmed">27600654</ArticleId></ArticleIdList></Reference><Reference><Citation>Kino Y., Washizu C., Kurosawa M., Yamada M., Miyazaki H., Akagi T., Hashikawa T., Doi H., Takumi T., Hicks G.G., et al. FUS/TLS deficiency causes behavioral and pathological abnormalities distinct from amyotrophic lateral sclerosis. Acta Neuropathol. Commun. 2015;3:24. doi: 10.1186/s40478-015-0202-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-015-0202-6</ArticleId><ArticleId IdType="pmc">PMC4408580</ArticleId><ArticleId IdType="pubmed">25907258</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma A., Lyashchenko A.K., Lu L., Nasrabady S.E., Elmaleh M., Mendelsohn M., Nemes A., Tapia J.C., Mentis G.Z., Shneider N.A. ALS-associated mutant FUS induces selective motor neuron degeneration through toxic gain of function. Nat. Commun. 2016;7:10465. doi: 10.1038/ncomms10465.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms10465</ArticleId><ArticleId IdType="pmc">PMC4742863</ArticleId><ArticleId IdType="pubmed">26842965</ArticleId></ArticleIdList></Reference><Reference><Citation>Scekic-Zahirovic J., Oussini H.E.l., Mersmann S., Drenner K., Wagner M., Sun Y., Allmeroth K., Dieterl&#xe9; S., Sinniger J., Dirrig-Grosch S., et al. Motor neuron intrinsic and extrinsic mechanisms contribute to the pathogenesis of FUS-associated amyotrophic lateral sclerosis. Acta Neuropathol. 2017;133:887&#x2013;906. doi: 10.1007/s00401-017-1687-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-017-1687-9</ArticleId><ArticleId IdType="pmc">PMC5427169</ArticleId><ArticleId IdType="pubmed">28243725</ArticleId></ArticleIdList></Reference><Reference><Citation>Soo K.Y., Halloran M., Sundaramoorthy V., Parakh S., Toth R.P., Southam K.A., McLean C.A., Lock P., King A., Farg M.A., et al. Rab1-dependent ER-Golgi transport dysfunction is a common pathogenic mechanism in SOD1, TDP-43 and FUS-associated ALS. Acta Neuropathol. 2015;130:679&#x2013;697. doi: 10.1007/s00401-015-1468-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-015-1468-2</ArticleId><ArticleId IdType="pubmed">26298469</ArticleId></ArticleIdList></Reference><Reference><Citation>De&#x12d;kin A.V., Kovrazhkina E.A., Ovchinnikov R.K., Bronovitski&#x12d; E.V., Razinskaia O.D., Smirnov A.P., Ermolkevich T.G., Eliakov A.B., Popov A.N., Fedorov E.N., et al. A mice model of amyotrophic lateral sclerosis expressing mutant human FUS protein. Zhurnal Nevrol. 2014;114:62&#x2013;69.</Citation><ArticleIdList><ArticleId IdType="pubmed">25345633</ArticleId></ArticleIdList></Reference><Reference><Citation>Devoy A., Kalmar B., Stewart M., Park H., Burke B., Noy S.J., Redhead Y., Humphrey J., Lo K., Jaeger J., et al. Humanized mutant FUS drives progressive motor neuron degeneration without aggregation in &#x201c;FUSDelta14&#x201d; knockin mice. Brain. 2017;140:2797&#x2013;2805. doi: 10.1093/brain/awx248.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awx248</ArticleId><ArticleId IdType="pmc">PMC5841203</ArticleId><ArticleId IdType="pubmed">29053787</ArticleId></ArticleIdList></Reference><Reference><Citation>Shelkovnikova T.A., Peters O.M., Deykin A.V., Connor-Robson N., Robinson H., Ustyugov A.A., Bachurin S.O., Ermolkevich T.G., Goldman I.L., Sadchikova E.R., et al. Fused in sarcoma (FUS) protein lacking nuclear localization signal (NLS) and major RNA binding motifs triggers proteinopathy and severe motor phenotype in transgenic mice. J. Biol. Chem. 2013;288:25266&#x2013;25274. doi: 10.1074/jbc.M113.492017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M113.492017</ArticleId><ArticleId IdType="pmc">PMC3757190</ArticleId><ArticleId IdType="pubmed">23867462</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitchell J.C., McGoldrick P., Vance C., Hortobagyi T., Sreedharan J., Rogelj B., Tudor E.L., Smith B.N., Klasen C., Miller C.C.J., et al. Overexpression of human wild-type FUS causes progressive motor neuron degeneration in an age- and dose-dependent fashion. Acta Neuropathol. 2013;125:273&#x2013;288. doi: 10.1007/s00401-012-1043-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-012-1043-z</ArticleId><ArticleId IdType="pmc">PMC3549237</ArticleId><ArticleId IdType="pubmed">22961620</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu H., Lee S., Shang Y., Wang W.-Y., Au K.F., Kamiya S., Barmada S.J., Finkbeiner S., Lui H., Carlton C.E., et al. ALS-associated mutation FUS-R521C causes DNA damage and RNA splicing defects. J. Clin. Investig. 2014;124:981&#x2013;999. doi: 10.1172/JCI72723.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI72723</ArticleId><ArticleId IdType="pmc">PMC3938263</ArticleId><ArticleId IdType="pubmed">24509083</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson K.L., Dhaibar H.A., Dayton R.D., Cananzi S.G., Mayhan W.G., Glasscock E., Klein R.L. Severe respiratory changes at end stage in a FUS-induced disease state in adult rats. BMC Neurosci. 2016;17:69. doi: 10.1186/s12868-016-0304-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12868-016-0304-5</ArticleId><ArticleId IdType="pmc">PMC5086065</ArticleId><ArticleId IdType="pubmed">27793099</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C., Zhou H., Tong J., Chen H., Liu Y.-J., Wang D., Wei X., Xia X.-G. FUS transgenic rats develop the phenotypes of amyotrophic lateral sclerosis and frontotemporal lobar degeneration. PLoS Genet. 2011;7:e1002011. doi: 10.1371/journal.pgen.1002011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pgen.1002011</ArticleId><ArticleId IdType="pmc">PMC3048370</ArticleId><ArticleId IdType="pubmed">21408206</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton A.E., Majounie E., Waite A., Sim&#xf3;n-S&#xe1;nchez J., Rollinson S., Gibbs J.R., Schymick J.C., Laaksovirta H., van Swieten J.C., Myllykangas L., et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron. 2011;72:257&#x2013;268. doi: 10.1016/j.neuron.2011.09.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2011.09.010</ArticleId><ArticleId IdType="pmc">PMC3200438</ArticleId><ArticleId IdType="pubmed">21944779</ArticleId></ArticleIdList></Reference><Reference><Citation>Tabet R., Schaeffer L., Freyermuth F., Jambeau M., Workman M., Lee C.-Z., Lin C.-C., Jiang J., Jansen-West K., Abou-Hamdan H., et al. CUG initiation and frameshifting enable production of dipeptide repeat proteins from ALS/FTD C9ORF72 transcripts. Nat. Commun. 2018;9:152. doi: 10.1038/s41467-017-02643-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-017-02643-5</ArticleId><ArticleId IdType="pmc">PMC5764992</ArticleId><ArticleId IdType="pubmed">29323119</ArticleId></ArticleIdList></Reference><Reference><Citation>Smeyers J., Banchi E.-G., Latouche M. C9ORF72: What It Is, What It Does, and Why It Matters. Front. Cell. Neurosci. 2021;15:661447. doi: 10.3389/fncel.2021.661447.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2021.661447</ArticleId><ArticleId IdType="pmc">PMC8131521</ArticleId><ArticleId IdType="pubmed">34025358</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Z., Poidevin M., Li X., Li Y., Shu L., Nelson D.L., Li H., Hales C.M., Gearing M., Wingo T.S., et al. Expanded GGGGCC repeat RNA associated with amyotrophic lateral sclerosis and frontotemporal dementia causes neurodegeneration. Proc. Natl. Acad. Sci. USA. 2013;110:7778&#x2013;7783. doi: 10.1073/pnas.1219643110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1219643110</ArticleId><ArticleId IdType="pmc">PMC3651485</ArticleId><ArticleId IdType="pubmed">23553836</ArticleId></ArticleIdList></Reference><Reference><Citation>Herranz-Martin S., Chandran J., Lewis K., Mulcahy P., Higginbottom A., Walker C., Valenzuela I.M.-P.Y., Jones R.A., Coldicott I., Iannitti T., et al. Viral delivery of C9orf72 hexanucleotide repeat expansions in mice leads to repeat-length-dependent neuropathology and behavioural deficits. Dis. Model. Mech. 2017;10:859&#x2013;868.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5536911</ArticleId><ArticleId IdType="pubmed">28550099</ArticleId></ArticleIdList></Reference><Reference><Citation>Chew J., Gendron T.F., Prudencio M., Sasaguri H., Zhang Y.-J., Castanedes-Casey M., Lee C.W., Jansen-West K., Kurti A., Murray M.E., et al. Neurodegeneration. C9ORF72 repeat expansions in mice cause TDP-43 pathology, neuronal loss, and behavioral deficits. Science. 2015;348:1151&#x2013;1154. doi: 10.1126/science.aaa9344.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aaa9344</ArticleId><ArticleId IdType="pmc">PMC4692360</ArticleId><ArticleId IdType="pubmed">25977373</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y., Pattamatta A., Zu T., Reid T., Bardhi O., Borchelt D.R., Yachnis A.T., Ranum L.P.W. C9orf72 BAC Mouse Model with Motor Deficits and Neurodegenerative Features of ALS/FTD. Neuron. 2016;90:521&#x2013;534. doi: 10.1016/j.neuron.2016.04.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2016.04.005</ArticleId><ArticleId IdType="pubmed">27112499</ArticleId></ArticleIdList></Reference><Reference><Citation>Schludi M.H., Becker L., Garrett L., Gendron T.F., Zhou Q., Schreiber F., Popper B., Dimou L., Strom T.M., Winkelmann J., et al. Spinal poly-GA inclusions in a C9orf72 mouse model trigger motor deficits and inflammation without neuron loss. Acta Neuropathol. 2017;134:241&#x2013;254. doi: 10.1007/s00401-017-1711-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-017-1711-0</ArticleId><ArticleId IdType="pmc">PMC5508040</ArticleId><ArticleId IdType="pubmed">28409281</ArticleId></ArticleIdList></Reference><Reference><Citation>Koppers M., Blokhuis A.M., Westeneng H.-J., Terpstra M.L., Zundel C.A.C., Vieira de S&#xe1; R., Schellevis R.D., Waite A.J., Blake D.J., Veldink J.H., et al. C9orf72 ablation in mice does not cause motor neuron degeneration or motor deficits. Ann. Neurol. 2015;78:426&#x2013;438. doi: 10.1002/ana.24453.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24453</ArticleId><ArticleId IdType="pmc">PMC4744979</ArticleId><ArticleId IdType="pubmed">26044557</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Rourke J.G., Bogdanik L., Y&#xe1;&#xf1;ez A., Lall D., Wolf A.J., Muhammad A.K.M.G., Ho R., Carmona S., Vit J.P., Zarrow J., et al. C9orf72 is required for proper macrophage and microglial function in mice. Science. 2016;351:1324&#x2013;1329. doi: 10.1126/science.aaf1064.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aaf1064</ArticleId><ArticleId IdType="pmc">PMC5120541</ArticleId><ArticleId IdType="pubmed">26989253</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang J., Zhu Q., Gendron T.F., Saberi S., McAlonis-Downes M., Seelman A., Stauffer J.E., Jafar-Nejad P., Drenner K., Schulte D., et al. Gain of Toxicity from ALS/FTD-Linked Repeat Expansions in C9ORF72 Is Alleviated by Antisense Oligonucleotides Targeting GGGGCC-Containing RNAs. Neuron. 2016;90:535&#x2013;550. doi: 10.1016/j.neuron.2016.04.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2016.04.006</ArticleId><ArticleId IdType="pmc">PMC4860075</ArticleId><ArticleId IdType="pubmed">27112497</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickinson M.E., Flenniken A.M., Ji X., Teboul L., Wong M.D., White J.K., Meehan T.F., Weninger W.J., Westerberg H., Adissu H., et al. High-throughput discovery of novel developmental phenotypes. Nature. 2016;537:508&#x2013;514. doi: 10.1038/nature19356.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature19356</ArticleId><ArticleId IdType="pmc">PMC5295821</ArticleId><ArticleId IdType="pubmed">27626380</ArticleId></ArticleIdList></Reference><Reference><Citation>Burberry A., Suzuki N., Wang J.-Y., Moccia R., Mordes D.A., Stewart M.H., Suzuki-Uematsu S., Ghosh S., Singh A., Merkle F.T., et al. Loss-of-function mutations in the C9ORF72 mouse ortholog cause fatal autoimmune disease. Sci. Transl. Med. 2016;8:347ra93. doi: 10.1126/scitranslmed.aaf6038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aaf6038</ArticleId><ArticleId IdType="pmc">PMC5024536</ArticleId><ArticleId IdType="pubmed">27412785</ArticleId></ArticleIdList></Reference><Reference><Citation>Atanasio A., Decman V., White D., Ramos M., Ikiz B., Lee H.-C., Siao C.-J., Brydges S., LaRosa E., Bai Y., et al. C9orf72 ablation causes immune dysregulation characterized by leukocyte expansion, autoantibody production, and glomerulonephropathy in mice. Sci. Rep. 2016;6:23204. doi: 10.1038/srep23204.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep23204</ArticleId><ArticleId IdType="pmc">PMC4793236</ArticleId><ArticleId IdType="pubmed">26979938</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Rourke J.G., Bogdanik L., Muhammad A.K.M.G., Gendron T.F., Kim K.J., Austin A., Cady J., Liu E.Y., Zarrow J., Grant S., et al. C9orf72 BAC Transgenic Mice Display Typical Pathologic Features of ALS/FTD. Neuron. 2015;88:892&#x2013;901. doi: 10.1016/j.neuron.2015.10.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2015.10.027</ArticleId><ArticleId IdType="pmc">PMC4672384</ArticleId><ArticleId IdType="pubmed">26637796</ArticleId></ArticleIdList></Reference><Reference><Citation>Peters O.M., Cabrera G.T., Tran H., Gendron T.F., McKeon J.E., Metterville J., Weiss A., Wightman N., Salameh J., Kim J., et al. Human C9ORF72 Hexanucleotide Expansion Reproduces RNA Foci and Dipeptide Repeat Proteins but Not Neurodegeneration in BAC Transgenic Mice. Neuron. 2015;88:902&#x2013;909. doi: 10.1016/j.neuron.2015.11.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2015.11.018</ArticleId><ArticleId IdType="pmc">PMC4828340</ArticleId><ArticleId IdType="pubmed">26637797</ArticleId></ArticleIdList></Reference><Reference><Citation>Batra R., Lee C.W. Mouse Models of C9orf72 Hexanucleotide Repeat Expansion in Amyotrophic Lateral Sclerosis/Frontotemporal Dementia. Front. Cell. Neurosci. 2017;11:196. doi: 10.3389/fncel.2017.00196.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2017.00196</ArticleId><ArticleId IdType="pmc">PMC5498553</ArticleId><ArticleId IdType="pubmed">28729824</ArticleId></ArticleIdList></Reference><Reference><Citation>Schludi M.H., Edbauer D. Targeting RNA G-quadruplexes as new treatment strategy for C9orf72 ALS/FTD. EMBO Mol. Med. 2018;10:4&#x2013;6. doi: 10.15252/emmm.201708572.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.201708572</ArticleId><ArticleId IdType="pmc">PMC5760851</ArticleId><ArticleId IdType="pubmed">29175945</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong W., Ma Y., Guan F., Zhang X., Chen W., Zhang L., Zhang L. Ablation of C9orf72 together with excitotoxicity induces ALS in rats. FEBS J. 2021;288:1712&#x2013;1723. doi: 10.1111/febs.15501.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/febs.15501</ArticleId><ArticleId IdType="pubmed">32745320</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong W., Zhang L., Sun C., Gao X., Guan F., Li J., Chen W., Ma Y., Zhang L. Knock in of a hexanucleotide repeat expansion in the C9orf72 gene induces ALS in rats. Anim. Model. Exp. Med. 2020;3:237&#x2013;244. doi: 10.1002/ame2.12129.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ame2.12129</ArticleId><ArticleId IdType="pmc">PMC7529333</ArticleId><ArticleId IdType="pubmed">33024945</ArticleId></ArticleIdList></Reference><Reference><Citation>Hadano S., Hand C.K., Osuga H., Yanagisawa Y., Otomo A., Devon R.S., Miyamoto N., Showguchi-Miyata J., Okada Y., Singaraja R., et al. A gene encoding a putative GTPase regulator is mutated in familial amyotrophic lateral sclerosis 2. Nat. Genet. 2001;29:166&#x2013;173. doi: 10.1038/ng1001-166.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng1001-166</ArticleId><ArticleId IdType="pubmed">11586298</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y., Hentati A., Deng H.X., Dabbagh O., Sasaki T., Hirano M., Hung W.Y., Ouahchi K., Yan J., Azim A.C., et al. The gene encoding alsin, a protein with three guanine-nucleotide exchange factor domains, is mutated in a form of recessive amyotrophic lateral sclerosis. Nat. Genet. 2001;29:160&#x2013;165. doi: 10.1038/ng1001-160.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng1001-160</ArticleId><ArticleId IdType="pubmed">11586297</ArticleId></ArticleIdList></Reference><Reference><Citation>Kress J.A., K&#xfc;hnlein P., Winter P., Ludolph A.C., Kassubek J., M&#xfc;ller U., Sperfeld A.-D. Novel mutation in the ALS2 gene in juvenile amyotrophic lateral sclerosis. Ann. Neurol. 2005;58:800&#x2013;803. doi: 10.1002/ana.20665.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.20665</ArticleId><ArticleId IdType="pubmed">16240357</ArticleId></ArticleIdList></Reference><Reference><Citation>Chandran J., Ding J., Cai H. Alsin and the molecular pathways of amyotrophic lateral sclerosis. Mol. Neurobiol. 2007;36:224&#x2013;231. doi: 10.1007/s12035-007-0034-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-007-0034-x</ArticleId><ArticleId IdType="pmc">PMC2364715</ArticleId><ArticleId IdType="pubmed">17955197</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai H., Shim H., Lai C., Xie C., Lin X., Yang W.J., Chandran J. ALS2/alsin knockout mice and motor neuron diseases. Neurodegener. Dis. 2008;5:359&#x2013;366. doi: 10.1159/000151295.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000151295</ArticleId><ArticleId IdType="pmc">PMC2556598</ArticleId><ArticleId IdType="pubmed">18714162</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai H., Lin X., Xie C., Laird F.M., Lai C., Wen H., Chiang H.-C., Shim H., Farah M.H., Hoke A., et al. Loss of ALS2 function is insufficient to trigger motor neuron degeneration in knock-out mice but predisposes neurons to oxidative stress. J. Neurosci. 2005;25:7567&#x2013;7574. doi: 10.1523/JNEUROSCI.1645-05.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1645-05.2005</ArticleId><ArticleId IdType="pmc">PMC2364727</ArticleId><ArticleId IdType="pubmed">16107644</ArticleId></ArticleIdList></Reference><Reference><Citation>Hadano S., Benn S.C., Kakuta S., Otomo A., Sudo K., Kunita R., Suzuki-Utsunomiya K., Mizumura H., Shefner J.M., Cox G.A., et al. Mice deficient in the Rab5 guanine nucleotide exchange factor ALS2/alsin exhibit age-dependent neurological deficits and altered endosome trafficking. Hum. Mol. Genet. 2006;15:233&#x2013;250. doi: 10.1093/hmg/ddi440.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddi440</ArticleId><ArticleId IdType="pubmed">16321985</ArticleId></ArticleIdList></Reference><Reference><Citation>Devon R.S., Orban P.C., Gerrow K., Barbieri M.A., Schwab C., Cao L.P., Helm J.R., Bissada N., Cruz-Aguado R., Davidson T.-L., et al. Als2-deficient mice exhibit disturbances in endosome trafficking associated with motor behavioral abnormalities. Proc. Natl. Acad. Sci. USA. 2006;103:9595&#x2013;9600. doi: 10.1073/pnas.0510197103.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0510197103</ArticleId><ArticleId IdType="pmc">PMC1480452</ArticleId><ArticleId IdType="pubmed">16769894</ArticleId></ArticleIdList></Reference><Reference><Citation>Gros-Louis F., Kriz J., Kabashi E., McDearmid J., Millecamps S., Urushitani M., Lin L., Dion P., Zhu Q., Drapeau P., et al. Als2 mRNA splicing variants detected in KO mice rescue severe motor dysfunction phenotype in Als2 knock-down zebrafish. Hum. Mol. Genet. 2008;17:2691&#x2013;2702. doi: 10.1093/hmg/ddn171.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddn171</ArticleId><ArticleId IdType="pubmed">18558633</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamanaka K., Miller T.M., McAlonis-Downes M., Chun S.J., Cleveland D.W. Progressive spinal axonal degeneration and slowness in ALS2-deficient mice. Ann. Neurol. 2006;60:95&#x2013;104. doi: 10.1002/ana.20888.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.20888</ArticleId><ArticleId IdType="pubmed">16802286</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett C.L., Dastidar S.G., Ling S.-C., Malik B., Ashe T., Wadhwa M., Miller D.B., Lee C., Mitchell M.B., van Es M.A., et al. Senataxin mutations elicit motor neuron degeneration phenotypes and yield TDP-43 mislocalization in ALS4 mice and human patients. Acta Neuropathol. 2018;136:425&#x2013;443. doi: 10.1007/s00401-018-1852-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-018-1852-9</ArticleId><ArticleId IdType="pmc">PMC6098723</ArticleId><ArticleId IdType="pubmed">29725819</ArticleId></ArticleIdList></Reference><Reference><Citation>Maruyama H., Morino H., Ito H., Izumi Y., Kato H., Watanabe Y., Kinoshita Y., Kamada M., Nodera H., Suzuki H., et al. Mutations of optineurin in amyotrophic lateral sclerosis. Nature. 2010;465:223&#x2013;226. doi: 10.1038/nature08971.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature08971</ArticleId><ArticleId IdType="pubmed">20428114</ArticleId></ArticleIdList></Reference><Reference><Citation>Hortob&#xe1;gyi T., Troakes C., Nishimura A.L., Vance C., van Swieten J.C., Seelaar H., King A., Al-Sarraj S., Rogelj B., Shaw C.E. Optineurin inclusions occur in a minority of TDP-43 positive ALS and FTLD-TDP cases and are rarely observed in other neurodegenerative disorders. Acta Neuropathol. 2011;121:519&#x2013;527. doi: 10.1007/s00401-011-0813-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-011-0813-3</ArticleId><ArticleId IdType="pubmed">21360076</ArticleId></ArticleIdList></Reference><Reference><Citation>Osawa T., Mizuno Y., Fujita Y., Takatama M., Nakazato Y., Okamoto K. Optineurin in neurodegenerative diseases. Neuropathology. 2011;31:569&#x2013;574. doi: 10.1111/j.1440-1789.2011.01199.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1440-1789.2011.01199.x</ArticleId><ArticleId IdType="pubmed">21284751</ArticleId></ArticleIdList></Reference><Reference><Citation>Ito H., Nakamura M., Komure O., Ayaki T., Wate R., Maruyama H., Nakamura Y., Fujita K., Kaneko S., Okamoto Y., et al. Clinicopathologic study on an ALS family with a heterozygous E478G optineurin mutation. Acta Neuropathol. 2011;122:223&#x2013;229. doi: 10.1007/s00401-011-0842-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-011-0842-y</ArticleId><ArticleId IdType="pubmed">21644038</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamada M., Izumi Y., Ayaki T., Nakamura M., Kagawa S., Kudo E., Sako W., Maruyama H., Nishida Y., Kawakami H., et al. Clinicopathologic features of autosomal recessive amyotrophic lateral sclerosis associated with optineurin mutation. Neuropathology. 2014;34:64&#x2013;70. doi: 10.1111/neup.12051.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/neup.12051</ArticleId><ArticleId IdType="pubmed">23889540</ArticleId></ArticleIdList></Reference><Reference><Citation>Gleason C.E., Ordureau A., Gourlay R., Arthur J.S.C., Cohen P. Polyubiquitin binding to optineurin is required for optimal activation of TANK-binding kinase 1 and production of interferon &#x3b2;. J. Biol. Chem. 2011;286:35663&#x2013;35674. doi: 10.1074/jbc.M111.267567.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M111.267567</ArticleId><ArticleId IdType="pmc">PMC3195586</ArticleId><ArticleId IdType="pubmed">21862579</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng T., Yang Y., Casta&#xf1;eda C.A. Structure, dynamics and functions of UBQLNs: At the crossroads of protein quality control machinery. Biochem. J. 2020;477:3471&#x2013;3497. doi: 10.1042/BCJ20190497.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BCJ20190497</ArticleId><ArticleId IdType="pmc">PMC7737201</ArticleId><ArticleId IdType="pubmed">32965492</ArticleId></ArticleIdList></Reference><Reference><Citation>Renaud L., Picher-Martel V., Codron P., Julien J.-P. Key role of UBQLN2 in pathogenesis of amyotrophic lateral sclerosis and frontotemporal dementia. Acta Neuropathol. Commun. 2019;7:103. doi: 10.1186/s40478-019-0758-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-019-0758-7</ArticleId><ArticleId IdType="pmc">PMC6889556</ArticleId><ArticleId IdType="pubmed">31319884</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorrie G.H., Fecto F., Radzicki D., Weiss C., Shi Y., Dong H., Zhai H., Fu R., Liu E., Li S., et al. Dendritic spinopathy in transgenic mice expressing ALS/dementia-linked mutant UBQLN2. Proc. Natl. Acad. Sci. USA. 2014;111:14524&#x2013;14529. doi: 10.1073/pnas.1405741111.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1405741111</ArticleId><ArticleId IdType="pmc">PMC4209984</ArticleId><ArticleId IdType="pubmed">25246588</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Q., Liu M., Huang C., Liu X., Huang B., Li N., Zhou H., Xia X.-G. Pathogenic Ubqln2 gains toxic properties to induce neuron death. Acta Neuropathol. 2015;129:417&#x2013;428. doi: 10.1007/s00401-014-1367-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-014-1367-y</ArticleId><ArticleId IdType="pmc">PMC4777328</ArticleId><ArticleId IdType="pubmed">25388785</ArticleId></ArticleIdList></Reference><Reference><Citation>Hjerpe R., Bett J.S., Keuss M.J., Solovyova A., McWilliams T.G., Johnson C., Sahu I., Varghese J., Wood N., Wightman M., et al. UBQLN2 Mediates Autophagy-Independent Protein Aggregate Clearance by the Proteasome. Cell. 2016;166:935&#x2013;949. doi: 10.1016/j.cell.2016.07.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2016.07.001</ArticleId><ArticleId IdType="pmc">PMC5003816</ArticleId><ArticleId IdType="pubmed">27477512</ArticleId></ArticleIdList></Reference><Reference><Citation>Le N.T.T., Chang L., Kovlyagina I., Georgiou P., Safren N., Braunstein K.E., Kvarta M.D., Van Dyke A.M., LeGates T.A., Philips T., et al. Motor neuron disease, TDP-43 pathology, and memory deficits in mice expressing ALS-FTD-linked UBQLN2 mutations. Proc. Natl. Acad. Sci. USA. 2016;113:E7580&#x2013;E7589. doi: 10.1073/pnas.1608432113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1608432113</ArticleId><ArticleId IdType="pmc">PMC5127348</ArticleId><ArticleId IdType="pubmed">27834214</ArticleId></ArticleIdList></Reference><Reference><Citation>Picher-Martel V., Renaud L., Bareil C., Julien J.-P. Neuronal Expression of UBQLN2(P497H) Exacerbates TDP-43 Pathology in TDP-43 (G348C) Mice through Interaction with Ubiquitin. Mol. Neurobiol. 2019;56:4680&#x2013;4696. doi: 10.1007/s12035-018-1411-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-018-1411-3</ArticleId><ArticleId IdType="pmc">PMC6647471</ArticleId><ArticleId IdType="pubmed">30377984</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang C., Huang M., DeBiasio J., Pring M., Joyce M., Miki H., Takenawa T., Zigmond S.H. Profilin enhances Cdc42-induced nucleation of actin polymerization. J. Cell Biol. 2000;150:1001&#x2013;1012. doi: 10.1083/jcb.150.5.1001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.150.5.1001</ArticleId><ArticleId IdType="pmc">PMC2175244</ArticleId><ArticleId IdType="pubmed">10973991</ArticleId></ArticleIdList></Reference><Reference><Citation>Dominguez R. Structural insights into de novo actin polymerization. Curr. Opin. Struct. Biol. 2010;20:217&#x2013;225. doi: 10.1016/j.sbi.2009.12.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.sbi.2009.12.012</ArticleId><ArticleId IdType="pmc">PMC2854303</ArticleId><ArticleId IdType="pubmed">20096561</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu C.-H., Fallini C., Ticozzi N., Keagle P.J., Sapp P.C., Piotrowska K., Lowe P., Koppers M., McKenna-Yasek D., Baron D.M., et al. Mutations in the profilin 1 gene cause familial amyotrophic lateral sclerosis. Nature. 2012;488:499&#x2013;503. doi: 10.1038/nature11280.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature11280</ArticleId><ArticleId IdType="pmc">PMC3575525</ArticleId><ArticleId IdType="pubmed">22801503</ArticleId></ArticleIdList></Reference><Reference><Citation>Alkam D., Feldman E.Z., Singh A., Kiaei M. Profilin1 biology and its mutation, actin(g) in disease. Cell. Mol. Life Sci. 2017;74:967&#x2013;981. doi: 10.1007/s00018-016-2372-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00018-016-2372-1</ArticleId><ArticleId IdType="pmc">PMC5311022</ArticleId><ArticleId IdType="pubmed">27669692</ArticleId></ArticleIdList></Reference><Reference><Citation>Boopathy S., Silvas T.V., Tischbein M., Jansen S., Shandilya S.M., Zitzewitz J.A., Landers J.E., Goode B.L., Schiffer C.A., Bosco D.A. Structural basis for mutation-induced destabilization of profilin 1 in ALS. Proc. Natl. Acad. Sci. USA. 2015;112:7984&#x2013;7989. doi: 10.1073/pnas.1424108112.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1424108112</ArticleId><ArticleId IdType="pmc">PMC4491777</ArticleId><ArticleId IdType="pubmed">26056300</ArticleId></ArticleIdList></Reference><Reference><Citation>Henty-Ridilla J.L., Juanes M.A., Goode B.L. Profilin Directly Promotes Microtubule Growth through Residues Mutated in Amyotrophic Lateral Sclerosis. Curr. Biol. 2017;27:3535&#x2013;3543.e4. doi: 10.1016/j.cub.2017.10.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cub.2017.10.002</ArticleId><ArticleId IdType="pmc">PMC5772683</ArticleId><ArticleId IdType="pubmed">29129529</ArticleId></ArticleIdList></Reference><Reference><Citation>Brettle M., Suchowerska A.K., Chua S.W., Ittner L.M., Fath T. Amyotrophic lateral sclerosis-associated mutant profilin 1 increases dendritic arborisation and spine formation in primary hippocampal neurons. Neurosci. Lett. 2015;609:223&#x2013;228. doi: 10.1016/j.neulet.2015.09.034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2015.09.034</ArticleId><ArticleId IdType="pubmed">26499959</ArticleId></ArticleIdList></Reference><Reference><Citation>Fil D., DeLoach A., Yadav S., Alkam D., MacNicol M., Singh A., Compadre C.M., Goellner J.J., O&#x2019;Brien C.A., Fahmi T., et al. Mutant Profilin1 transgenic mice recapitulate cardinal features of motor neuron disease. Hum. Mol. Genet. 2017;26:686&#x2013;701. doi: 10.1093/hmg/ddw429.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddw429</ArticleId><ArticleId IdType="pmc">PMC5968635</ArticleId><ArticleId IdType="pubmed">28040732</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang C., Danielson E.W., Qiao T., Metterville J., Brown R.H.J., Landers J.E., Xu Z. Mutant PFN1 causes ALS phenotypes and progressive motor neuron degeneration in mice by a gain of toxicity. Proc. Natl. Acad. Sci. USA. 2016;113:E6209&#x2013;E6218. doi: 10.1073/pnas.1605964113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1605964113</ArticleId><ArticleId IdType="pmc">PMC5068285</ArticleId><ArticleId IdType="pubmed">27681617</ArticleId></ArticleIdList></Reference><Reference><Citation>Brettle M., Stefen H., Djordjevic A., Fok S.Y.Y., Chan J.W., van Hummel A., van der Hoven J., Przybyla M., Volkerling A., Ke Y.D., et al. Developmental Expression of Mutant PFN1 in Motor Neurons Impacts Neuronal Growth and Motor Performance of Young and Adult Mice. Front. Mol. Neurosci. 2019;12:231. doi: 10.3389/fnmol.2019.00231.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2019.00231</ArticleId><ArticleId IdType="pmc">PMC6776973</ArticleId><ArticleId IdType="pubmed">31611772</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson J.O., Mandrioli J., Benatar M., Abramzon Y., Van Deerlin V.M., Trojanowski J.Q., Gibbs J.R., Brunetti M., Gronka S., Wuu J., et al. Exome sequencing reveals VCP mutations as a cause of familial ALS. Neuron. 2010;68:857&#x2013;864. doi: 10.1016/j.neuron.2010.11.036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2010.11.036</ArticleId><ArticleId IdType="pmc">PMC3032425</ArticleId><ArticleId IdType="pubmed">21145000</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonz&#xe1;lez-P&#xe9;rez P., Cirulli E.T., Drory V.E., Dabby R., Nisipeanu P., Carasso R.L., Sadeh M., Fox A., Festoff B.W., Sapp P.C., et al. Novel mutation in VCP gene causes atypical amyotrophic lateral sclerosis. Neurology. 2012;79:2201&#x2013;2208. doi: 10.1212/WNL.0b013e318275963b.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e318275963b</ArticleId><ArticleId IdType="pmc">PMC3570818</ArticleId><ArticleId IdType="pubmed">23152587</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun X., Qiu H. Valosin-Containing Protein, a Calcium-Associated ATPase Protein, in Endoplasmic Reticulum and Mitochondrial Function and Its Implications for Diseases. Int. J. Mol. Sci. 2020;21:1216. doi: 10.3390/ijms21113842.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21113842</ArticleId><ArticleId IdType="pmc">PMC7312078</ArticleId><ArticleId IdType="pubmed">32481679</ArticleId></ArticleIdList></Reference><Reference><Citation>Badadani M., Nalbandian A., Watts G.D., Vesa J., Kitazawa M., Su H., Tanaja J., Dec E., Wallace D.C., Mukherjee J., et al. VCP associated inclusion body myopathy and paget disease of bone knock-in mouse model exhibits tissue pathology typical of human disease. PLoS ONE. 2010;5:e13183. doi: 10.1371/journal.pone.0013183.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0013183</ArticleId><ArticleId IdType="pmc">PMC2950155</ArticleId><ArticleId IdType="pubmed">20957154</ArticleId></ArticleIdList></Reference><Reference><Citation>Custer S.K., Neumann M., Lu H., Wright A.C., Taylor J.P. Transgenic mice expressing mutant forms VCP/p97 recapitulate the full spectrum of IBMPFD including degeneration in muscle, brain and bone. Hum. Mol. Genet. 2010;19:1741&#x2013;1755. doi: 10.1093/hmg/ddq050.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddq050</ArticleId><ArticleId IdType="pubmed">20147319</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin H.Z., Nalbandian A., Hsu C.-I., Li S., Llewellyn K.J., Mozaffar T., Kimonis V.E., Weiss J.H. Slow development of ALS-like spinal cord pathology in mutant valosin-containing protein gene knock-in mice. Cell Death Dis. 2012;3:e374. doi: 10.1038/cddis.2012.115.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cddis.2012.115</ArticleId><ArticleId IdType="pmc">PMC3434652</ArticleId><ArticleId IdType="pubmed">22898872</ArticleId></ArticleIdList></Reference><Reference><Citation>Clemen C.S., Winter L., Strucksberg K.-H., Berwanger C., T&#xfc;rk M., Kornblum C., Florin A., Aguilar-Pimentel J.A., Amarie O.V., Becker L., et al. The heterozygous R155C VCP mutation: Toxic in humans! Harmless in mice? Biochem. Biophys. Res. Commun. 2018;503:2770&#x2013;2777. doi: 10.1016/j.bbrc.2018.08.038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2018.08.038</ArticleId><ArticleId IdType="pubmed">30100055</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbandian A., Llewellyn K.J., Kitazawa M., Yin H.Z., Badadani M., Khanlou N., Edwards R., Nguyen C., Mukherjee J., Mozaffar T., et al. The homozygote VCP(R155H/R155H) mouse model exhibits accelerated human VCP-associated disease pathology. PLoS ONE. 2012;7:e46308. doi: 10.1371/journal.pone.0046308.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0046308</ArticleId><ArticleId IdType="pmc">PMC3460820</ArticleId><ArticleId IdType="pubmed">23029473</ArticleId></ArticleIdList></Reference><Reference><Citation>Skehel P.A., Martin K.C., Kandel E.R., Bartsch D. A VAMP-binding protein from Aplysia required for neurotransmitter release. Science. 1995;269:1580&#x2013;1583. doi: 10.1126/science.7667638.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.7667638</ArticleId><ArticleId IdType="pubmed">7667638</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy S.E., Levine T.P. VAP, a Versatile Access Point for the Endoplasmic Reticulum: Review and analysis of FFAT-like motifs in the VAPome. Biochim. Biophys. Acta. 2016;1861:952&#x2013;961. doi: 10.1016/j.bbalip.2016.02.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbalip.2016.02.009</ArticleId><ArticleId IdType="pubmed">26898182</ArticleId></ArticleIdList></Reference><Reference><Citation>Lev S., Ben Halevy D., Peretti D., Dahan N. The VAP protein family: From cellular functions to motor neuron disease. Trends Cell Biol. 2008;18:282&#x2013;290. doi: 10.1016/j.tcb.2008.03.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tcb.2008.03.006</ArticleId><ArticleId IdType="pubmed">18468439</ArticleId></ArticleIdList></Reference><Reference><Citation>Borgese N., Iacomino N., Colombo S.F., Navone F. The Link between VAPB Loss of Function and Amyotrophic Lateral Sclerosis. Cells. 2021;10:1865. doi: 10.3390/cells10081865.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells10081865</ArticleId><ArticleId IdType="pmc">PMC8392409</ArticleId><ArticleId IdType="pubmed">34440634</ArticleId></ArticleIdList></Reference><Reference><Citation>Dud&#xe1;s E.F., Huynen M.A., Lesk A.M., Pastore A. Invisible leashes: The tethering VAPs from infectious diseases to neurodegeneration. J. Biol. Chem. 2021;296:100421. doi: 10.1016/j.jbc.2021.100421.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbc.2021.100421</ArticleId><ArticleId IdType="pmc">PMC8005810</ArticleId><ArticleId IdType="pubmed">33609524</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishimura A.L., Mitne-Neto M., Silva H.C.A., Richieri-Costa A., Middleton S., Cascio D., Kok F., Oliveira J.R.M., Gillingwater T., Webb J., et al. A mutation in the vesicle-trafficking protein VAPB causes late-onset spinal muscular atrophy and amyotrophic lateral sclerosis. Am. J. Hum. Genet. 2004;75:822&#x2013;831. doi: 10.1086/425287.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/425287</ArticleId><ArticleId IdType="pmc">PMC1182111</ArticleId><ArticleId IdType="pubmed">15372378</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen H.-J., Anagnostou G., Chai A., Withers J., Morris A., Adhikaree J., Pennetta G., de Belleroche J.S. Characterization of the properties of a novel mutation in VAPB in familial amyotrophic lateral sclerosis. J. Biol. Chem. 2010;285:40266&#x2013;40281. doi: 10.1074/jbc.M110.161398.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M110.161398</ArticleId><ArticleId IdType="pmc">PMC3001007</ArticleId><ArticleId IdType="pubmed">20940299</ArticleId></ArticleIdList></Reference><Reference><Citation>Kabashi E., El Oussini H., Bercier V., Gros-Louis F., Valdmanis P.N., McDearmid J., Mejier I.A., Dion P.A., Dupre N., Hollinger D., et al. Investigating the contribution of VAPB/ALS8 loss of function in amyotrophic lateral sclerosis. Hum. Mol. Genet. 2013;22:2350&#x2013;2360. doi: 10.1093/hmg/ddt080.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddt080</ArticleId><ArticleId IdType="pubmed">23446633</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuijpers M., van Dis V., Haasdijk E.D., Harterink M., Vocking K., Post J.A., Scheper W., Hoogenraad C.C., Jaarsma D. Amyotrophic lateral sclerosis (ALS)-associated VAPB-P56S inclusions represent an ER quality control compartment. Acta Neuropathol. Commun. 2013;1:24. doi: 10.1186/2051-5960-1-24.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/2051-5960-1-24</ArticleId><ArticleId IdType="pmc">PMC3893532</ArticleId><ArticleId IdType="pubmed">24252306</ArticleId></ArticleIdList></Reference><Reference><Citation>Aliaga L., Lai C., Yu J., Chub N., Shim H., Sun L., Xie C., Yang W.-J., Lin X., O&#x2019;Donovan M.J., et al. Amyotrophic lateral sclerosis-related VAPB P56S mutation differentially affects the function and survival of corticospinal and spinal motor neurons. Hum. Mol. Genet. 2013;22:4293&#x2013;4305. doi: 10.1093/hmg/ddt279.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddt279</ArticleId><ArticleId IdType="pmc">PMC3792689</ArticleId><ArticleId IdType="pubmed">23771029</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu L., Qiao T., Beers M., Tan W., Wang H., Yang B., Xu Z. Widespread aggregation of mutant VAPB associated with ALS does not cause motor neuron degeneration or modulate mutant SOD1 aggregation and toxicity in mice. Mol. Neurodegener. 2013;8:1. doi: 10.1186/1750-1326-8-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1750-1326-8-1</ArticleId><ArticleId IdType="pmc">PMC3538568</ArticleId><ArticleId IdType="pubmed">23281774</ArticleId></ArticleIdList></Reference><Reference><Citation>Larroquette F., Seto L., Gaub P.L., Kamal B., Wallis D., Larivi&#xe8;re R., Vall&#xe9;e J., Robitaille R., Tsuda H. Vapb/Amyotrophic lateral sclerosis 8 knock-in mice display slowly progressive motor behavior defects accompanying ER stress and autophagic response. Hum. Mol. Genet. 2015;24:6515&#x2013;6529. doi: 10.1093/hmg/ddv360.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddv360</ArticleId><ArticleId IdType="pmc">PMC4614709</ArticleId><ArticleId IdType="pubmed">26362257</ArticleId></ArticleIdList></Reference><Reference><Citation>den Hartog Jager W.A. Experimental amyotrophic lateral sclerosis in the guinea-pig. J. Neurol. Sci. 1985;67:133&#x2013;142. doi: 10.1016/0022-510X(85)90110-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0022-510X(85)90110-8</ArticleId><ArticleId IdType="pubmed">3981216</ArticleId></ArticleIdList></Reference><Reference><Citation>Engelhardt J.I., Appel S.H., Killian J.M. Experimental autoimmune motoneuron disease. Ann. Neurol. 1989;26:368&#x2013;376. doi: 10.1002/ana.410260310.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.410260310</ArticleId><ArticleId IdType="pubmed">2802536</ArticleId></ArticleIdList></Reference><Reference><Citation>Engelhardt J.I., Appel S.H., Killian J.M. Motor neuron destruction in guinea pigs immunized with bovine spinal cord ventral horn homogenate: Experimental autoimmune gray matter disease. J. Neuroimmunol. 1990;27:21&#x2013;31. doi: 10.1016/0165-5728(90)90132-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0165-5728(90)90132-7</ArticleId><ArticleId IdType="pubmed">1690752</ArticleId></ArticleIdList></Reference><Reference><Citation>Engelhardt J.I., Sikl&#xf3;s L., Appel S.H. Immunization of guinea pigs with human choline acetyltransferase induces selective lower motoneuron destruction. J. Neuroimmunol. 1997;78:57&#x2013;68. doi: 10.1016/S0165-5728(97)00082-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0165-5728(97)00082-9</ArticleId><ArticleId IdType="pubmed">9307228</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett S.A., Tanaz R., Cobos S.N., Torrente M.P. Epigenetics in amyotrophic lateral sclerosis: A role for histone post-translational modifications in neurodegenerative disease. Transl. Res. 2019;204:19&#x2013;30. doi: 10.1016/j.trsl.2018.10.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.trsl.2018.10.002</ArticleId><ArticleId IdType="pmc">PMC6331271</ArticleId><ArticleId IdType="pubmed">30391475</ArticleId></ArticleIdList></Reference><Reference><Citation>Nowicka N., Juranek J., Juranek J.K., Wojtkiewicz J. Risk Factors and Emerging Therapies in Amyotrophic Lateral Sclerosis. Int. J. Mol. Sci. 2019;20 doi: 10.3390/ijms20112616.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms20112616</ArticleId><ArticleId IdType="pmc">PMC6600314</ArticleId><ArticleId IdType="pubmed">31141951</ArticleId></ArticleIdList></Reference><Reference><Citation>de Munck E., Mu&#xf1;oz-S&#xe1;ez E., Miguel B.G., Solas M.T., Ojeda I., Mart&#xed;nez A., Gil C., Arahuetes R.M. &#x3b2;-N-methylamino-l-alanine causes neurological and pathological phenotypes mimicking Amyotrophic Lateral Sclerosis (ALS): The first step towards an experimental model for sporadic ALS. Environ. Toxicol. Pharmacol. 2013;36:243&#x2013;255. doi: 10.1016/j.etap.2013.04.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.etap.2013.04.007</ArticleId><ArticleId IdType="pubmed">23688553</ArticleId></ArticleIdList></Reference><Reference><Citation>de Munck E., Mu&#xf1;oz-S&#xe1;ez E., Miguel B.G., Solas M.T., Mart&#xed;nez A., Arahuetes R.M. Morphometric and neurochemical alterations found in l-BMAA treated rats. Environ. Toxicol. Pharmacol. 2015;39:1232&#x2013;1245. doi: 10.1016/j.etap.2015.04.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.etap.2015.04.022</ArticleId><ArticleId IdType="pubmed">26002186</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin H.Z., Yu S., Hsu C.-I., Liu J., Acab A., Wu R., Tao A., Chiang B.J., Weiss J.H. Intrathecal infusion of BMAA induces selective motor neuron damage and astrogliosis in the ventral horn of the spinal cord. Exp. Neurol. 2014;261:1&#x2013;9. doi: 10.1016/j.expneurol.2014.06.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2014.06.003</ArticleId><ArticleId IdType="pmc">PMC4194249</ArticleId><ArticleId IdType="pubmed">24918341</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian K.-W., Jiang H., Wang B.-B., Zhang F., Han S. Intravenous injection of l-BMAA induces a rat model with comprehensive characteristics of amyotrophic lateral sclerosis/Parkinson-dementia complex. Toxicol. Res. 2016;5:79&#x2013;96. doi: 10.1039/C5TX00272A.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/C5TX00272A</ArticleId><ArticleId IdType="pmc">PMC6060832</ArticleId><ArticleId IdType="pubmed">30090328</ArticleId></ArticleIdList></Reference><Reference><Citation>Bolus H., Crocker K., Boekhoff-Falk G., Chtarbanova S. Modeling Neurodegenerative Disorders in Drosophila melanogaster. Int. J. Mol. Sci. 2020;21 doi: 10.3390/ijms21093055.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21093055</ArticleId><ArticleId IdType="pmc">PMC7246467</ArticleId><ArticleId IdType="pubmed">32357532</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamaguchi M., Lee I.-S., Jantrapirom S., Suda K., Yoshida H. Drosophila models to study causative genes for human rare intractable neurological diseases. Exp. Cell Res. 2021;403:112584. doi: 10.1016/j.yexcr.2021.112584.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.yexcr.2021.112584</ArticleId><ArticleId IdType="pubmed">33812867</ArticleId></ArticleIdList></Reference><Reference><Citation>Adams M.D., Celniker S.E., Holt R.A., Evans C.A., Gocayne J.D., Amanatides P.G., Scherer S.E., Li P.W., Hoskins R.A., Galle R.F., et al. The genome sequence of Drosophila melanogaster. Science. 2000;287:2185&#x2013;2195. doi: 10.1126/science.287.5461.2185.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.287.5461.2185</ArticleId><ArticleId IdType="pubmed">10731132</ArticleId></ArticleIdList></Reference><Reference><Citation>Myers E.W., Sutton G.G., Delcher A.L., Dew I.M., Fasulo D.P., Flanigan M.J., Kravitz S.A., Mobarry C.M., Reinert K.H., Remington K.A., et al. A whole-genome assembly of Drosophila. Science. 2000;287:2196&#x2013;2204. doi: 10.1126/science.287.5461.2196.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.287.5461.2196</ArticleId><ArticleId IdType="pubmed">10731133</ArticleId></ArticleIdList></Reference><Reference><Citation>Brand A.H., Perrimon N. Targeted gene expression as a means of altering cell fates and generating dominant phenotypes. Development. 1993;118:401&#x2013;415. doi: 10.1242/dev.118.2.401.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/dev.118.2.401</ArticleId><ArticleId IdType="pubmed">8223268</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiter L.T., Potocki L., Chien S., Gribskov M., Bier E. A systematic analysis of human disease-associated gene sequences in Drosophila melanogaster. Genome Res. 2001;11:1114&#x2013;1125. doi: 10.1101/gr.169101.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gr.169101</ArticleId><ArticleId IdType="pmc">PMC311089</ArticleId><ArticleId IdType="pubmed">11381037</ArticleId></ArticleIdList></Reference><Reference><Citation>Casci I., Pandey U.B. A fruitful endeavor: Modeling ALS in the fruit fly. Brain Res. 2015;1607:47&#x2013;74. doi: 10.1016/j.brainres.2014.09.064.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2014.09.064</ArticleId><ArticleId IdType="pmc">PMC4385417</ArticleId><ArticleId IdType="pubmed">25289585</ArticleId></ArticleIdList></Reference><Reference><Citation>Liguori F., Amadio S., Volont&#xe9; C. Fly for ALS: Drosophila modeling on the route to amyotrophic lateral sclerosis modifiers. Cell. Mol. Life Sci. 2021;78:6143&#x2013;6160. doi: 10.1007/s00018-021-03905-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00018-021-03905-8</ArticleId><ArticleId IdType="pubmed">34322715</ArticleId></ArticleIdList></Reference><Reference><Citation>Braems E., Tziortzouda P., Van Den Bosch L. Exploring the alternative: Fish, flies and worms as preclinical models for ALS. Neurosci. Lett. 2021;759:136041. doi: 10.1016/j.neulet.2021.136041.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2021.136041</ArticleId><ArticleId IdType="pubmed">34118308</ArticleId></ArticleIdList></Reference><Reference><Citation>Marsh J.L., Thompson L.M. Drosophila in the study of neurodegenerative disease. Neuron. 2006;52:169&#x2013;178. doi: 10.1016/j.neuron.2006.09.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2006.09.025</ArticleId><ArticleId IdType="pubmed">17015234</ArticleId></ArticleIdList></Reference><Reference><Citation>McGurk L., Berson A., Bonini N.M. Drosophila as an In Vivo Model for Human Neurodegenerative Disease. Genetics. 2015;201:377&#x2013;402. doi: 10.1534/genetics.115.179457.</Citation><ArticleIdList><ArticleId IdType="doi">10.1534/genetics.115.179457</ArticleId><ArticleId IdType="pmc">PMC4596656</ArticleId><ArticleId IdType="pubmed">26447127</ArticleId></ArticleIdList></Reference><Reference><Citation>&#x15e;ent&#xfc;rk M., Bellen H.J. Genetic strategies to tackle neurological diseases in fruit flies. Curr. Opin. Neurobiol. 2018;50:24&#x2013;32. doi: 10.1016/j.conb.2017.10.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.conb.2017.10.017</ArticleId><ArticleId IdType="pmc">PMC5940587</ArticleId><ArticleId IdType="pubmed">29128849</ArticleId></ArticleIdList></Reference><Reference><Citation>Layalle S., They L., Ourghani S., Raoul C., Soustelle L. Amyotrophic Lateral Sclerosis Genes in Drosophila melanogaster. Int. J. Mol. Sci. 2021;22 doi: 10.3390/ijms22020904.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22020904</ArticleId><ArticleId IdType="pmc">PMC7831090</ArticleId><ArticleId IdType="pubmed">33477509</ArticleId></ArticleIdList></Reference><Reference><Citation>Phillips J.P., Campbell S.D., Michaud D., Charbonneau M., Hilliker A.J. Null mutation of copper/zinc superoxide dismutase in Drosophila confers hypersensitivity to paraquat and reduced longevity. Proc. Natl. Acad. Sci. USA. 1989;86:2761&#x2013;2765. doi: 10.1073/pnas.86.8.2761.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.86.8.2761</ArticleId><ArticleId IdType="pmc">PMC286998</ArticleId><ArticleId IdType="pubmed">2539600</ArticleId></ArticleIdList></Reference><Reference><Citation>Staveley B.E., Phillips J.P., Hilliker A.J. Phenotypic consequences of copper-zinc superoxide dismutase overexpression in Drosophila melanogaster. Genome. 1990;33:867&#x2013;872. doi: 10.1139/g90-130.</Citation><ArticleIdList><ArticleId IdType="doi">10.1139/g90-130</ArticleId><ArticleId IdType="pubmed">1964925</ArticleId></ArticleIdList></Reference><Reference><Citation>Phillips J.P., Tainer J.A., Getzoff E.D., Boulianne G.L., Kirby K., Hilliker A.J. Subunit-destabilizing mutations in Drosophila copper/zinc superoxide dismutase: Neuropathology and a model of dimer dysequilibrium. Proc. Natl. Acad. Sci. USA. 1995;92:8574&#x2013;8578. doi: 10.1073/pnas.92.19.8574.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.92.19.8574</ArticleId><ArticleId IdType="pmc">PMC41008</ArticleId><ArticleId IdType="pubmed">7567977</ArticleId></ArticleIdList></Reference><Reference><Citation>Mockett R.J., Radyuk S.N., Benes J.J., Orr W.C., Sohal R.S. Phenotypic effects of familial amyotrophic lateral sclerosis mutant Sod alleles in transgenic Drosophila. Proc. Natl. Acad. Sci. USA. 2003;100:301&#x2013;306. doi: 10.1073/pnas.0136976100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0136976100</ArticleId><ArticleId IdType="pmc">PMC140958</ArticleId><ArticleId IdType="pubmed">12502789</ArticleId></ArticleIdList></Reference><Reference><Citation>Watson M.R., Lagow R.D., Xu K., Zhang B., Bonini N.M. A drosophila model for amyotrophic lateral sclerosis reveals motor neuron damage by human SOD1. J. Biol. Chem. 2008;283:24972&#x2013;24981. doi: 10.1074/jbc.M804817200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M804817200</ArticleId><ArticleId IdType="pmc">PMC2529125</ArticleId><ArticleId IdType="pubmed">18596033</ArticleId></ArticleIdList></Reference><Reference><Citation>Islam R., Kumimoto E.L., Bao H., Zhang B. ALS-linked SOD1 in glial cells enhances &#xdf;-N-Methylamino L-Alanine (BMAA)-induced toxicity in Drosophila. F1000Research. 2012;1:47. doi: 10.12688/f1000research.1-47.v1.</Citation><ArticleIdList><ArticleId IdType="doi">10.12688/f1000research.1-47.v1</ArticleId><ArticleId IdType="pmc">PMC3945777</ArticleId><ArticleId IdType="pubmed">24627764</ArticleId></ArticleIdList></Reference><Reference><Citation>&#x15e;ahin A., Held A., Bredvik K., Major P., Achilli T.-M., Kerson A.G., Wharton K., Stilwell G., Reenan R. Human SOD1 ALS Mutations in a Drosophila Knock-In Model Cause Severe Phenotypes and Reveal Dosage-Sensitive Gain- and Loss-of-Function Components. Genetics. 2017;205:707&#x2013;723. doi: 10.1534/genetics.116.190850.</Citation><ArticleIdList><ArticleId IdType="doi">10.1534/genetics.116.190850</ArticleId><ArticleId IdType="pmc">PMC5289846</ArticleId><ArticleId IdType="pubmed">27974499</ArticleId></ArticleIdList></Reference><Reference><Citation>Held A., Major P., Sahin A., Reenan R.A., Lipscombe D., Wharton K.A. Circuit Dysfunction in SOD1-ALS Model First Detected in Sensory Feedback Prior to Motor Neuron Degeneration Is Alleviated by BMP Signaling. J. Neurosci. 2019;39:2347&#x2013;2364. doi: 10.1523/JNEUROSCI.1771-18.2019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1771-18.2019</ArticleId><ArticleId IdType="pmc">PMC6433758</ArticleId><ArticleId IdType="pubmed">30659087</ArticleId></ArticleIdList></Reference><Reference><Citation>Bahadorani S., Mukai S.T., Rabie J., Beckman J.S., Phillips J.P., Hilliker A.J. Expression of zinc-deficient human superoxide dismutase in Drosophila neurons produces a locomotor defect linked to mitochondrial dysfunction. Neurobiol. Aging. 2013;34:2322&#x2013;2330. doi: 10.1016/j.neurobiolaging.2013.03.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2013.03.024</ArticleId><ArticleId IdType="pmc">PMC4145400</ArticleId><ArticleId IdType="pubmed">23601674</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H.-Y., Wang I.-F., Bose J., Shen C.-K.J. Structural diversity and functional implications of the eukaryotic TDP gene family. Genomics. 2004;83:130&#x2013;139. doi: 10.1016/S0888-7543(03)00214-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0888-7543(03)00214-3</ArticleId><ArticleId IdType="pubmed">14667816</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiesel F.C., Voigt A., Weber S.S., Van den Haute C., Waldenmaier A., G&#xf6;rner K., Walter M., Anderson M.L., Kern J.V., Rasse T.M., et al. Knockdown of transactive response DNA-binding protein (TDP-43) downregulates histone deacetylase 6. EMBO J. 2010;29:209&#x2013;221. doi: 10.1038/emboj.2009.324.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/emboj.2009.324</ArticleId><ArticleId IdType="pmc">PMC2808372</ArticleId><ArticleId IdType="pubmed">19910924</ArticleId></ArticleIdList></Reference><Reference><Citation>Hazelett D.J., Chang J.-C., Lakeland D.L., Morton D.B. Comparison of parallel high-throughput RNA sequencing between knockout of TDP-43 and its overexpression reveals primarily nonreciprocal and nonoverlapping gene expression changes in the central nervous system of Drosophila. Genes Genomes Genet. 2012;2:789&#x2013;802. doi: 10.1534/g3.112.002998.</Citation><ArticleIdList><ArticleId IdType="doi">10.1534/g3.112.002998</ArticleId><ArticleId IdType="pmc">PMC3385985</ArticleId><ArticleId IdType="pubmed">22870402</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin M.-J., Cheng C.-W., Shen C.-K.J. Neuronal function and dysfunction of Drosophila dTDP. PLoS ONE. 2011;6:e20371. doi: 10.1371/journal.pone.0020371.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0020371</ArticleId><ArticleId IdType="pmc">PMC3105987</ArticleId><ArticleId IdType="pubmed">21673800</ArticleId></ArticleIdList></Reference><Reference><Citation>Feiguin F., Godena V.K., Romano G., D&#x2019;Ambrogio A., Klima R., Baralle F.E. Depletion of TDP-43 affects Drosophila motoneurons terminal synapsis and locomotive behavior. FEBS Lett. 2009;583:1586&#x2013;1592. doi: 10.1016/j.febslet.2009.04.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.febslet.2009.04.019</ArticleId><ArticleId IdType="pubmed">19379745</ArticleId></ArticleIdList></Reference><Reference><Citation>Diaper D.C., Adachi Y., Lazarou L., Greenstein M., Simoes F.A., Di Domenico A., Solomon D.A., Lowe S., Alsubaie R., Cheng D., et al. Drosophila TDP-43 dysfunction in glia and muscle cells cause cytological and behavioural phenotypes that characterize ALS and FTLD. Hum. Mol. Genet. 2013;22:3883&#x2013;3893. doi: 10.1093/hmg/ddt243.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddt243</ArticleId><ArticleId IdType="pmc">PMC3766182</ArticleId><ArticleId IdType="pubmed">23727833</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu Y., Ferris J., Gao F.-B. Frontotemporal dementia and amyotrophic lateral sclerosis-associated disease protein TDP-43 promotes dendritic branching. Mol. Brain. 2009;2:30. doi: 10.1186/1756-6606-2-30.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1756-6606-2-30</ArticleId><ArticleId IdType="pmc">PMC2762964</ArticleId><ArticleId IdType="pubmed">19781077</ArticleId></ArticleIdList></Reference><Reference><Citation>Baldwin K.R., Godena V.K., Hewitt V.L., Whitworth A.J. Axonal transport defects are a common phenotype in Drosophila models of ALS. Hum. Mol. Genet. 2016;25:2378&#x2013;2392.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5181624</ArticleId><ArticleId IdType="pubmed">27056981</ArticleId></ArticleIdList></Reference><Reference><Citation>Diaper D.C., Adachi Y., Sutcliffe B., Humphrey D.M., Elliott C.J.H., Stepto A., Ludlow Z.N., Vanden Broeck L., Callaerts P., Dermaut B., et al. Loss and gain of Drosophila TDP-43 impair synaptic efficacy and motor control leading to age-related neurodegeneration by loss-of-function phenotypes. Hum. Mol. Genet. 2013;22:1539&#x2013;1557. doi: 10.1093/hmg/ddt005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddt005</ArticleId><ArticleId IdType="pmc">PMC3605831</ArticleId><ArticleId IdType="pubmed">23307927</ArticleId></ArticleIdList></Reference><Reference><Citation>Magran&#xe9; J., Cortez C., Gan W.-B., Manfredi G. Abnormal mitochondrial transport and morphology are common pathological denominators in SOD1 and TDP43 ALS mouse models. Hum. Mol. Genet. 2014;23:1413&#x2013;1424. doi: 10.1093/hmg/ddt528.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddt528</ArticleId><ArticleId IdType="pmc">PMC3929084</ArticleId><ArticleId IdType="pubmed">24154542</ArticleId></ArticleIdList></Reference><Reference><Citation>Choksi D.K., Roy B., Chatterjee S., Yusuff T., Bakhoum M.F., Sengupta U., Ambegaokar S., Kayed R., Jackson G.R. TDP-43 Phosphorylation by casein kinase I&#x3b5; promotes oligomerization and enhances toxicity in vivo. Hum. Mol. Genet. 2014;23:1025&#x2013;1035. doi: 10.1093/hmg/ddt498.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddt498</ArticleId><ArticleId IdType="pubmed">24105464</ArticleId></ArticleIdList></Reference><Reference><Citation>Voigt A., Herholz D., Fiesel F.C., Kaur K., M&#xfc;ller D., Karsten P., Weber S.S., Kahle P.J., Marquardt T., Schulz J.B. TDP-43-mediated neuron loss in vivo requires RNA-binding activity. PLoS ONE. 2010;5:e12247. doi: 10.1371/journal.pone.0012247.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0012247</ArticleId><ArticleId IdType="pmc">PMC2923622</ArticleId><ArticleId IdType="pubmed">20806063</ArticleId></ArticleIdList></Reference><Reference><Citation>McGurk L., Gomes E., Guo L., Mojsilovic-Petrovic J., Tran V., Kalb R.G., Shorter J., Bonini N.M. Poly(ADP-Ribose) Prevents Pathological Phase Separation of TDP-43 by Promoting Liquid Demixing and Stress Granule Localization. Mol. Cell. 2018;71:703&#x2013;717.e9. doi: 10.1016/j.molcel.2018.07.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molcel.2018.07.002</ArticleId><ArticleId IdType="pmc">PMC6128762</ArticleId><ArticleId IdType="pubmed">30100264</ArticleId></ArticleIdList></Reference><Reference><Citation>Krug L., Chatterjee N., Borges-Monroy R., Hearn S., Liao W.-W., Morrill K., Prazak L., Rozhkov N., Theodorou D., Hammell M., et al. Retrotransposon activation contributes to neurodegeneration in a Drosophila TDP-43 model of ALS. PLoS Genet. 2017;13:e1006635. doi: 10.1371/journal.pgen.1006635.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pgen.1006635</ArticleId><ArticleId IdType="pmc">PMC5354250</ArticleId><ArticleId IdType="pubmed">28301478</ArticleId></ArticleIdList></Reference><Reference><Citation>Khalil B., Cabirol-Pol M.-J., Miguel L., Whitworth A.J., Lecourtois M., Li&#xe9;vens J.-C. Enhancing Mitofusin/Marf ameliorates neuromuscular dysfunction in Drosophila models of TDP-43 proteinopathies. Neurobiol. Aging. 2017;54:71&#x2013;83. doi: 10.1016/j.neurobiolaging.2017.02.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2017.02.016</ArticleId><ArticleId IdType="pubmed">28324764</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang J.-C., Hazelett D.J., Stewart J.A., Morton D.B. Motor neuron expression of the voltage-gated calcium channel cacophony restores locomotion defects in a Drosophila, TDP-43 loss of function model of ALS. Brain Res. 2014;1584:39&#x2013;51. doi: 10.1016/j.brainres.2013.11.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2013.11.019</ArticleId><ArticleId IdType="pmc">PMC4031311</ArticleId><ArticleId IdType="pubmed">24275199</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang J.-C., Morton D.B. Drosophila lines with mutant and wild type human TDP-43 replacing the endogenous gene reveals phosphorylation and ubiquitination in mutant lines in the absence of viability or lifespan defects. PLoS ONE. 2017;12:e0180828. doi: 10.1371/journal.pone.0180828.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0180828</ArticleId><ArticleId IdType="pmc">PMC5501610</ArticleId><ArticleId IdType="pubmed">28686708</ArticleId></ArticleIdList></Reference><Reference><Citation>Estes P.S., Boehringer A., Zwick R., Tang J.E., Grigsby B., Zarnescu D.C. Wild-type and A315T mutant TDP-43 exert differential neurotoxicity in a Drosophila model of ALS. Hum. Mol. Genet. 2011;20:2308&#x2013;2321. doi: 10.1093/hmg/ddr124.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddr124</ArticleId><ArticleId IdType="pmc">PMC3098735</ArticleId><ArticleId IdType="pubmed">21441568</ArticleId></ArticleIdList></Reference><Reference><Citation>Estes P.S., Daniel S.G., McCallum A.P., Boehringer A.V., Sukhina A.S., Zwick R.A., Zarnescu D.C. Motor neurons and glia exhibit specific individualized responses to TDP-43 expression in a Drosophila model of amyotrophic lateral sclerosis. Dis. Model. Mech. 2013;6:721&#x2013;733. doi: 10.1242/dmm.010710.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/dmm.010710</ArticleId><ArticleId IdType="pmc">PMC3634655</ArticleId><ArticleId IdType="pubmed">23471911</ArticleId></ArticleIdList></Reference><Reference><Citation>Ritson G.P., Custer S.K., Freibaum B.D., Guinto J.B., Geffel D., Moore J., Tang W., Winton M.J., Neumann M., Trojanowski J.Q., et al. TDP-43 mediates degeneration in a novel Drosophila model of disease caused by mutations in VCP/p97. J. Neurosci. 2010;30:7729&#x2013;7739. doi: 10.1523/JNEUROSCI.5894-09.2010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.5894-09.2010</ArticleId><ArticleId IdType="pmc">PMC2890254</ArticleId><ArticleId IdType="pubmed">20519548</ArticleId></ArticleIdList></Reference><Reference><Citation>Sreedharan J., Neukomm L.J., Brown R.H.J., Freeman M.R. Age-Dependent TDP-43-Mediated Motor Neuron Degeneration Requires GSK3, hat-trick, and xmas-2. Curr. Biol. 2015;25:2130&#x2013;2136. doi: 10.1016/j.cub.2015.06.045.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cub.2015.06.045</ArticleId><ArticleId IdType="pmc">PMC4546534</ArticleId><ArticleId IdType="pubmed">26234214</ArticleId></ArticleIdList></Reference><Reference><Citation>Stolow D.T., Haynes S.R. Cabeza, a Drosophila gene encoding a novel RNA binding protein, shares homology with EWS and TLS, two genes involved in human sarcoma formation. Nucleic Acids Res. 1995;23:835&#x2013;843. doi: 10.1093/nar/23.5.835.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/23.5.835</ArticleId><ArticleId IdType="pmc">PMC306767</ArticleId><ArticleId IdType="pubmed">7708500</ArticleId></ArticleIdList></Reference><Reference><Citation>Frickenhaus M., Wagner M., Mallik M., Catinozzi M., Storkebaum E. Highly efficient cell-type-specific gene inactivation reveals a key function for the Drosophila FUS homolog cabeza in neurons. Sci. Rep. 2015;5:9107. doi: 10.1038/srep09107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep09107</ArticleId><ArticleId IdType="pmc">PMC5390904</ArticleId><ArticleId IdType="pubmed">25772687</ArticleId></ArticleIdList></Reference><Reference><Citation>Sasayama H., Shimamura M., Tokuda T., Azuma Y., Yoshida T., Mizuno T., Nakagawa M., Fujikake N., Nagai Y., Yamaguchi M. Knockdown of the Drosophila fused in sarcoma (FUS) homologue causes deficient locomotive behavior and shortening of motoneuron terminal branches. PLoS ONE. 2012;7:e39483. doi: 10.1371/journal.pone.0039483.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0039483</ArticleId><ArticleId IdType="pmc">PMC3378546</ArticleId><ArticleId IdType="pubmed">22724023</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimamura M., Kyotani A., Azuma Y., Yoshida H., Binh Nguyen T., Mizuta I., Yoshida T., Mizuno T., Nakagawa M., Tokuda T., et al. Genetic link between Cabeza, a Drosophila homologue of Fused in Sarcoma (FUS), and the EGFR signaling pathway. Exp. Cell Res. 2014;326:36&#x2013;45. doi: 10.1016/j.yexcr.2014.06.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.yexcr.2014.06.004</ArticleId><ArticleId IdType="pubmed">24928275</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J.-W., Brent J.R., Tomlinson A., Shneider N.A., McCabe B.D. The ALS-associated proteins FUS and TDP-43 function together to affect Drosophila locomotion and life span. J. Clin. Investig. 2011;121:4118&#x2013;4126. doi: 10.1172/JCI57883.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI57883</ArticleId><ArticleId IdType="pmc">PMC3195475</ArticleId><ArticleId IdType="pubmed">21881207</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia R., Liu Y., Yang L., Gal J., Zhu H., Jia J. Motor neuron apoptosis and neuromuscular junction perturbation are prominent features in a Drosophila model of Fus-mediated ALS. Mol. Neurodegener. 2012;7:10. doi: 10.1186/1750-1326-7-10.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1750-1326-7-10</ArticleId><ArticleId IdType="pmc">PMC3325858</ArticleId><ArticleId IdType="pubmed">22443542</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y., Yang M., Deng J., Chen X., Ye Y., Zhu L., Liu J., Ye H., Shen Y., Li Y., et al. Expression of human FUS protein in Drosophila leads to progressive neurodegeneration. Protein Cell. 2011;2:477&#x2013;486. doi: 10.1007/s13238-011-1065-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13238-011-1065-7</ArticleId><ArticleId IdType="pmc">PMC3563268</ArticleId><ArticleId IdType="pubmed">21748598</ArticleId></ArticleIdList></Reference><Reference><Citation>J&#xe4;ckel S., Summerer A.K., Th&#xf6;mmes C.M., Pan X., Voigt A., Schulz J.B., Rasse T.M., Dormann D., Haass C., Kahle P.J. Nuclear import factor transportin and arginine methyltransferase 1 modify FUS neurotoxicity in Drosophila. Neurobiol. Dis. 2015;74:76&#x2013;88. doi: 10.1016/j.nbd.2014.11.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2014.11.003</ArticleId><ArticleId IdType="pubmed">25447237</ArticleId></ArticleIdList></Reference><Reference><Citation>Lanson N.A.J., Maltare A., King H., Smith R., Kim J.H., Taylor J.P., Lloyd T.E., Pandey U.B. A Drosophila model of FUS-related neurodegeneration reveals genetic interaction between FUS and TDP-43. Hum. Mol. Genet. 2011;20:2510&#x2013;2523. doi: 10.1093/hmg/ddr150.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddr150</ArticleId><ArticleId IdType="pmc">PMC4288133</ArticleId><ArticleId IdType="pubmed">21487023</ArticleId></ArticleIdList></Reference><Reference><Citation>Machamer J.B., Collins S.E., Lloyd T.E. The ALS gene FUS regulates synaptic transmission at the Drosophila neuromuscular junction. Hum. Mol. Genet. 2014;23:3810&#x2013;3822. doi: 10.1093/hmg/ddu094.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddu094</ArticleId><ArticleId IdType="pmc">PMC4065154</ArticleId><ArticleId IdType="pubmed">24569165</ArticleId></ArticleIdList></Reference><Reference><Citation>Miguel L., Avequin T., Delarue M., Feuillette S., Fr&#xe9;bourg T., Campion D., Lecourtois M. Accumulation of insoluble forms of FUS protein correlates with toxicity in Drosophila. Neurobiol. Aging. 2012;33:e1&#x2013;e15. doi: 10.1016/j.neurobiolaging.2011.10.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2011.10.008</ArticleId><ArticleId IdType="pubmed">22118902</ArticleId></ArticleIdList></Reference><Reference><Citation>Iyer S., Acharya K.R., Subramanian V. A comparative bioinformatic analysis of C9orf72. PeerJ. 2018;6:e4391. doi: 10.7717/peerj.4391.</Citation><ArticleIdList><ArticleId IdType="doi">10.7717/peerj.4391</ArticleId><ArticleId IdType="pmc">PMC5822839</ArticleId><ArticleId IdType="pubmed">29479499</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuva-Aydemir Y., Almeida S., Gao F.-B. Insights into C9ORF72-Related ALS/FTD from Drosophila and iPSC Models. Trends Neurosci. 2018;41:457&#x2013;469. doi: 10.1016/j.tins.2018.04.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tins.2018.04.002</ArticleId><ArticleId IdType="pmc">PMC6015541</ArticleId><ArticleId IdType="pubmed">29729808</ArticleId></ArticleIdList></Reference><Reference><Citation>Celona B., von Dollen J., Vatsavayai S.C., Kashima R., Johnson J.R., Tang A.A., Hata A., Miller B.L., Huang E.J., Krogan N.J., et al. Suppression of C9orf72 RNA repeat-induced neurotoxicity by the ALS-associated RNA-binding protein Zfp106. eLife. 2017;6:e19032. doi: 10.7554/eLife.19032.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.19032</ArticleId><ArticleId IdType="pmc">PMC5283830</ArticleId><ArticleId IdType="pubmed">28072389</ArticleId></ArticleIdList></Reference><Reference><Citation>Freibaum B.D., Lu Y., Lopez-Gonzalez R., Kim N.C., Almeida S., Lee K.-H., Badders N., Valentine M., Miller B.L., Wong P.C., et al. GGGGCC repeat expansion in C9orf72 compromises nucleocytoplasmic transport. Nature. 2015;525:129&#x2013;133. doi: 10.1038/nature14974.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature14974</ArticleId><ArticleId IdType="pmc">PMC4631399</ArticleId><ArticleId IdType="pubmed">26308899</ArticleId></ArticleIdList></Reference><Reference><Citation>Kramer N.J., Carlomagno Y., Zhang Y.-J., Almeida S., Cook C.N., Gendron T.F., Prudencio M., Van Blitterswijk M., Belzil V., Couthouis J., et al. Spt4 selectively regulates the expression of C9orf72 sense and antisense mutant transcripts. Science. 2016;353:708&#x2013;712. doi: 10.1126/science.aaf7791.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aaf7791</ArticleId><ArticleId IdType="pmc">PMC5823025</ArticleId><ArticleId IdType="pubmed">27516603</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang K., Donnelly C.J., Haeusler A.R., Grima J.C., Machamer J.B., Steinwald P., Daley E.L., Miller S.J., Cunningham K.M., Vidensky S., et al. The C9orf72 repeat expansion disrupts nucleocytoplasmic transport. Nature. 2015;525:56&#x2013;61. doi: 10.1038/nature14973.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature14973</ArticleId><ArticleId IdType="pmc">PMC4800742</ArticleId><ArticleId IdType="pubmed">26308891</ArticleId></ArticleIdList></Reference><Reference><Citation>Gendron T.F., Belzil V.V., Zhang Y.-J., Petrucelli L. Mechanisms of toxicity in C9FTLD/ALS. Acta Neuropathol. 2014;127:359&#x2013;376. doi: 10.1007/s00401-013-1237-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-013-1237-z</ArticleId><ArticleId IdType="pmc">PMC4002260</ArticleId><ArticleId IdType="pubmed">24394885</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori K., Weng S.-M., Arzberger T., May S., Rentzsch K., Kremmer E., Schmid B., Kretzschmar H.A., Cruts M., Van Broeckhoven C., et al. The C9orf72 GGGGCC repeat is translated into aggregating dipeptide-repeat proteins in FTLD/ALS. Science. 2013;339:1335&#x2013;1338. doi: 10.1126/science.1232927.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1232927</ArticleId><ArticleId IdType="pubmed">23393093</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee K.-H., Zhang P., Kim H.J., Mitrea D.M., Sarkar M., Freibaum B.D., Cika J., Coughlin M., Messing J., Molliex A., et al. C9orf72 Dipeptide Repeats Impair the Assembly, Dynamics, and Function of Membrane-Less Organelles. Cell. 2016;167:774&#x2013;788.e17. doi: 10.1016/j.cell.2016.10.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2016.10.002</ArticleId><ArticleId IdType="pmc">PMC5079111</ArticleId><ArticleId IdType="pubmed">27768896</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizielinska S., Gr&#xf6;nke S., Niccoli T., Ridler C.E., Clayton E.L., Devoy A., Moens T., Norona F.E., Woollacott I.O.C., Pietrzyk J., et al. C9orf72 repeat expansions cause neurodegeneration in Drosophila through arginine-rich proteins. Science. 2014;345:1192&#x2013;1194. doi: 10.1126/science.1256800.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1256800</ArticleId><ArticleId IdType="pmc">PMC4944841</ArticleId><ArticleId IdType="pubmed">25103406</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen X., Tan W., Westergard T., Krishnamurthy K., Markandaiah S.S., Shi Y., Lin S., Shneider N.A., Monaghan J., Pandey U.B., et al. Antisense proline-arginine RAN dipeptides linked to C9ORF72-ALS/FTD form toxic nuclear aggregates that initiate in vitro and in vivo neuronal death. Neuron. 2014;84:1213&#x2013;1225. doi: 10.1016/j.neuron.2014.12.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2014.12.010</ArticleId><ArticleId IdType="pmc">PMC4632245</ArticleId><ArticleId IdType="pubmed">25521377</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizielinska S., Ridler C.E., Balendra R., Thoeng A., Woodling N.S., Gr&#xe4;sser F.A., Plagnol V., Lashley T., Partridge L., Isaacs A.M. Bidirectional nucleolar dysfunction in C9orf72 frontotemporal lobar degeneration. Acta Neuropathol. Commun. 2017;5:29. doi: 10.1186/s40478-017-0432-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-017-0432-x</ArticleId><ArticleId IdType="pmc">PMC5395972</ArticleId><ArticleId IdType="pubmed">28420437</ArticleId></ArticleIdList></Reference><Reference><Citation>Tran H., Almeida S., Moore J., Gendron T.F., Chalasani U., Lu Y., Du X., Nickerson J.A., Petrucelli L., Weng Z., et al. Differential Toxicity of Nuclear RNA Foci versus Dipeptide Repeat Proteins in a Drosophila Model of C9ORF72 FTD/ALS. Neuron. 2015;87:1207&#x2013;1214. doi: 10.1016/j.neuron.2015.09.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2015.09.015</ArticleId><ArticleId IdType="pmc">PMC4589299</ArticleId><ArticleId IdType="pubmed">26402604</ArticleId></ArticleIdList></Reference><Reference><Citation>Phillips J.B., Westerfield M. Zebrafish models in translational research: Tipping the scales toward advancements in human health. DMM Dis. Model. Mech. 2014;7:739&#x2013;743. doi: 10.1242/dmm.015545.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/dmm.015545</ArticleId><ArticleId IdType="pmc">PMC4073263</ArticleId><ArticleId IdType="pubmed">24973743</ArticleId></ArticleIdList></Reference><Reference><Citation>Patten S.A., Armstrong G.A.B., Lissouba A., Kabashi E., Parker J.A., Drapeau P. Fishing for causes and cures of motor neuron disorders. Dis. Model. Mech. 2014;7:799&#x2013;809. doi: 10.1242/dmm.015719.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/dmm.015719</ArticleId><ArticleId IdType="pmc">PMC4073270</ArticleId><ArticleId IdType="pubmed">24973750</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Damme P., Robberecht W., Van Den Bosch L. Modelling amyotrophic lateral sclerosis: Progress and possibilities. Dis. Model. Mech. 2017;10:537&#x2013;549. doi: 10.1242/dmm.029058.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/dmm.029058</ArticleId><ArticleId IdType="pmc">PMC5451175</ArticleId><ArticleId IdType="pubmed">28468939</ArticleId></ArticleIdList></Reference><Reference><Citation>Fortier G., Butti Z., Patten S.A. Modelling C9orf72-Related Amyotrophic Lateral Sclerosis in Zebrafish. Biomedicines. 2020;8:e19032. doi: 10.3390/biomedicines8100440.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines8100440</ArticleId><ArticleId IdType="pmc">PMC7589578</ArticleId><ArticleId IdType="pubmed">33096681</ArticleId></ArticleIdList></Reference><Reference><Citation>Gois A.M., Mendon&#xe7;a D.M.F., Freire M.A.M., Santos J.R. In vitro and in vivo models of amyotrophic lateral sclerosis: An updated overview. Brain Res. Bull. 2020;159:32&#x2013;43. doi: 10.1016/j.brainresbull.2020.03.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainresbull.2020.03.012</ArticleId><ArticleId IdType="pubmed">32247802</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerety S.S., Wilkinson D.G. Morpholino artifacts provide pitfalls and reveal a novel role for pro-apoptotic genes in hindbrain boundary development. Dev. Biol. 2011;350:279&#x2013;289. doi: 10.1016/j.ydbio.2010.11.030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ydbio.2010.11.030</ArticleId><ArticleId IdType="pmc">PMC3111810</ArticleId><ArticleId IdType="pubmed">21145318</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramesh T., Lyon A.N., Pineda R.H., Wang C., Janssen P.M.L., Canan B.D., Burghes A.H.M., Beattie C.E. A genetic model of amyotrophic lateral sclerosis in zebrafish displays phenotypic hallmarks of motoneuron disease. Dis. Model. Mech. 2010;3:652&#x2013;662. doi: 10.1242/dmm.005538.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/dmm.005538</ArticleId><ArticleId IdType="pmc">PMC2931540</ArticleId><ArticleId IdType="pubmed">20504969</ArticleId></ArticleIdList></Reference><Reference><Citation>Lemmens R., Van Hoecke A., Hersmus N., Geelen V., D&#x2019;Hollander I., Thijs V., Van Den Bosch L., Carmeliet P., Robberecht W. Overexpression of mutant superoxide dismutase 1 causes a motor axonopathy in the zebrafish. Hum. Mol. Genet. 2007;16:2359&#x2013;2365. doi: 10.1093/hmg/ddm193.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddm193</ArticleId><ArticleId IdType="pubmed">17636250</ArticleId></ArticleIdList></Reference><Reference><Citation>Da Costa M.M.J., Allen C.E., Higginbottom A., Ramesh T., Shaw P.J., McDermott C.J. A new zebrafish model produced by TILLING of SOD1-related amyotrophic lateral sclerosis replicates key features of the disease and represents a tool for in vivo therapeutic screening. Dis. Model. Mech. 2014;7:73&#x2013;81. doi: 10.1242/dmm.012013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/dmm.012013</ArticleId><ArticleId IdType="pmc">PMC3882050</ArticleId><ArticleId IdType="pubmed">24092880</ArticleId></ArticleIdList></Reference><Reference><Citation>Benedetti L., Ghilardi A., Rottoli E., De Maglie M., Prosperi L., Perego C., Baruscotti M., Bucchi A., Del Giacco L., Francolini M. INaP selective inhibition reverts precocious inter- and motorneurons hyperexcitability in the Sod1-G93R zebrafish ALS model. Sci. Rep. 2016;6:24515. doi: 10.1038/srep24515.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep24515</ArticleId><ArticleId IdType="pmc">PMC4832213</ArticleId><ArticleId IdType="pubmed">27079797</ArticleId></ArticleIdList></Reference><Reference><Citation>Powers S., Kwok S., Lovejoy E., Lavin T., Sher R.B. Editor&#x2019;s Highlight: Embryonic Exposure to the Environmental Neurotoxin BMAA Negatively Impacts Early Neuronal Development and Progression of Neurodegeneration in the Sod1-G93R Zebrafish Model of Amyotrophic Lateral Sclerosis. Toxicol. Sci. 2017;157:129&#x2013;140.</Citation><ArticleIdList><ArticleId IdType="pubmed">28123103</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi S.Y., Lee J.-H., Chung A.-Y., Jo Y., Shin J.-H., Park H.-C., Kim H., Lopez-Gonzalez R., Ryu J.R., Sun W. Prevention of mitochondrial impairment by inhibition of protein phosphatase 1 activity in amyotrophic lateral sclerosis. Cell Death Dis. 2020;11:888. doi: 10.1038/s41419-020-03102-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41419-020-03102-8</ArticleId><ArticleId IdType="pmc">PMC7578657</ArticleId><ArticleId IdType="pubmed">33087694</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldshtein H., Muhire A., Petel L&#xe9;gar&#xe9; V., Pushett A., Rotkopf R., Shefner J.M., Peterson R.T., Armstrong G.A.B., Russek-Blum N. Efficacy of Ciprofloxacin/Celecoxib combination in zebrafish models of amyotrophic lateral sclerosis. Ann. Clin. Transl. Neurol. 2020;7:1883&#x2013;1897. doi: 10.1002/acn3.51174.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.51174</ArticleId><ArticleId IdType="pmc">PMC7545590</ArticleId><ArticleId IdType="pubmed">32915525</ArticleId></ArticleIdList></Reference><Reference><Citation>Parakh S., Shadfar S., Perri E.R., Ragagnin A.M.G., Piattoni C.V., Fogol&#xed;n M.B., Yuan K.C., Shahheydari H., Don E.K., Thomas C.J., et al. The Redox Activity of Protein Disulfide Isomerase Inhibits ALS Phenotypes in Cellular and Zebrafish Models. iScience. 2020;23:101097. doi: 10.1016/j.isci.2020.101097.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.isci.2020.101097</ArticleId><ArticleId IdType="pmc">PMC7240177</ArticleId><ArticleId IdType="pubmed">32446203</ArticleId></ArticleIdList></Reference><Reference><Citation>Laird A.S., Van Hoecke A., De Muynck L., Timmers M., Van den Bosch L., Van Damme P., Robberecht W. Progranulin is neurotrophic in vivo and protects against a mutant TDP-43 induced axonopathy. PLoS ONE. 2010;5:e13368. doi: 10.1371/journal.pone.0013368.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0013368</ArticleId><ArticleId IdType="pmc">PMC2954192</ArticleId><ArticleId IdType="pubmed">20967127</ArticleId></ArticleIdList></Reference><Reference><Citation>Kabashi E., Lin L., Tradewell M.L., Dion P.A., Bercier V., Bourgouin P., Rochefort D., Bel Hadj S., Durham H.D., Vande Velde C., et al. Gain and loss of function of ALS-related mutations of TARDBP (TDP-43) cause motor deficits in vivo. Hum. Mol. Genet. 2010;19:671&#x2013;683. doi: 10.1093/hmg/ddp534.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddp534</ArticleId><ArticleId IdType="pubmed">19959528</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccaro A., Patten S.A., Aggad D., Julien C., Maios C., Kabashi E., Drapeau P., Parker J.A. Pharmacological reduction of ER stress protects against TDP-43 neuronal toxicity in vivo. Neurobiol. Dis. 2013;55:64&#x2013;75. doi: 10.1016/j.nbd.2013.03.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2013.03.015</ArticleId><ArticleId IdType="pubmed">23567652</ArticleId></ArticleIdList></Reference><Reference><Citation>Hewamadduma C.A.A., Grierson A.J., Ma T.P., Pan L., Moens C.B., Ingham P.W., Ramesh T., Shaw P.J. Tardbpl splicing rescues motor neuron and axonal development in a mutant tardbp zebrafish. Hum. Mol. Genet. 2013;22:2376&#x2013;2386. doi: 10.1093/hmg/ddt082.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddt082</ArticleId><ArticleId IdType="pmc">PMC3658164</ArticleId><ArticleId IdType="pubmed">23427147</ArticleId></ArticleIdList></Reference><Reference><Citation>Kabashi E., Brustein E., Champagne N., Drapeau P. Zebrafish models for the functional genomics of neurogenetic disorders. Biochim. Biophys. Acta. 2011;1812:335&#x2013;345. doi: 10.1016/j.bbadis.2010.09.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbadis.2010.09.011</ArticleId><ArticleId IdType="pubmed">20887784</ArticleId></ArticleIdList></Reference><Reference><Citation>Armstrong G.A.B., Drapeau P. Loss and gain of FUS function impair neuromuscular synaptic transmission in a genetic model of ALS. Hum. Mol. Genet. 2013;22:4282&#x2013;4292. doi: 10.1093/hmg/ddt278.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddt278</ArticleId><ArticleId IdType="pubmed">23771027</ArticleId></ArticleIdList></Reference><Reference><Citation>Bosco D.A., Lemay N., Ko H.K., Zhou H., Burke C., Kwiatkowski T.J.J., Sapp P., McKenna-Yasek D., Brown R.H.J., Hayward L.J. Mutant FUS proteins that cause amyotrophic lateral sclerosis incorporate into stress granules. Hum. Mol. Genet. 2010;19:4160&#x2013;4175. doi: 10.1093/hmg/ddq335.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddq335</ArticleId><ArticleId IdType="pmc">PMC2981014</ArticleId><ArticleId IdType="pubmed">20699327</ArticleId></ArticleIdList></Reference><Reference><Citation>Acosta J.R., Goldsbury C., Winnick C., Badrock A.P., Fraser S.T., Laird A.S., Hall T.E., Don E.K., Fifita J.A., Blair I.P., et al. Mutant human FUS Is ubiquitously mislocalized and generates persistent stress granules in primary cultured transgenic zebrafish cells. PLoS ONE. 2014;9:e90572. doi: 10.1371/journal.pone.0090572.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0090572</ArticleId><ArticleId IdType="pmc">PMC4049593</ArticleId><ArticleId IdType="pubmed">24912067</ArticleId></ArticleIdList></Reference><Reference><Citation>Armstrong G.A.B., Liao M., You Z., Lissouba A., Chen B.E., Drapeau P. Homology Directed Knockin of Point Mutations in the Zebrafish tardbp and fus Genes in ALS Using the CRISPR/Cas9 System. PLoS ONE. 2016;11:e0150188. doi: 10.1371/journal.pone.0150188.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0150188</ArticleId><ArticleId IdType="pmc">PMC4773037</ArticleId><ArticleId IdType="pubmed">26930076</ArticleId></ArticleIdList></Reference><Reference><Citation>Bourefis A.-R., Campanari M.-L., Buee-Scherrer V., Kabashi E. Functional characterization of a FUS mutant zebrafish line as a novel genetic model for ALS. Neurobiol. Dis. 2020;142:104935. doi: 10.1016/j.nbd.2020.104935.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2020.104935</ArticleId><ArticleId IdType="pubmed">32380281</ArticleId></ArticleIdList></Reference><Reference><Citation>Campanari M.-L., Bourefis A.-R., Buee-Scherrer V., Kabashi E. Freezing activity brief data from a new FUS mutant zebrafish line. Data Br. 2020;31:105921. doi: 10.1016/j.dib.2020.105921.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dib.2020.105921</ArticleId><ArticleId IdType="pmc">PMC7352050</ArticleId><ArticleId IdType="pubmed">32676526</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciura S., Lattante S., Le Ber I., Latouche M., Tostivint H., Brice A., Kabashi E. Loss of function of C9orf72 causes motor deficits in a zebrafish model of amyotrophic lateral sclerosis. Ann. Neurol. 2013;74:180&#x2013;187. doi: 10.1002/ana.23946.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.23946</ArticleId><ArticleId IdType="pubmed">23720273</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeh T.-H., Liu H.-F., Li Y.-W., Lu C.-S., Shih H.-Y., Chiu C.-C., Lin S.-J., Huang Y.-C., Cheng Y.-C. C9orf72 is essential for neurodevelopment and motility mediated by Cyclin G1. Exp. Neurol. 2018;304:114&#x2013;124. doi: 10.1016/j.expneurol.2018.03.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2018.03.002</ArticleId><ArticleId IdType="pubmed">29522758</ArticleId></ArticleIdList></Reference><Reference><Citation>Butti Z., Pan Y.E., Giacomotto J., Patten S.A. Reduced C9orf72 function leads to defective synaptic vesicle release and neuromuscular dysfunction in zebrafish. Commun. Biol. 2021;4:792. doi: 10.1038/s42003-021-02302-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s42003-021-02302-y</ArticleId><ArticleId IdType="pmc">PMC8233344</ArticleId><ArticleId IdType="pubmed">34172817</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee Y.-B., Chen H.-J., Peres J.N., Gomez-Deza J., Attig J., Stalekar M., Troakes C., Nishimura A.L., Scotter E.L., Vance C., et al. Hexanucleotide repeats in ALS/FTD form length-dependent RNA foci, sequester RNA binding proteins, and are neurotoxic. Cell Rep. 2013;5:1178&#x2013;1186. doi: 10.1016/j.celrep.2013.10.049.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2013.10.049</ArticleId><ArticleId IdType="pmc">PMC3898469</ArticleId><ArticleId IdType="pubmed">24290757</ArticleId></ArticleIdList></Reference><Reference><Citation>Swinnen B., Bento-Abreu A., Gendron T.F., Boeynaems S., Bogaert E., Nuyts R., Timmers M., Scheveneels W., Hersmus N., Wang J., et al. A zebrafish model for C9orf72 ALS reveals RNA toxicity as a pathogenic mechanism. Acta Neuropathol. 2018;135:427&#x2013;443. doi: 10.1007/s00401-017-1796-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-017-1796-5</ArticleId><ArticleId IdType="pubmed">29302778</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaw M.P., Higginbottom A., McGown A., Castelli L.M., James E., Hautbergue G.M., Shaw P.J., Ramesh T.M. Stable transgenic C9orf72 zebrafish model key aspects of the ALS/FTD phenotype and reveal novel pathological features. Acta Neuropathol. Commun. 2018;6:125. doi: 10.1186/s40478-018-0629-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-018-0629-7</ArticleId><ArticleId IdType="pmc">PMC6240957</ArticleId><ArticleId IdType="pubmed">30454072</ArticleId></ArticleIdList></Reference><Reference><Citation>Schludi M.H., May S., Gr&#xe4;sser F.A., Rentzsch K., Kremmer E., K&#xfc;pper C., Klopstock T., Arzberger T., Edbauer D. Distribution of dipeptide repeat proteins in cellular models and C9orf72 mutation cases suggests link to transcriptional silencing. Acta Neuropathol. 2015;130:537&#x2013;555. doi: 10.1007/s00401-015-1450-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-015-1450-z</ArticleId><ArticleId IdType="pmc">PMC4575390</ArticleId><ArticleId IdType="pubmed">26085200</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohki Y., Wenninger-Weinzierl A., Hruscha A., Asakawa K., Kawakami K., Haass C., Edbauer D., Schmid B. Glycine-alanine dipeptide repeat protein contributes to toxicity in a zebrafish model of C9orf72 associated neurodegeneration. Mol. Neurodegener. 2017;12:6. doi: 10.1186/s13024-016-0146-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-016-0146-8</ArticleId><ArticleId IdType="pmc">PMC5237533</ArticleId><ArticleId IdType="pubmed">28088213</ArticleId></ArticleIdList></Reference><Reference><Citation>Swaminathan A., Bouffard M., Liao M., Ryan S., Callister J.B., Pickering-Brown S.M., Armstrong G.A.B., Drapeau P. Expression of C9orf72-related dipeptides impairs motor function in a vertebrate model. Hum. Mol. Genet. 2018;27:1754&#x2013;1762. doi: 10.1093/hmg/ddy083.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddy083</ArticleId><ArticleId IdType="pmc">PMC5932562</ArticleId><ArticleId IdType="pubmed">29528390</ArticleId></ArticleIdList></Reference><Reference><Citation>Caldwell K.A., Willicott C.W., Caldwell G.A. Modeling neurodegeneration in Caenorhabditis elegans. Dis. Model. Mech. 2020;13 doi: 10.1242/dmm.046110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/dmm.046110</ArticleId><ArticleId IdType="pmc">PMC7648605</ArticleId><ArticleId IdType="pubmed">33106318</ArticleId></ArticleIdList></Reference><Reference><Citation>Patten S.A., Parker J.A., Wen X.-Y., Drapeau P. Simple animal models for amyotrophic lateral sclerosis drug discovery. Expert Opin. Drug Discov. 2016;11:797&#x2013;804. doi: 10.1080/17460441.2016.1196183.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17460441.2016.1196183</ArticleId><ArticleId IdType="pubmed">27249162</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma L., Zhao Y., Chen Y., Cheng B., Peng A., Huang K. Caenorhabditis elegans as a model system for target identification and drug screening against neurodegenerative diseases. Eur. J. Pharmacol. 2018;819:169&#x2013;180. doi: 10.1016/j.ejphar.2017.11.051.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejphar.2017.11.051</ArticleId><ArticleId IdType="pubmed">29208474</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaye D.D., Greenwald I. OrthoList: A compendium of C. elegans genes with human orthologs. PLoS ONE. 2011;6:e20085. doi: 10.1371/journal.pone.0020085.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0020085</ArticleId><ArticleId IdType="pmc">PMC3102077</ArticleId><ArticleId IdType="pubmed">21647448</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim W., Underwood R.S., Greenwald I., Shaye D.D. OrthoList 2: A New Comparative Genomic Analysis of Human and Caenorhabditis elegans Genes. Genetics. 2018;210:445&#x2013;461. doi: 10.1534/genetics.118.301307.</Citation><ArticleIdList><ArticleId IdType="doi">10.1534/genetics.118.301307</ArticleId><ArticleId IdType="pmc">PMC6216590</ArticleId><ArticleId IdType="pubmed">30120140</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J., Farr G.W., Hall D.H., Li F., Furtak K., Dreier L., Horwich A.L. An ALS-linked mutant SOD1 produces a locomotor defect associated with aggregation and synaptic dysfunction when expressed in neurons of Caenorhabditis elegans. PLoS Genet. 2009;5:e1000350. doi: 10.1371/journal.pgen.1000350.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pgen.1000350</ArticleId><ArticleId IdType="pmc">PMC2621352</ArticleId><ArticleId IdType="pubmed">19165329</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J., Li T., Zhang X., Tang Y., Yang J., Le W. Human superoxide dismutase 1 overexpression in motor neurons of Caenorhabditis elegans causes axon guidance defect and neurodegeneration. Neurobiol. Aging. 2014;35:837&#x2013;846. doi: 10.1016/j.neurobiolaging.2013.09.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2013.09.003</ArticleId><ArticleId IdType="pubmed">24126158</ArticleId></ArticleIdList></Reference><Reference><Citation>Baskoylu S.N., Yersak J., O&#x2019;Hern P., Grosser S., Simon J., Kim S., Schuch K., Dimitriadi M., Yanagi K.S., Lins J., et al. Single copy/knock-in models of ALS SOD1 in C. elegans suggest loss and gain of function have different contributions to cholinergic and glutamatergic neurodegeneration. PLoS Genet. 2018;14:e1007682. doi: 10.1371/journal.pgen.1007682.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pgen.1007682</ArticleId><ArticleId IdType="pmc">PMC6200258</ArticleId><ArticleId IdType="pubmed">30296255</ArticleId></ArticleIdList></Reference><Reference><Citation>Gidalevitz T., Krupinski T., Garcia S., Morimoto R.I. Destabilizing protein polymorphisms in the genetic background direct phenotypic expression of mutant SOD1 toxicity. PLoS Genet. 2009;5:e1000399. doi: 10.1371/journal.pgen.1000399.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pgen.1000399</ArticleId><ArticleId IdType="pmc">PMC2642731</ArticleId><ArticleId IdType="pubmed">19266020</ArticleId></ArticleIdList></Reference><Reference><Citation>Ash P.E.A., Zhang Y.-J., Roberts C.M., Saldi T., Hutter H., Buratti E., Petrucelli L., Link C.D. Neurotoxic effects of TDP-43 overexpression in C. elegans. Hum. Mol. Genet. 2010;19:3206&#x2013;3218. doi: 10.1093/hmg/ddq230.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddq230</ArticleId><ArticleId IdType="pmc">PMC2908471</ArticleId><ArticleId IdType="pubmed">20530643</ArticleId></ArticleIdList></Reference><Reference><Citation>Liachko N.F., Guthrie C.R., Kraemer B.C. Phosphorylation promotes neurotoxicity in a Caenorhabditis elegans model of TDP-43 proteinopathy. J. Neurosci. 2010;30:16208&#x2013;16219. doi: 10.1523/JNEUROSCI.2911-10.2010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2911-10.2010</ArticleId><ArticleId IdType="pmc">PMC3075589</ArticleId><ArticleId IdType="pubmed">21123567</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccaro A., Tauffenberger A., Ash P.E.A., Carlomagno Y., Petrucelli L., Parker J.A. TDP-1/TDP-43 regulates stress signaling and age-dependent proteotoxicity in Caenorhabditis elegans. PLoS Genet. 2012;8:e1002806. doi: 10.1371/journal.pgen.1002806.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pgen.1002806</ArticleId><ArticleId IdType="pmc">PMC3390363</ArticleId><ArticleId IdType="pubmed">22792076</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang T., Hwang H.-Y., Hao H., Talbot C.J., Wang J. Caenorhabditis elegans RNA-processing protein TDP-1 regulates protein homeostasis and life span. J. Biol. Chem. 2012;287:8371&#x2013;8382. doi: 10.1074/jbc.M111.311977.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M111.311977</ArticleId><ArticleId IdType="pmc">PMC3318719</ArticleId><ArticleId IdType="pubmed">22232551</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccaro A., Tauffenberger A., Aggad D., Rouleau G., Drapeau P., Parker J.A. Mutant TDP-43 and FUS cause age-dependent paralysis and neurodegeneration in C. elegans. PLoS ONE. 2012;7:e31321. doi: 10.1371/journal.pone.0031321.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0031321</ArticleId><ArticleId IdType="pmc">PMC3283630</ArticleId><ArticleId IdType="pubmed">22363618</ArticleId></ArticleIdList></Reference><Reference><Citation>Murakami T., Yang S.-P., Xie L., Kawano T., Fu D., Mukai A., Bohm C., Chen F., Robertson J., Suzuki H., et al. ALS mutations in FUS cause neuronal dysfunction and death in Caenorhabditis elegans by a dominant gain-of-function mechanism. Hum. Mol. Genet. 2012;21:1&#x2013;9. doi: 10.1093/hmg/ddr417.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddr417</ArticleId><ArticleId IdType="pmc">PMC3235006</ArticleId><ArticleId IdType="pubmed">21949354</ArticleId></ArticleIdList></Reference><Reference><Citation>Therrien M., Rouleau G.A., Dion P.A., Parker J.A. Deletion of C9ORF72 results in motor neuron degeneration and stress sensitivity in C. elegans. PLoS ONE. 2013;8:e83450. doi: 10.1371/journal.pone.0083450.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0083450</ArticleId><ArticleId IdType="pmc">PMC3861484</ArticleId><ArticleId IdType="pubmed">24349511</ArticleId></ArticleIdList></Reference><Reference><Citation>Corrionero A., Horvitz H.R. A C9orf72 ALS/FTD Ortholog Acts in Endolysosomal Degradation and Lysosomal Homeostasis. Curr. Biol. 2018;28:1522&#x2013;1535.e5. doi: 10.1016/j.cub.2018.03.063.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cub.2018.03.063</ArticleId><ArticleId IdType="pubmed">29731301</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X., Hao L., Saur T., Joyal K., Zhao Y., Zhai D., Li J., Pribadi M., Coppola G., Cohen B.M., et al. Forward Genetic Screen in Caenorhabditis elegans Suggests F57A10.2 and acp-4 As Suppressors of C9ORF72 Related Phenotypes. Front. Mol. Neurosci. 2016;9:113. doi: 10.3389/fnmol.2016.00113.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2016.00113</ArticleId><ArticleId IdType="pmc">PMC5100550</ArticleId><ArticleId IdType="pubmed">27877110</ArticleId></ArticleIdList></Reference><Reference><Citation>Cherry J.M., Hong E.L., Amundsen C., Balakrishnan R., Binkley G., Chan E.T., Christie K.R., Costanzo M.C., Dwight S.S., Engel S.R., et al. Saccharomyces Genome Database: The genomics resource of budding yeast. Nucleic Acids Res. 2012;40:D700&#x2013;D705. doi: 10.1093/nar/gkr1029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkr1029</ArticleId><ArticleId IdType="pmc">PMC3245034</ArticleId><ArticleId IdType="pubmed">22110037</ArticleId></ArticleIdList></Reference><Reference><Citation>Kryndushkin D., Shewmaker F. Modeling ALS and FTLD proteinopathies in yeast: An efficient approach for studying protein aggregation and toxicity. Prion. 2011;5:250&#x2013;257. doi: 10.4161/pri.17229.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/pri.17229</ArticleId><ArticleId IdType="pmc">PMC4012400</ArticleId><ArticleId IdType="pubmed">22052354</ArticleId></ArticleIdList></Reference><Reference><Citation>Tenreiro S., Munder M.C., Alberti S., Outeiro T.F. Harnessing the power of yeast to unravel the molecular basis of neurodegeneration. J. Neurochem. 2013;127:438&#x2013;452. doi: 10.1111/jnc.12271.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.12271</ArticleId><ArticleId IdType="pubmed">23600759</ArticleId></ArticleIdList></Reference><Reference><Citation>Monahan Z.T., Rhoads S.N., Yee D.S., Shewmaker F.P. Yeast Models of Prion-Like Proteins That Cause Amyotrophic Lateral Sclerosis Reveal Pathogenic Mechanisms. Front. Mol. Neurosci. 2018;11:453. doi: 10.3389/fnmol.2018.00453.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2018.00453</ArticleId><ArticleId IdType="pmc">PMC6297178</ArticleId><ArticleId IdType="pubmed">30618605</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabizadeh S., Gralla E.B., Borchelt D.R., Gwinn R., Valentine J.S., Sisodia S., Wong P., Lee M., Hahn H., Bredesen D.E. Mutations associated with amyotrophic lateral sclerosis convert superoxide dismutase from an antiapoptotic gene to a proapoptotic gene: Studies in yeast and neural cells. Proc. Natl. Acad. Sci. USA. 1995;92:3024&#x2013;3028. doi: 10.1073/pnas.92.7.3024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.92.7.3024</ArticleId><ArticleId IdType="pmc">PMC42351</ArticleId><ArticleId IdType="pubmed">7708768</ArticleId></ArticleIdList></Reference><Reference><Citation>Kryndushkin D., Ihrke G., Piermartiri T.C., Shewmaker F. A yeast model of optineurin proteinopathy reveals a unique aggregation pattern associated with cellular toxicity. Mol. Microbiol. 2012;86:1531&#x2013;1547. doi: 10.1111/mmi.12075.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/mmi.12075</ArticleId><ArticleId IdType="pubmed">23078282</ArticleId></ArticleIdList></Reference><Reference><Citation>Armakola M., Hart M.P., Gitler A.D. TDP-43 toxicity in yeast. Methods. 2011;53:238&#x2013;245. doi: 10.1016/j.ymeth.2010.11.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymeth.2010.11.006</ArticleId><ArticleId IdType="pmc">PMC3073690</ArticleId><ArticleId IdType="pubmed">21115123</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurney M.E. The use of transgenic mouse models of amyotrophic lateral sclerosis in preclinical drug studies. J. Neurol. Sci. 1997;152:S67&#x2013;S73. doi: 10.1016/S0022-510X(97)00247-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-510X(97)00247-5</ArticleId><ArticleId IdType="pubmed">9419057</ArticleId></ArticleIdList></Reference><Reference><Citation>Reaume A.G., Elliott J.L., Hoffman E.K., Kowall N.W., Ferrante R.J., Siwek D.F., Wilcox H.M., Flood D.G., Beal M.F., Brown R.H.J., et al. Motor neurons in Cu/Zn superoxide dismutase-deficient mice develop normally but exhibit enhanced cell death after axonal injury. Nat. Genet. 1996;13:43&#x2013;47. doi: 10.1038/ng0596-43.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng0596-43</ArticleId><ArticleId IdType="pubmed">8673102</ArticleId></ArticleIdList></Reference><Reference><Citation>Kl&#xf6;ppel C., Michels C., Zimmer J., Herrmann J.M., Riemer J. In yeast redistribution of Sod1 to the mitochondrial intermembrane space provides protection against respiration derived oxidative stress. Biochem. Biophys. Res. Commun. 2010;403:114&#x2013;119. doi: 10.1016/j.bbrc.2010.10.129.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2010.10.129</ArticleId><ArticleId IdType="pubmed">21055392</ArticleId></ArticleIdList></Reference><Reference><Citation>Sturtz L.A., Diekert K., Jensen L.T., Lill R., Culotta V.C. A fraction of yeast Cu,Zn-superoxide dismutase and its metallochaperone, CCS, localize to the intermembrane space of mitochondria. A physiological role for SOD1 in guarding against mitochondrial oxidative damage. J. Biol. Chem. 2001;276:38084&#x2013;38089. doi: 10.1074/jbc.M105296200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M105296200</ArticleId><ArticleId IdType="pubmed">11500508</ArticleId></ArticleIdList></Reference><Reference><Citation>Bastow E.L., Peswani A.R., Tarrant D.S.J., Pentland D.R., Chen X., Morgan A., Staniforth G.L., Tullet J.M., Rowe M.L., Howard M.J., et al. New links between SOD1 and metabolic dysfunction from a yeast model of amyotrophic lateral sclerosis. J. Cell Sci. 2016;129:4118&#x2013;4129. doi: 10.1242/jcs.190298.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/jcs.190298</ArticleId><ArticleId IdType="pmc">PMC5117206</ArticleId><ArticleId IdType="pubmed">27656112</ArticleId></ArticleIdList></Reference><Reference><Citation>Armakola M., Higgins M.J., Figley M.D., Barmada S.J., Scarborough E.A., Diaz Z., Fang X., Shorter J., Krogan N.J., Finkbeiner S., et al. Inhibition of RNA lariat debranching enzyme suppresses TDP-43 toxicity in ALS disease models. Nat. Genet. 2012;44:1302&#x2013;1309. doi: 10.1038/ng.2434.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.2434</ArticleId><ArticleId IdType="pmc">PMC3510335</ArticleId><ArticleId IdType="pubmed">23104007</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson B.S., McCaffery J.M., Lindquist S., Gitler A.D. A yeast TDP-43 proteinopathy model: Exploring the molecular determinants of TDP-43 aggregation and cellular toxicity. Proc. Natl. Acad. Sci. USA. 2008;105:6439&#x2013;6444. doi: 10.1073/pnas.0802082105.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0802082105</ArticleId><ArticleId IdType="pmc">PMC2359814</ArticleId><ArticleId IdType="pubmed">18434538</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson B.S., Snead D., Lee J.J., McCaffery J.M., Shorter J., Gitler A.D. TDP-43 is intrinsically aggregation-prone, and amyotrophic lateral sclerosis-linked mutations accelerate aggregation and increase toxicity. J. Biol. Chem. 2009;284:20329&#x2013;20339. doi: 10.1074/jbc.M109.010264.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M109.010264</ArticleId><ArticleId IdType="pmc">PMC2740458</ArticleId><ArticleId IdType="pubmed">19465477</ArticleId></ArticleIdList></Reference><Reference><Citation>Figley M.D., Gitler A.D. Yeast genetic screen reveals novel therapeutic strategy for ALS. Rare Dis. 2013;1:e24420. doi: 10.4161/rdis.24420.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/rdis.24420</ArticleId><ArticleId IdType="pmc">PMC3933050</ArticleId><ArticleId IdType="pubmed">25002991</ArticleId></ArticleIdList></Reference><Reference><Citation>Bharathi V., Girdhar A., Patel B.K. Role of CNC1 gene in TDP-43 aggregation-induced oxidative stress-mediated cell death in S. cerevisiae model of ALS. Biochim. Biophys. Acta Mol. Cell Res. 2021;1868:118993. doi: 10.1016/j.bbamcr.2021.118993.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbamcr.2021.118993</ArticleId><ArticleId IdType="pubmed">33647321</ArticleId></ArticleIdList></Reference><Reference><Citation>Fushimi K., Long C., Jayaram N., Chen X., Li L., Wu J.Y. Expression of human FUS/TLS in yeast leads to protein aggregation and cytotoxicity, recapitulating key features of FUS proteinopathy. Protein Cell. 2011;2:141&#x2013;149. doi: 10.1007/s13238-011-1014-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13238-011-1014-5</ArticleId><ArticleId IdType="pmc">PMC3093303</ArticleId><ArticleId IdType="pubmed">21327870</ArticleId></ArticleIdList></Reference><Reference><Citation>Ju S., Tardiff D.F., Han H., Divya K., Zhong Q., Maquat L.E., Bosco D.A., Hayward L.J., Brown R.H.J., Lindquist S., et al. A yeast model of FUS/TLS-dependent cytotoxicity. PLoS Biol. 2011;9:e1001052. doi: 10.1371/journal.pbio.1001052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pbio.1001052</ArticleId><ArticleId IdType="pmc">PMC3082520</ArticleId><ArticleId IdType="pubmed">21541368</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun Z., Diaz Z., Fang X., Hart M.P., Chesi A., Shorter J., Gitler A.D. Molecular determinants and genetic modifiers of aggregation and toxicity for the ALS disease protein FUS/TLS. PLoS Biol. 2011;9:e1000614. doi: 10.1371/journal.pbio.1000614.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pbio.1000614</ArticleId><ArticleId IdType="pmc">PMC3082519</ArticleId><ArticleId IdType="pubmed">21541367</ArticleId></ArticleIdList></Reference><Reference><Citation>Gal J., Zhang J., Kwinter D.M., Zhai J., Jia H., Jia J., Zhu H. Nuclear localization sequence of FUS and induction of stress granules by ALS mutants. Neurobiol. Aging. 2011;32:e27&#x2013;e40. doi: 10.1016/j.neurobiolaging.2010.06.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2010.06.010</ArticleId><ArticleId IdType="pmc">PMC2997923</ArticleId><ArticleId IdType="pubmed">20674093</ArticleId></ArticleIdList></Reference><Reference><Citation>Park S.-K., Arslan F., Kanneganti V., Barmada S.J., Purushothaman P., Verma S.C., Liebman S.W. Overexpression of a conserved HSP40 chaperone reduces toxicity of several neurodegenerative disease proteins. Prion. 2018;12:16&#x2013;22. doi: 10.1080/19336896.2017.1423185.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/19336896.2017.1423185</ArticleId><ArticleId IdType="pmc">PMC5871033</ArticleId><ArticleId IdType="pubmed">29308690</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayden E., Chen S., Chumley A., Xia C., Zhong Q., Ju S. A Genetic Screen for Human Genes Suppressing FUS Induced Toxicity in Yeast. G3 Bethesda. 2020;10:1843&#x2013;1852. doi: 10.1534/g3.120.401164.</Citation><ArticleIdList><ArticleId IdType="doi">10.1534/g3.120.401164</ArticleId><ArticleId IdType="pmc">PMC7263679</ArticleId><ArticleId IdType="pubmed">32276960</ArticleId></ArticleIdList></Reference><Reference><Citation>Averill D.R.J. Degenerative myelopathy in the aging German Shepherd dog: Clinical and pathologic findings. J. Am. Vet. Med. Assoc. 1973;162:1045&#x2013;1051.</Citation><ArticleIdList><ArticleId IdType="pubmed">4196853</ArticleId></ArticleIdList></Reference><Reference><Citation>Nardone R., H&#xf6;ller Y., Taylor A.C., Lochner P., Tezzon F., Golaszewski S., Brigo F., Trinka E. Canine degenerative myelopathy: A model of human amyotrophic lateral sclerosis. Zoology. 2016;119:64&#x2013;73. doi: 10.1016/j.zool.2015.09.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.zool.2015.09.003</ArticleId><ArticleId IdType="pubmed">26432396</ArticleId></ArticleIdList></Reference><Reference><Citation>ENGEL W.K., KURLAND L.T., KLATZO I. An inherited disease similar to amyotrophic lateral sclerosis with a pattern of posterior column involvement. An intermediate form? Brain. 1959;82:203&#x2013;220. doi: 10.1093/brain/82.2.203.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/82.2.203</ArticleId><ArticleId IdType="pubmed">13849712</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirano A., Kurland L.T., Sayre G.P. Familial amyotrophic lateral sclerosis. A subgroup characterized by posterior and spinocerebellar tract involvement and hyaline inclusions in the anterior horn cells. Arch. Neurol. 1967;16:232&#x2013;243. doi: 10.1001/archneur.1967.00470210008002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.1967.00470210008002</ArticleId><ArticleId IdType="pubmed">6018874</ArticleId></ArticleIdList></Reference><Reference><Citation>Awano T., Johnson G.S., Wade C.M., Katz M.L., Johnson G.C., Taylor J.F., Perloski M., Biagi T., Baranowska I., Long S., et al. Genome-wide association analysis reveals a SOD1 mutation in canine degenerative myelopathy that resembles amyotrophic lateral sclerosis. Proc. Natl. Acad. Sci. USA. 2009;106:2794&#x2013;2799. doi: 10.1073/pnas.0812297106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0812297106</ArticleId><ArticleId IdType="pmc">PMC2634802</ArticleId><ArticleId IdType="pubmed">19188595</ArticleId></ArticleIdList></Reference><Reference><Citation>Wininger F.A., Zeng R., Johnson G.S., Katz M.L., Johnson G.C., Bush W.W., Jarboe J.M., Coates J.R. Degenerative myelopathy in a Bernese Mountain Dog with a novel SOD1 missense mutation. J. Vet. Intern. Med. 2011;25:1166&#x2013;1170. doi: 10.1111/j.1939-1676.2011.0760.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1939-1676.2011.0760.x</ArticleId><ArticleId IdType="pubmed">21848967</ArticleId></ArticleIdList></Reference><Reference><Citation>Crisp M.J., Beckett J., Coates J.R., Miller T.M. Canine degenerative myelopathy: Biochemical characterization of superoxide dismutase 1 in the first naturally occurring non-human amyotrophic lateral sclerosis model. Exp. Neurol. 2013;248:1&#x2013;9. doi: 10.1016/j.expneurol.2013.05.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2013.05.009</ArticleId><ArticleId IdType="pmc">PMC3773294</ArticleId><ArticleId IdType="pubmed">23707216</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimura S., Kamatari Y.O., Kuwahara Y., Hara H., Yamato O., Maeda S., Kamishina H., Honda R. Canine SOD1 harboring E40K or T18S mutations promotes protein aggregation without reducing the global structural stability. PeerJ. 2020;8:e9512. doi: 10.7717/peerj.9512.</Citation><ArticleIdList><ArticleId IdType="doi">10.7717/peerj.9512</ArticleId><ArticleId IdType="pmc">PMC7368427</ArticleId><ArticleId IdType="pubmed">32742795</ArticleId></ArticleIdList></Reference><Reference><Citation>Golubczyk D., Malysz-Cymborska I., Kalkowski L., Janowski M., Coates J.R., Wojtkiewicz J., Maksymowicz W., Walczak P. The Role of Glia in Canine Degenerative Myelopathy: Relevance to Human Amyotrophic Lateral Sclerosis. Mol. Neurobiol. 2019;56:5740&#x2013;5748. doi: 10.1007/s12035-019-1488-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-019-1488-3</ArticleId><ArticleId IdType="pmc">PMC6614142</ArticleId><ArticleId IdType="pubmed">30674036</ArticleId></ArticleIdList></Reference><Reference><Citation>Toedebusch C.M., Snyder J.C., Jones M.R., Garcia V.B., Johnson G.C., Villal&#xf3;n E.L., Coates J.R., Garcia M.L. Arginase-1 expressing microglia in close proximity to motor neurons were increased early in disease progression in canine degenerative myelopathy, a model of amyotrophic lateral sclerosis. Mol. Cell. Neurosci. 2018;88:148&#x2013;157. doi: 10.1016/j.mcn.2018.01.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mcn.2018.01.009</ArticleId><ArticleId IdType="pubmed">29408267</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-Trapero M., Espejo-Porras F., Rodr&#xed;guez-Cueto C., Coates J.R., P&#xe9;rez-D&#xed;az C., de Lago E., Fern&#xe1;ndez-Ruiz J. Upregulation of CB(2) receptors in reactive astrocytes in canine degenerative myelopathy, a disease model of amyotrophic lateral sclerosis. Dis. Model. Mech. 2017;10:551&#x2013;558.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5451172</ArticleId><ArticleId IdType="pubmed">28069688</ArticleId></ArticleIdList></Reference><Reference><Citation>Bendixen E., Danielsen M., Larsen K., Bendixen C. Advances in porcine genomics and proteomics--a toolbox for developing the pig as a model organism for molecular biomedical research. Brief. Funct. Genom. 2010;9:208&#x2013;219. doi: 10.1093/bfgp/elq004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bfgp/elq004</ArticleId><ArticleId IdType="pubmed">20495211</ArticleId></ArticleIdList></Reference><Reference><Citation>Lind N.M., Moustgaard A., Jelsing J., Vajta G., Cumming P., Hansen A.K. The use of pigs in neuroscience: Modeling brain disorders. Neurosci. Biobehav. Rev. 2007;31:728&#x2013;751. doi: 10.1016/j.neubiorev.2007.02.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neubiorev.2007.02.003</ArticleId><ArticleId IdType="pubmed">17445892</ArticleId></ArticleIdList></Reference><Reference><Citation>Bjarkam C.R., Nielsen M.S., Glud A.N., Rosendal F., Mogensen P., Bender D., Doudet D., M&#xf8;ller A., S&#xf8;rensen J.C. Neuromodulation in a minipig MPTP model of Parkinson disease. Br. J. Neurosurg. 2008;22((Suppl. 1)):S9&#x2013;S12. doi: 10.1080/02688690802448285.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/02688690802448285</ArticleId><ArticleId IdType="pubmed">19085346</ArticleId></ArticleIdList></Reference><Reference><Citation>Kragh P.M., Nielsen A.L., Li J., Du Y., Lin L., Schmidt M., B&#xf8;gh I.B., Holm I.E., Jakobsen J.E., Johansen M.G., et al. Hemizygous minipigs produced by random gene insertion and handmade cloning express the Alzheimer&#x2019;s disease-causing dominant mutation APPsw. Transgenic Res. 2009;18:545&#x2013;558. doi: 10.1007/s11248-009-9245-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11248-009-9245-4</ArticleId><ArticleId IdType="pubmed">19184503</ArticleId></ArticleIdList></Reference><Reference><Citation>Lorson M.A., Spate L.D., Samuel M.S., Murphy C.N., Lorson C.L., Prather R.S., Wells K.D. Disruption of the Survival Motor Neuron (SMN) gene in pigs using ssDNA. Transgenic Res. 2011;20:1293&#x2013;1304. doi: 10.1007/s11248-011-9496-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11248-011-9496-8</ArticleId><ArticleId IdType="pmc">PMC4455718</ArticleId><ArticleId IdType="pubmed">21350916</ArticleId></ArticleIdList></Reference><Reference><Citation>Uchida M., Shimatsu Y., Onoe K., Matsuyama N., Niki R., Ikeda J.E., Imai H. Production of transgenic miniature pigs by pronuclear microinjection. Transgenic Res. 2001;10:577&#x2013;582. doi: 10.1023/A:1013059917280.</Citation><ArticleIdList><ArticleId IdType="doi">10.1023/A:1013059917280</ArticleId><ArticleId IdType="pubmed">11817545</ArticleId></ArticleIdList></Reference><Reference><Citation>Dolezalova D., Hruska-Plochan M., Bjarkam C.R., S&#xf8;rensen J.C.H., Cunningham M., Weingarten D., Ciacci J.D., Juhas S., Juhasova J., Motlik J., et al. Pig models of neurodegenerative disorders: Utilization in cell replacement-based preclinical safety and efficacy studies. J. Comp. Neurol. 2014;522:2784&#x2013;2801. doi: 10.1002/cne.23575.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cne.23575</ArticleId><ArticleId IdType="pubmed">24610493</ArticleId></ArticleIdList></Reference><Reference><Citation>Holm I.E., Alstrup A.K.O., Luo Y. Genetically modified pig models for neurodegenerative disorders. J. Pathol. 2016;238:267&#x2013;287. doi: 10.1002/path.4654.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/path.4654</ArticleId><ArticleId IdType="pubmed">26446984</ArticleId></ArticleIdList></Reference><Reference><Citation>Chieppa M.N., Perota A., Corona C., Grindatto A., Lagutina I., Vallino Costassa E., Lazzari G., Colleoni S., Duchi R., Lucchini F., et al. Modeling amyotrophic lateral sclerosis in hSOD1 transgenic swine. Neurodegener. Dis. 2014;13:246&#x2013;254. doi: 10.1159/000353472.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000353472</ArticleId><ArticleId IdType="pubmed">24157939</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang H., Wang G., Sun H., Shu R., Liu T., Wang C.-E., Liu Z., Zhao Y., Zhao B., Ouyang Z., et al. Species-dependent neuropathology in transgenic SOD1 pigs. Cell Res. 2014;24:464&#x2013;481. doi: 10.1038/cr.2014.25.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cr.2014.25</ArticleId><ArticleId IdType="pmc">PMC3975503</ArticleId><ArticleId IdType="pubmed">24577199</ArticleId></ArticleIdList></Reference><Reference><Citation>Crociara P., Chieppa M.N., Vallino Costassa E., Berrone E., Gallo M., Lo Faro M., Pintore M.D., Iulini B., D&#x2019;Angelo A., Perona G., et al. Motor neuron degeneration, severe myopathy and TDP-43 increase in a transgenic pig model of SOD1-linked familiar ALS. Neurobiol. Dis. 2019;124:263&#x2013;275. doi: 10.1016/j.nbd.2018.11.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2018.11.021</ArticleId><ArticleId IdType="pubmed">30471417</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang G., Yang H., Yan S., Wang C.-E., Liu X., Zhao B., Ouyang Z., Yin P., Liu Z., Zhao Y., et al. Cytoplasmic mislocalization of RNA splicing factors and aberrant neuronal gene splicing in TDP-43 transgenic pig brain. Mol. Neurodegener. 2015;10:42. doi: 10.1186/s13024-015-0036-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-015-0036-5</ArticleId><ArticleId IdType="pmc">PMC4557629</ArticleId><ArticleId IdType="pubmed">26334913</ArticleId></ArticleIdList></Reference><Reference><Citation>Bravo-Hernandez M., Tadokoro T., Navarro M.R., Platoshyn O., Kobayashi Y., Marsala S., Miyanohara A., Juhas S., Juhasova J., Skalnikova H., et al. Spinal subpial delivery of AAV9 enables widespread gene silencing and blocks motoneuron degeneration in ALS. Nat. Med. 2020;26:118&#x2013;130. doi: 10.1038/s41591-019-0674-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-019-0674-1</ArticleId><ArticleId IdType="pmc">PMC8171115</ArticleId><ArticleId IdType="pubmed">31873312</ArticleId></ArticleIdList></Reference><Reference><Citation>Harding J.D. Nonhuman Primates and Translational Research: Progress, Opportunities, and Challenges. ILAR J. 2017;58:141&#x2013;150. doi: 10.1093/ilar/ilx033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ilar/ilx033</ArticleId><ArticleId IdType="pmc">PMC5886318</ArticleId><ArticleId IdType="pubmed">29253273</ArticleId></ArticleIdList></Reference><Reference><Citation>Teil M., Arotcarena M.-L., Dehay B. A New Rise of Non-Human Primate Models of Synucleinopathies. Biomedicines. 2021;9:671&#x2013;683. doi: 10.3390/biomedicines9030272.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines9030272</ArticleId><ArticleId IdType="pmc">PMC7999604</ArticleId><ArticleId IdType="pubmed">33803341</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnsten A.F.T., Datta D., Preuss T.M. Studies of aging nonhuman primates illuminate the etiology of early-stage Alzheimer&#x2019;s-like neuropathology: An evolutionary perspective. Am. J. Primatol. 2021:e23254. doi: 10.1002/ajp.23254.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ajp.23254</ArticleId><ArticleId IdType="pmc">PMC8550995</ArticleId><ArticleId IdType="pubmed">33960505</ArticleId></ArticleIdList></Reference><Reference><Citation>Uchida A., Sasaguri H., Kimura N., Tajiri M., Ohkubo T., Ono F., Sakaue F., Kanai K., Hirai T., Sano T., et al. Non-human primate model of amyotrophic lateral sclerosis with cytoplasmic mislocalization of TDP-43. Brain. 2012;135:833&#x2013;846. doi: 10.1093/brain/awr348.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awr348</ArticleId><ArticleId IdType="pmc">PMC3286326</ArticleId><ArticleId IdType="pubmed">22252998</ArticleId></ArticleIdList></Reference><Reference><Citation>Borel F., Gernoux G., Cardozo B., Metterville J.P., Toro Cabrera G.C., Song L., Su Q., Gao G.P., Elmallah M.K., Brown R.H.J., et al. Therapeutic rAAVrh10 Mediated SOD1 Silencing in Adult SOD1(G93A) Mice and Nonhuman Primates. Hum. Gene Ther. 2016;27:19&#x2013;31. doi: 10.1089/hum.2015.122.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/hum.2015.122</ArticleId><ArticleId IdType="pmc">PMC4741242</ArticleId><ArticleId IdType="pubmed">26710998</ArticleId></ArticleIdList></Reference><Reference><Citation>Borel F., Gernoux G., Sun H., Stock R., Blackwood M., Brown R.H.J., Mueller C. Safe and effective superoxide dismutase 1 silencing using artificial microRNA in macaques. Sci. Transl. Med. 2018;10:eaau6414. doi: 10.1126/scitranslmed.aau6414.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aau6414</ArticleId><ArticleId IdType="pubmed">30381409</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson J.O., Pioro E.P., Boehringer A., Chia R., Feit H., Renton A.E., Pliner H.A., Abramzon Y., Marangi G., Winborn B.J., et al. Mutations in the Matrin 3 gene cause familial amyotrophic lateral sclerosis. Nat. Neurosci. 2014;17:664&#x2013;666. doi: 10.1038/nn.3688.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.3688</ArticleId><ArticleId IdType="pmc">PMC4000579</ArticleId><ArticleId IdType="pubmed">24686783</ArticleId></ArticleIdList></Reference><Reference><Citation>Bannwarth S., Ait-El-Mkadem S., Chaussenot A., Genin E.C., Lacas-Gervais S., Fragaki K., Berg-Alonso L., Kageyama Y., Serre V., Moore D.G., et al. A mitochondrial origin for frontotemporal dementia and amyotrophic lateral sclerosis through CHCHD10 involvement. Brain. 2014;137:2329&#x2013;2345. doi: 10.1093/brain/awu138.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awu138</ArticleId><ArticleId IdType="pmc">PMC4107737</ArticleId><ArticleId IdType="pubmed">24934289</ArticleId></ArticleIdList></Reference><Reference><Citation>Freischmidt A., Wieland T., Richter B., Ruf W., Schaeffer V., M&#xfc;ller K., Marroquin N., Nordin F., H&#xfc;bers A., Weydt P., et al. Haploinsufficiency of TBK1 causes familial ALS and fronto-temporal dementia. Nat. Neurosci. 2015;18:631&#x2013;636. doi: 10.1038/nn.4000.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.4000</ArticleId><ArticleId IdType="pubmed">25803835</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirulli E.T., Lasseigne B.N., Petrovski S., Sapp P.C., Dion P.A., Leblond C.S., Couthouis J., Lu Y.-F., Wang Q., Krueger B.J., et al. Exome sequencing in amyotrophic lateral sclerosis identifies risk genes and pathways. Science. 2015;347:1436&#x2013;1441. doi: 10.1126/science.aaa3650.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aaa3650</ArticleId><ArticleId IdType="pmc">PMC4437632</ArticleId><ArticleId IdType="pubmed">25700176</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith B.N., Ticozzi N., Fallini C., Gkazi A.S., Topp S., Kenna K.P., Scotter E.L., Kost J., Keagle P., Miller J.W., et al. Exome-wide rare variant analysis identifies TUBA4A mutations associated with familial ALS. Neuron. 2014;84:324&#x2013;331. doi: 10.1016/j.neuron.2014.09.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2014.09.027</ArticleId><ArticleId IdType="pmc">PMC4521390</ArticleId><ArticleId IdType="pubmed">25374358</ArticleId></ArticleIdList></Reference><Reference><Citation>Kenna K.P., van Doormaal P.T.C., Dekker A.M., Ticozzi N., Kenna B.J., Diekstra F.P., van Rheenen W., van Eijk K.R., Jones A.R., Keagle P., et al. NEK1 variants confer susceptibility to amyotrophic lateral sclerosis. Nat. Genet. 2016;48:1037&#x2013;1042. doi: 10.1038/ng.3626.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.3626</ArticleId><ArticleId IdType="pmc">PMC5560030</ArticleId><ArticleId IdType="pubmed">27455347</ArticleId></ArticleIdList></Reference><Reference><Citation>Brenner D., M&#xfc;ller K., Wieland T., Weydt P., B&#xf6;hm S., Lul&#xe9; D., H&#xfc;bers A., Neuwirth C., Weber M., Borck G., et al. NEK1 mutations in familial amyotrophic lateral sclerosis. Brain. 2016;139:e28. doi: 10.1093/brain/aww033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/aww033</ArticleId><ArticleId IdType="pubmed">26945885</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith B.N., Topp S.D., Fallini C., Shibata H., Chen H.-J., Troakes C., King A., Ticozzi N., Kenna K.P., Soragia-Gkazi A., et al. Mutations in the vesicular trafficking protein annexin A11 are associated with amyotrophic lateral sclerosis. Sci. Transl. Med. 2017;9:aad9157. doi: 10.1126/scitranslmed.aad9157.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aad9157</ArticleId><ArticleId IdType="pmc">PMC6599403</ArticleId><ArticleId IdType="pubmed">28469040</ArticleId></ArticleIdList></Reference><Reference><Citation>van Rheenen W., Shatunov A., Dekker A.M., McLaughlin R.L., Diekstra F.P., Pulit S.L., van der Spek R.A.A., V&#xf5;sa U., de Jong S., Robinson M.R., et al. Genome-wide association analyses identify new risk variants and the genetic architecture of amyotrophic lateral sclerosis. Nat. Genet. 2016;48:1043&#x2013;1048. doi: 10.1038/ng.3622.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.3622</ArticleId><ArticleId IdType="pmc">PMC5556360</ArticleId><ArticleId IdType="pubmed">27455348</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams K.L., Topp S., Yang S., Smith B., Fifita J.A., Warraich S.T., Zhang K.Y., Farrawell N., Vance C., Hu X., et al. CCNF mutations in amyotrophic lateral sclerosis and frontotemporal dementia. Nat. Commun. 2016;7:11253. doi: 10.1038/ncomms11253.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms11253</ArticleId><ArticleId IdType="pmc">PMC4835537</ArticleId><ArticleId IdType="pubmed">27080313</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakayasu H., Berezney R. Nuclear matrins: Identification of the major nuclear matrix proteins. Proc. Natl. Acad. Sci. USA. 1991;88:10312&#x2013;10316. doi: 10.1073/pnas.88.22.10312.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.88.22.10312</ArticleId><ArticleId IdType="pmc">PMC52918</ArticleId><ArticleId IdType="pubmed">1946450</ArticleId></ArticleIdList></Reference><Reference><Citation>Malik A.M., Barmada S.J. Matrin 3 in neuromuscular disease: Physiology and pathophysiology. JCI Insight. 2021;6:e143948. doi: 10.1172/jci.insight.143948.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.143948</ArticleId><ArticleId IdType="pmc">PMC7821588</ArticleId><ArticleId IdType="pubmed">33427209</ArticleId></ArticleIdList></Reference><Reference><Citation>Moloney C., Rayaprolu S., Howard J., Fromholt S., Brown H., Collins M., Cabrera M., Duffy C., Siemienski Z., Miller D., et al. Transgenic mice overexpressing the ALS-linked protein Matrin 3 develop a profound muscle phenotype. Acta Neuropathol. Commun. 2016;4:122. doi: 10.1186/s40478-016-0393-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-016-0393-5</ArticleId><ArticleId IdType="pmc">PMC5116203</ArticleId><ArticleId IdType="pubmed">27863507</ArticleId></ArticleIdList></Reference><Reference><Citation>Moloney C., Rayaprolu S., Howard J., Fromholt S., Brown H., Collins M., Cabrera M., Duffy C., Siemienski Z., Miller D., et al. Analysis of spinal and muscle pathology in transgenic mice overexpressing wild-type and ALS-linked mutant MATR3. Acta Neuropathol. Commun. 2018;6:137. doi: 10.1186/s40478-018-0631-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-018-0631-0</ArticleId><ArticleId IdType="pmc">PMC6299607</ArticleId><ArticleId IdType="pubmed">30563574</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X., Yamashita S., Hara K., Doki T., Tawara N., Ikeda T., Misumi Y., Zhang Z., Matsuo Y., Nagai M., et al. A mutant MATR3 mouse model to explain multisystem proteinopathy. J. Pathol. 2019;249:182&#x2013;192. doi: 10.1002/path.5289.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/path.5289</ArticleId><ArticleId IdType="pubmed">31056746</ArticleId></ArticleIdList></Reference><Reference><Citation>Kao C.S., van Bruggen R., Kim J.R., Chen X.X.L., Chan C., Lee J., Cho W.I., Zhao M., Arndt C., Maksimovic K., et al. Selective neuronal degeneration in MATR3 S85C knock-in mouse model of early-stage ALS. Nat. Commun. 2020;11:5304. doi: 10.1038/s41467-020-18949-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-18949-w</ArticleId><ArticleId IdType="pmc">PMC7576598</ArticleId><ArticleId IdType="pubmed">33082323</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao M., Kao C.S., Arndt C., Tran D.D., Cho W.I., Maksimovic K., Chen X.X.L., Khan M., Zhu H., Qiao J., et al. Knockdown of genes involved in axonal transport enhances the toxicity of human neuromuscular disease-linked MATR3 mutations in Drosophila. FEBS Lett. 2020;594:2800&#x2013;2818. doi: 10.1002/1873-3468.13858.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/1873-3468.13858</ArticleId><ArticleId IdType="pubmed">32515490</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramesh N., Kour S., Anderson E.N., Rajasundaram D., Pandey U.B. RNA-recognition motif in Matrin-3 mediates neurodegeneration through interaction with hnRNPM. Acta Neuropathol. Commun. 2020;8:138. doi: 10.1186/s40478-020-01021-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-020-01021-5</ArticleId><ArticleId IdType="pmc">PMC7437177</ArticleId><ArticleId IdType="pubmed">32811564</ArticleId></ArticleIdList></Reference><Reference><Citation>Imai Y., Meng H., Shiba-Fukushima K., Hattori N. Twin CHCH Proteins, CHCHD2, and CHCHD10: Key Molecules of Parkinson&#x2019;s Disease, Amyotrophic Lateral Sclerosis, and Frontotemporal Dementia. Int. J. Mol. Sci. 2019;20:908. doi: 10.3390/ijms20040908.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms20040908</ArticleId><ArticleId IdType="pmc">PMC6412816</ArticleId><ArticleId IdType="pubmed">30791515</ArticleId></ArticleIdList></Reference><Reference><Citation>Burstein S.R., Valsecchi F., Kawamata H., Bourens M., Zeng R., Zuberi A., Milner T.A., Cloonan S.M., Lutz C., Barrientos A., et al. In vitro and in vivo studies of the ALS-FTLD protein CHCHD10 reveal novel mitochondrial topology and protein interactions. Hum. Mol. Genet. 2018;27:160&#x2013;177. doi: 10.1093/hmg/ddx397.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddx397</ArticleId><ArticleId IdType="pmc">PMC5886281</ArticleId><ArticleId IdType="pubmed">29112723</ArticleId></ArticleIdList></Reference><Reference><Citation>Genin E.C., Madji Hounoum B., Bannwarth S., Fragaki K., Lacas-Gervais S., Mauri-Crouzet A., Lespinasse F., Neveu J., Ropert B., Aug&#xe9; G., et al. Mitochondrial defect in muscle precedes neuromuscular junction degeneration and motor neuron death in CHCHD10(S59L/+) mouse. Acta Neuropathol. 2019;138:123&#x2013;145. doi: 10.1007/s00401-019-01988-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-019-01988-z</ArticleId><ArticleId IdType="pubmed">30874923</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson C.J., Bredvik K., Burstein S.R., Davis C., Meadows S.M., Dash J., Case L., Milner T.A., Kawamata H., Zuberi A., et al. ALS/FTD mutant CHCHD10 mice reveal a tissue-specific toxic gain-of-function and mitochondrial stress response. Acta Neuropathol. 2019;138:103&#x2013;121. doi: 10.1007/s00401-019-01989-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-019-01989-y</ArticleId><ArticleId IdType="pmc">PMC6571048</ArticleId><ArticleId IdType="pubmed">30877432</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan &#xc9;.B., Yan J., Miller N., Dayanidhi S., Ma Y.C., Deng H.-X., Siddique T. Early death of ALS-linked CHCHD10-R15L transgenic mice with central nervous system, skeletal muscle, and cardiac pathology. iScience. 2021;24:102061. doi: 10.1016/j.isci.2021.102061.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.isci.2021.102061</ArticleId><ArticleId IdType="pmc">PMC7890413</ArticleId><ArticleId IdType="pubmed">33659869</ArticleId></ArticleIdList></Reference><Reference><Citation>Oakes J.A., Davies M.C., Collins M.O. TBK1: A new player in ALS linking autophagy and neuroinflammation. Mol. Brain. 2017;10:5. doi: 10.1186/s13041-017-0287-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13041-017-0287-x</ArticleId><ArticleId IdType="pmc">PMC5288885</ArticleId><ArticleId IdType="pubmed">28148298</ArticleId></ArticleIdList></Reference><Reference><Citation>Pottier C., Bieniek K.F., Finch N., van de Vorst M., Baker M., Perkersen R., Brown P., Ravenscroft T., van Blitterswijk M., Nicholson A.M., et al. Whole-genome sequencing reveals important role for TBK1 and OPTN mutations in frontotemporal lobar degeneration without motor neuron disease. Acta Neuropathol. 2015;130:77&#x2013;92. doi: 10.1007/s00401-015-1436-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-015-1436-x</ArticleId><ArticleId IdType="pmc">PMC4470809</ArticleId><ArticleId IdType="pubmed">25943890</ArticleId></ArticleIdList></Reference><Reference><Citation>Catanese A., Olde Heuvel F., Mulaw M., Demestre M., Higelin J., Barbi G., Freischmidt A., Weishaupt J.H., Ludolph A.C., Roselli F., et al. Retinoic acid worsens ATG10-dependent autophagy impairment in TBK1-mutant hiPSC-derived motoneurons through SQSTM1/p62 accumulation. Autophagy. 2019;15:1719&#x2013;1737. doi: 10.1080/15548627.2019.1589257.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/15548627.2019.1589257</ArticleId><ArticleId IdType="pmc">PMC6735587</ArticleId><ArticleId IdType="pubmed">30939964</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonnard M., Mirtsos C., Suzuki S., Graham K., Huang J., Ng M., Iti&#xe9; A., Wakeham A., Shahinian A., Henzel W.J., et al. Deficiency of T2K leads to apoptotic liver degeneration and impaired NF-kappaB-dependent gene transcription. EMBO J. 2000;19:4976&#x2013;4985. doi: 10.1093/emboj/19.18.4976.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/emboj/19.18.4976</ArticleId><ArticleId IdType="pmc">PMC314216</ArticleId><ArticleId IdType="pubmed">10990461</ArticleId></ArticleIdList></Reference><Reference><Citation>Marchlik E., Thakker P., Carlson T., Jiang Z., Ryan M., Marusic S., Goutagny N., Kuang W., Askew G.R., Roberts V., et al. Mice lacking Tbk1 activity exhibit immune cell infiltrates in multiple tissues and increased susceptibility to LPS-induced lethality. J. Leukoc. Biol. 2010;88:1171&#x2013;1180. doi: 10.1189/jlb.0210071.</Citation><ArticleIdList><ArticleId IdType="doi">10.1189/jlb.0210071</ArticleId><ArticleId IdType="pubmed">20651301</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerbino V., Kaunga E., Ye J., Canzio D., O&#x2019;Keeffe S., Rudnick N.D., Guarnieri P., Lutz C.M., Maniatis T. The Loss of TBK1 Kinase Activity in Motor Neurons or in All Cell Types Differentially Impacts ALS Disease Progression in SOD1 Mice. Neuron. 2020;106:789&#x2013;805.e5. doi: 10.1016/j.neuron.2020.03.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2020.03.005</ArticleId><ArticleId IdType="pubmed">32220666</ArticleId></ArticleIdList></Reference><Reference><Citation>Sieverding K., Ulmer J., Bruno C., Satoh T., Tsao W., Freischmidt A., Akira S., Wong P.C., Ludolph A.C., Danzer K.M., et al. Hemizygous deletion of Tbk1 worsens neuromuscular junction pathology in TDP-43(G298S) transgenic mice. Exp. Neurol. 2021;335:113496. doi: 10.1016/j.expneurol.2020.113496.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2020.113496</ArticleId><ArticleId IdType="pubmed">33038415</ArticleId></ArticleIdList></Reference><Reference><Citation>Hogan A.L., Don E.K., Rayner S.L., Lee A., Laird A.S., Watchon M., Winnick C., Tarr I.S., Morsch M., Fifita J.A., et al. Expression of ALS/FTD-linked mutant CCNF in zebrafish leads to increased cell death in the spinal cord and an aberrant motor phenotype. Hum. Mol. Genet. 2017;26:2616&#x2013;2626. doi: 10.1093/hmg/ddx136.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddx136</ArticleId><ArticleId IdType="pubmed">28444311</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J., He J., Tang L., Chen L., Ma Y., Fan D. Screening for TUBA4A mutations in a large Chinese cohort of patients with ALS: Re-evaluating the pathogenesis of TUBA4A in ALS. J. Neurol. Neurosurg. Psychiatry. 2018;89:1350&#x2013;1352. doi: 10.1136/jnnp-2017-317560.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2017-317560</ArticleId><ArticleId IdType="pubmed">29540513</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark J.A., Yeaman E.J., Blizzard C.A., Chuckowree J.A., Dickson T.C. A Case for Microtubule Vulnerability in Amyotrophic Lateral Sclerosis: Altered Dynamics During Disease. Front. Cell. Neurosci. 2016;10:204. doi: 10.3389/fncel.2016.00204.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2016.00204</ArticleId><ArticleId IdType="pmc">PMC5020100</ArticleId><ArticleId IdType="pubmed">27679561</ArticleId></ArticleIdList></Reference><Reference><Citation>Helferich A.M., Brockmann S.J., Reinders J., Deshpande D., Holzmann K., Brenner D., Andersen P.M., Petri S., Thal D.R., Michaelis J., et al. Dysregulation of a novel miR-1825/TBCB/TUBA4A pathway in sporadic and familial ALS. Cell. Mol. Life Sci. 2018;75:4301&#x2013;4319. doi: 10.1007/s00018-018-2873-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00018-018-2873-1</ArticleId><ArticleId IdType="pubmed">30030593</ArticleId></ArticleIdList></Reference><Reference><Citation>Maraldi T., Beretti F., Anselmi L., Franchin C., Arrigoni G., Braglia L., Mandrioli J., Vinceti M., Marmiroli S. Influence of selenium on the emergence of neuro tubule defects in a neuron-like cell line and its implications for amyotrophic lateral sclerosis. Neurotoxicology. 2019;75:209&#x2013;220. doi: 10.1016/j.neuro.2019.09.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuro.2019.09.015</ArticleId><ArticleId IdType="pubmed">31585128</ArticleId></ArticleIdList></Reference><Reference><Citation>Teyssou E., Muratet F., Amador M.-D.-M., Ferrien M., Lautrette G., Machat S., Boill&#xe9;e S., Larmonier T., Saker S., Leguern E., et al. Genetic screening of ANXA11 revealed novel mutations linked to amyotrophic lateral sclerosis. Neurobiol. Aging. 2021;99:102.e11&#x2013;102.e20. doi: 10.1016/j.neurobiolaging.2020.10.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2020.10.015</ArticleId><ArticleId IdType="pubmed">33218681</ArticleId></ArticleIdList></Reference><Reference><Citation>Iyer S., Acharya K.R., Subramanian V. Prediction of structural consequences for disease causing variants in C21orf2 protein using computational approaches. J. Biomol. Struct. Dyn. 2019;37:465&#x2013;480. doi: 10.1080/07391102.2018.1429313.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/07391102.2018.1429313</ArticleId><ArticleId IdType="pubmed">29343210</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu H., Le W.D., Xie Y.-Y., Wang X.-P. Current Therapy of Drugs in Amyotrophic Lateral Sclerosis. Curr. Neuropharmacol. 2016;14:314&#x2013;321. doi: 10.2174/1570159X14666160120152423.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1570159X14666160120152423</ArticleId><ArticleId IdType="pmc">PMC4876587</ArticleId><ArticleId IdType="pubmed">26786249</ArticleId></ArticleIdList></Reference><Reference><Citation>Abe K., Aoki M., Tsuji S., Itoyama Y., Sobue G., Togo M., Hamada C., Tanaka M., Akimoto M., Nakamura K., et al. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: A randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2017;16:505&#x2013;512. doi: 10.1016/S1474-4422(17)30115-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(17)30115-1</ArticleId><ArticleId IdType="pubmed">28522181</ArticleId></ArticleIdList></Reference><Reference><Citation>Verber N.S., Shepheard S.R., Sassani M., McDonough H.E., Moore S.A., Alix J.J.P., Wilkinson I.D., Jenkins T.M., Shaw P.J. Biomarkers in Motor Neuron Disease: A State of the Art Review. Front. Neurol. 2019;10:291. doi: 10.3389/fneur.2019.00291.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2019.00291</ArticleId><ArticleId IdType="pmc">PMC6456669</ArticleId><ArticleId IdType="pubmed">31001186</ArticleId></ArticleIdList></Reference><Reference><Citation>Tadenev A.L.D., Burgess R.W. Model validity for preclinical studies in precision medicine: Precisely how precise do we need to be? Mamm. Genome. 2019;30:111&#x2013;122. doi: 10.1007/s00335-019-09798-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00335-019-09798-0</ArticleId><ArticleId IdType="pmc">PMC6606658</ArticleId><ArticleId IdType="pubmed">30953144</ArticleId></ArticleIdList></Reference><Reference><Citation>Jankovska N., Matej R. Molecular Pathology of ALS: What We Currently Know and What Important Information Is Still Missing. Diagnostics. 2021;11:1365. doi: 10.3390/diagnostics11081365.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/diagnostics11081365</ArticleId><ArticleId IdType="pmc">PMC8391180</ArticleId><ArticleId IdType="pubmed">34441299</ArticleId></ArticleIdList></Reference><Reference><Citation>McGrath J.C., McLachlan E.M., Zeller R. Transparency in Research involving Animals: The Basel Declaration and new principles for reporting research in BJP manuscripts. Br. J. Pharmacol. 2015;172:2427&#x2013;2432. doi: 10.1111/bph.12956.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bph.12956</ArticleId><ArticleId IdType="pmc">PMC4409896</ArticleId><ArticleId IdType="pubmed">25899710</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludolph A.C., Bendotti C., Blaugrund E., Hengerer B., L&#xf6;ffler J.-P., Martin J., Meininger V., Meyer T., Moussaoui S., Robberecht W., et al. Guidelines for the preclinical in vivo evaluation of pharmacological active drugs for ALS/MND: Report on the 142nd ENMC international workshop. Amyotroph. Lateral Scler. 2007;8:217&#x2013;223. doi: 10.1080/17482960701292837.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17482960701292837</ArticleId><ArticleId IdType="pubmed">17653919</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>